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Abstract 
Student name: Lindsay Pike 
Thesis title: Characterising antibiotic susceptibility and resistance in human commensal gut 
bacteria 
The human commensal gut microbiota can act as a reservoir of antimicrobial resistance genes 
that can persist and spread to pathogens. However, the extent and diversity of antibiotic 
resistance encoded by human commensal bacteria remains to be determined. Due to 
immediate clinical relevance and our previous inability to culture these commensal bacteria, 
the majority of research into antibiotic resistance has focused on pathogenic organisms or 
well-characterized antibiotic resistance mechanisms. Here, I demonstrate the existence of 
unpredicted antibiotic resistance, not detected by several genome-based prediction methods, 
in diverse bacterial species from the human gastrointestinal tract.  
178 antibiotic resistance genes and mutations were identified in a culture collection of 737 
phylogenetically diverse gut bacteria from healthy humans. Recent developments in culturing 
anaerobic gut bacteria were used to determine antibiotic sensitivity phenotypes and observe 
the spectrum of clinically relevant antibiotics across the diversity of these isolates. These data 
were combined to assess the accuracy of genome-based predictions in human commensal gut 
bacteria, revealing multiple instances of unpredicted antibiotic resistance. This highlights the 
importance of combining computational genomic prediction with functional validation and 
increases our knowledge of antibiotic resistance in commensal human gut bacteria. 
In addition, the impact of therapeutic amoxicillin treatment on antibiotic resistance in mice 
with human-derived gut microbiota was studied. These experiments model processes in 
humans and reveal community- and strain-level changes in antibiotic resistance following 
antibiotic therapy. These experiments further elucidate the role of the gut microbiota as a 
reservoir of antibiotic resistance and the influence of antibiotics on this reservoir. 
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Chapter 1: Antibiotics and commensal human gut bacteria 
 
1.1 Antibiotics 
Antibiotics are a cornerstone of modern medicine and are used extensively throughout the 
developed and developing worlds, in humans and for veterinary and agricultural purposes. 
They are drugs that either kill or inhibit the growth and replication of a bacterium1 and are 
used to treat bacterial infections in, or on, the body. They are distinct from antiseptics (used 
to sterilise living tissue and reduce the risk of infection, rather than treat an infection) and 
disinfectants (non-selective antimicrobials that kill a range of microorganisms, not just 
bacteria, and are used on non-living surfaces)1. They are also not toxins, as toxins are defined 
as a poisonous substance produced by a microorganism, plant or animal that causes illness in 
the body; antibiotics do not cause direct harm to human cells. Antibiotics can be administered 
intravenously (into veins via syringe or catheter), intramuscular (into muscle via syringe), 
orally (in tablet, capsule or liquid form), or topically (e.g. creams, lotion, sprays or drops). 
Intravenous is considered the most effective route as it creates an immediate therapeutic 
blood level of the antibiotic, but oral routes are often preferred as they are less intrusive, do 
not require a hospital stay, and often achieve supra-inhibitory blood levels2.  
Antibiotics can now be synthesised in a laboratory, but are often based on compounds 
produced naturally by microorganisms to harm or kill bacteria in their environment. Not all 
microorganisms produce antibiotic compounds – in fact, there are only around 20 species that 
produce antibiotics that are now mass-produced and used in medicine3. Typically these are 
soil-dwelling microorganisms3, although the search for new antibiotics is now beginning to 
shift to marine microbes4. Both of these environments feature high diversity and density of 
microorganism; antibiotic production is thought to be a mechanism of attack against 
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neighbouring bacteria or defence, enabling survival of the antibiotic-producer5. Antibiotic 
compounds can also act as signalling molecules between bacterial cells, regulating bacterial 
behaviour such as biofilm formation6. Therefore, they have important roles in nature that 
humans have co-opted for our benefit and integrated antibiotics into human and animal 
medicine. It is difficult to quantify exactly the overall impact of antibiotics on infection 
dynamics and distinguish between the impacts of other factors such as the introduction of 
vaccines7 or improved sanitation8. Despite this, antibiotic use is associated with a decrease in 
deaths caused by communicable diseases per year9 and increase in average life expectancy9. 
 
1.2 The history of antibiotics 
It is only recently, and over a relatively short timeline, that antibiotics have become 
entrenched in our society to treat bacterial infections (Fig. 1.1). Just 110 years ago, Paul Ehrlich 
(the German biochemist, 1854-1915) coined the term “magic bullet” when theorising a 
chemical that could selectively target and kill disease-causing agents in the body without 
harming the patient10. The first “true” magic bullet antibiotic against bacteria that was used 
clinically against bacterial infections was in fact used a number of years before this term was 
used. Pyocyanase was an extract prepared from the Gram-negative bacterium Pseudomonas 
aeruginosa by Emmerich and Low in 189911. It was active against a number of pathogenic 
bacteria but since its effectiveness was inconsistent and it was mildly toxic to humans it was 
abandoned11. Ehrlich, now considered the founding father of chemotherapy and large-scale, 
systematic drug screens, developed his own magic bullet (‘Compound 606’) against the 
causative bacterium of syphilis, Treponema palladium12. Compound 606, or Salvarsan, was the 
most frequently prescribed drug after its discovery in 190913. Prontosil was another early 
antibiotic, a compound synthesised as part of a screen by Bayer chemists Josef Klarer and Fritz 
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Mietzsch and shown to have antibacterial properties against a number of diseases by Gerhard 
Domagk14. The active component sulphanilamide had been previously used in the dye industry 
and had already come off-patent, enabling sulphonamide derivatives to be produced by 
various companies15. Sulphonamides are the oldest class of synthetic antibiotics and new 
versions are still produced and used today. 
Figure 1.1. Timeline of antibiotic discovery. Adapted from Silver 201116. 
 
Probably the most well-known antibiotic, and one of the oldest mass-produced antibiotics, is 
penicillin, “discovered” in 1928 in the famous tale of Alexander Fleming (Scottish 
bacteriologist, 1881-1955) and an open window. A mysterious fungus had blown through an 
open window and contaminated plates being used to study Staphylococcus, which was known 
to cause infections in humans, and the fungus had managed to halt the growth of this 
bacterium17. The antimicrobial properties of moulds were already known, but Fleming was 
remarkably dedicated in his efforts to purify the exact compound responsible for this effect. 
Penicillin was eventually brought into mass production in 1945, overtaking Salvarsan in 
usage15. Penicillin antibiotics are still the most prescribed drug globally to this day18. The mass 
production of penicillin coincided with the discovery of streptomycin in 1943, an antibiotic 
isolated from the soil bacterium Streptomyces griseus that could treat Mycobacterium 
tuberculosis, the cause of tuberculosis (TB)19. These events heralded the start of the “golden 
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age of antibiotics” (Fig. 1.1): eighteen new types of antibiotics were discovered between 1944 
and 197016. The rate of discovery then began to decline, with only four new classes in the 
1970s and one in the 1980s. Since then, no new classes of antibiotics have been discovered16 
– only “re-discoveries” have occurred, involving modifications of already known antibiotics16 
(Table 1.1). The decline in discovery of novel classes of antibiotics is problematic due to the 
emergence and spread of antibiotic resistance, where bacterial infections can no longer be 
treated with the same drugs that were once so effective. Since antibiotics are inseparable 
from today’s world, there are concerns a “post-antibiotic era” may be approaching20. In light 
of this, extraordinary research is taking place across the world to discover new antibiotics, 
develop alternatives to antibiotics, and understand the evolution and spread of antibiotic 
resistance.
  
Table 1.1. Sources of antibiotics. The year of discovery and source of current antibiotic classes are described. Adapted from Silver, 201116 and Chandra and Kumar, 20163. 
 
Year Antibiotic Source Kingdom; Division (Fungi) or Phylum (Bacteria); Class; Order; Family) 
1928 Penicillins Penicillium Fungi; Ascomycota; Eurotiomycetes; Eurotiales; Trichocomaceae 
1932 Sulphonamides Synthetic  
1942 Aminoglycosides Streptomyces spp. Bacteria; Actinobacteria; Actinomycetes; Actinomycetales; Actinomycetaceae 
1942 Bacitracin Bacillus subtilis Bacteria 
1945 Tetracyclines Streptomyces spp. Bacteria; Actinobacteria; Actinomycetes; Actinomycetales; Actinomycetaceae 
1946 Nitrofurans Synthetic  
1947 Polymyxins Paenibacillus polymyxa Bacteria 
1947 Phenicols Streptomyces spp. Bacteria; Actinobacteria; Actinomycetes; Actinomycetales; Actinomycetaceae 
1948 Cephalosporins Acremonium Fungi; Ascomycota; Hypocreales; Hypocreaceae 
1950 Pleuromutilins Clitopilus passecherianus Fungi; Basidiomycota; Agaricomyctes; Agaricales; Entolomataceae 
1952 Glycopeptides Streptomyces spp. Bacteria; Actinobacteria; Actinomycetes; Actinomycetales; Actinomycetaceae 
1952 Nitroimidazoles Streptomyces spp. Bacteria; Actinobacteria; Actinomycetes; Actinomycetales; Actinomycetaceae 
1952 Streptogramins Streptomyces spp. Bacteria; Actinobacteria; Actinomycetes; Actinomycetales; Actinomycetaceae 
1955 Cycloserine Streptomyces spp. Bacteria; Actinobacteria; Actinomycetes; Actinomycetales; Actinomycetaceae 
1955 Novobiocin Streptomyces spp. Bacteria; Actinobacteria; Actinomycetes; Actinomycetales; Actinomycetaceae 
1957 Rifamycins Amycolatepsis rifamycinica Bacteria; Actinobacteria; Actinomycetes; Actinomycetales; Pseudonocardiaceae 
1961 Trimethoprim Synthetic  
1962 Quinolones Synthetic  
1962 Lincosamides Streptomyces spp. Bacteria; Actinobacteria; Actinomycetes; Actinomycetales; Actinomycetaceae 
1962 Fusidic acid Fusidium coccineum Fungi; Ascomycota; Hypocreales; Nectriaceae 
1969 Fosfomycin Streptomyces spp. Bacteria; Actinobacteria; Actinomycetes; Actinomycetales; Actinomycetaceae 
1971 Mupirocin Pseudomonas fluorescens Bacteria; Proteobacteria; Gammaproteobacteria; Pseudomonadales; Pseudomonadaceae 
1976 Carbapenems Streptomyces spp. Bacteria; Actinobacteria; Actinomycetes; Actinomycetales; Actinomycetaceae 
1978 Oxazolidinones Synthetic (derived from cycloserine)  
1979 Monobactams Synthetic (derived from Chromobacterium violaceum) Bacteria; Proteobacteria; Betaproteobacteria; Neisseriales; Neisseriaceae 
1987 Lipopeptides Streptomyces spp. Bacteria; Actinobacteria; Actinomycetes; Actinomycetales; Actinomycetaceae 
1995 Glycylcyclines Synthetic Synthetic (tetracycline derivative) 
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1.3 Clinically relevant antibiotics 
Today, seventeen classes of antibiotics are considered essential by the World Health 
Organisation21 (Table 1.2). There are three categories of essential antibiotics: Access (first or 
second line of defence options for common infections); Watch (higher resistance potential but 
still recommended as first or second line treatments); and Reserve (‘last resort’ options for 
serious antibiotic-resistant infections). Each antibiotic has a different mechanism of action 
(Fig. 1.2), mechanism of resistance and can target different types of bacterial pathogens (Table 
1.2). This may include Gram-negative and/or Gram-positive bacteria, as determined by the 
Gram staining technique developed by Hans Christian Gram in 188422. In addition, bacteria 
can be strictly aerobic or anaerobic, meaning that the absence or presence of oxygen 
respectively is toxic, or somewhere in between23. Antibiotics such as aminoglycosides rely on 
components of the aerobic respiration pathway, and as such their spectrum of activity is 
thought to only include aerobic bacteria and not anaerobes24. Essential antibiotics are 
discussed in more detail below, including their reported spectrum of activity. 
Figure 1.2. Mechanism of action for antibiotics on the WHO List of Essential Medicines 201721. Adapted from 
Shaikh et al. 201525. Vector images of DNA, folate and protein synthesis from Freepik.com and smart.servier.com.

























Table 1.2. The antibiotics included in the 20th Edition of the WHO List of Essential Medicines (2017)21. These antibiotics are considered essential by the WHO to treat bacterial 
infections. There are three categories: Access (first or second line options for common infections); Watch (higher resistance potential but still recommended as first or second line 
treatments); and Reserve (‘last resort’ options for serious antibiotic-resistant infections). Antibiotics can be considered both Access and Watch; here, they have been listed under 
the higher concern category of Watch for conciseness. 
WHO 
Category 
Antibiotic Class Sub-class Drug name Mechanism of action Mechanism of resistance Used against 
Access Aminocyclitol  Spectinomycin Protein synthesis inhibition: 
bind 30S ribosomal subunit 
Ribosomal mutations; enzymes 
that modify either the antibiotic 
or target  
Aerobic Gram-negative bacteria 
e.g. Pseudomonas aeruginosa 
and staphylococci 
Access Aminoglycoside  Amikacin 
Gentamicin 
Protein synthesis inhibition: 
bind 30S ribosomal subunit 
Ribosomal mutations; 
antibiotic- or target-modifying 
enzymes  
Aerobic Gram-negative bacteria 
e.g. Pseudomonas aeruginosa 
and staphylococci 
Access Amphenicol  Chloramphenicol Protein synthesis: interacts 





Gram-negative bacteria e.g. 
Haemophilus influenzae and 
Gram-positives e.g. 
Streptococcus pneumoniae 




Cell wall synthesis inhibition: 
interact with cell wall catalysis 
enzymes 
Antibiotic-degrading enzymes, 
beta-lactamases; mutations in 
cell wall proteins 
Gram-negative and Gram-
positives e.g. penicillin-resistant 
bacteria such as Pseudomonas 
aeruginosa 











Cell wall synthesis inhibition: 
interact with cell wall catalysis 
enzymes 
Antibiotic-degrading enzymes, 
beta-lactamases; mutations in 








Antibiotic Class Sub-class Drug name Mechanism of action Mechanism of resistance Used against 
Access Folic acid 
metabolism 
inhibitors 
 Sulphamethoxazole + 
trimethoprim 
Folate synthesis inhibition: 
inhibit enzymes in different 
stages of the folic acid 
biosynthesis pathway 
Mutations to increase 
expression of trimethoprim 
targets, or in the targets 
themselves, or acquisition of 
genes encoding less sensitive 
targets 
Gram-negative and Gram-
positives including MRSA 
Access Nitroimidazole  Metronidazole DNA replication inhibition: the 
prodrug is reduced and 
converted to the toxic drug 
that inhibits DNA synthesis 
Decreased uptake; altered 
reduction efficiency; efflux; 
drug inactivation; acquisition of 
genes that encode alternative 
reductases and convert prodrug 
to non-toxic alternative 
Anaerobic Gram-negative or 
Gram-positive bacteria e.g. 
Prevotella 
Access Nitrofuran  Nitrofurantoin DNA replication inhibition: the 
prodrug is reduced and the 
intermediate metabolites bind 
enzymes involved in DNA and 
RNA synthesis 
Mutations in reductases Gram-negative and Gram-
positives excluding intrinsically-
resistant Klebsiella and 
Pseudomonas spp. 
Access Tetracycline  Doxycycline Protein synthesis inhibitor: 
prevent translation by binding 
16S rRNA in 30S subunit 
Efflux; target-protection 
proteins that dislodge 
tetracycline 
Gram-negative and Gram-







Cell wall synthesis inhibition: 
interact with cell wall catalysis 
enzymes 
Antibiotic-degrading enzymes, 
beta-lactamases; mutations in 
cell wall proteins 
Gram-negative and Gram-
positives including Pseudomonas 
aeruginosa 
Watch Beta-lactam Carbapenem Imipenem + cilostatin 
Meropenem 
Cell wall synthesis inhibition: 
interact with cell wall catalysis 
enzymes 
Antibiotic-degrading enzymes, 
beta-lactamases; mutations in 
cell wall proteins 
Gram-negative and Gram-







Antibiotic Class Sub-class Drug name Mechanism of action Mechanism of resistance Used against 






Cell wall synthesis inhibition: 
interact with cell wall catalysis 
enzymes 
Antibiotic-degrading enzymes, 
beta-lactamases; mutations in 
cell wall proteins 
Gram-negative and Gram-
positives, especially for bacterial 
meningitis and sepsis 
Watch Beta-lactam Penem Faropenem Cell wall synthesis inhibition: 
interact with cell wall catalysis 
enzymes 
Antibiotic-degrading enzymes, 
beta-lactamases; mutations in 
cell wall proteins 
Gram-negative and Gram-
positives, especially multi-drug 
resistant infections 




DNA replication inhibition: 
inhibit DNA gyrase 
DNA gyrase mutations; efflux; 
Qnr production (protein that 
competes for fluoroquinolone 
binding site) 
Gram-negative and Gram-
positives, including anaerobes 
Watch Glycopeptide  Teicoplanin 
Vancomycin 
Cell wall synthesis inhibition: 
bind D-Ala-D-Ala cell wall 
molecules 
Acquisition of van gene cluster 
(replaces final D-Alanine in cell 
wall molecules to prevent 
glycopeptide binding and 
destroys normal D-Ala-D-Ala 
molecules) 
Gram-positives e.g. Enterococcus 
faecalis and Clostridioides difficile 
Watch Lincosamide  Clindamycin Protein synthesis inhibition: 
inhibit translocation by binding 
23S rRNA in 50S ribosomal 
subunit 
Ribosomal mutations or 
modifications; efflux 
Gram-positives and anaerobes, 
but not typically Gram-negative 
aerobes 
Watch Macrolide  Azithromycin 
Clarithromycin 
Protein synthesis inhibition: 
inhibit translocation by binding 
23S rRNA in 50S ribosomal 
subunit 
Ribosomal mutations or 
modifications; efflux 
Gram-positives and anaerobes, 
but not typically Gram-negative 
aerobes 
Reserve Beta-lactam Monobactam Aztreonam Cell wall synthesis inhibition: 
interact with cell wall catalysis 
enzymes 
Antibiotic-degrading enzymes, 
beta-lactamases; mutations in 









Antibiotic Class Sub-class Drug name Mechanism of action Mechanism of resistance Used against 
Reserve Beta-lactam 4th generation 
cephalosporin 
Cefepime Cell wall synthesis inhibition: 
interact with cell wall catalysis 
enzymes 
Antibiotic-degrading enzymes, 
beta-lactamases; mutations in 
cell wall proteins 
Gram-negative and Gram-
positives  
Reserve Beta-lactam 5th generation 
cephalosporin 
Ceftaroline Cell wall synthesis inhibition: 
interact with cell wall catalysis 
enzymes 
Antibiotic-degrading enzymes, 
beta-lactamases; mutations in 
cell wall proteins 
Gram-negative and Gram-
positives including MRSA 
Reserve Peptide: cyclic 
lipopeptide 
 Daptomycin Membrane function disruption: 
inserts into cytoplasmic 
membrane, disrupts integrity 
and triggers rapid cell death  
Mutations in genes that alter 
the target or entry of 
daptomycin into cytoplasmic 
membrane 
Gram-positives e.g. vancomycin-
resistant enterococci and MRSA 
Reserve Fosfomycin  Fosfomycin Cell wall synthesis inhibition: 
inhibits the first step of cell 
wall synthesis 
Mutations in murA, the protein 
that initiates cell wall synthesis; 
mutations in membrane 




positive bacteria, especially for 
antibiotic-resistant UTIs 
Reserve Glycylcycline  Tigecycline Protein synthesis inhibition: 
binds 30S ribosome, blocking 
tRNA entry 
Efflux Gram-negative and Gram-
positive, including tetracycline-
resistant bacteria 
Reserve Oxazolidinone  Linezolid Protein synthesis inhibition: 
binds 23S rRNA in 50S 
ribosomal subunit and 
interacts with tRNAs to prevent 
protein synthesis initiation 
Efflux (especially in Gram-
negative aerobes); ribosomal 
mutations 
Gram-positives e.g. vancomycin-






Outer membrane disruption: 
bind lipopolysaccharide to 
destabilise OM and IM, induce 
osmotic imbalance and 
oxidative stress 
Chromosomal mutations; 
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1.3.1 Access antibiotics: first or second line of defence 
Access antibiotics are those that, according to the WHO, are first or second line drugs for 
common infectious diseases and should be: widely available, affordable, appropriately 
formulated and quality controlled18. First line antibiotics are typically narrow spectrum: they 
only target a limited range of bacteria, such as the intended pathogenic bacterium and 
possibly some close relatives18. They should also have low resistance potential and positive 
benefit-to-risk ratios18; i.e., the risk of harm to the patient is low compared to the potential 
treatment of their infection. Broad spectrum antibiotics, that target a wider range of bacteria, 
are generally used as second line options, as are drugs with higher resistance potentials or less 
positive benefit-to-risk ratios21 (e.g. they might have more common or more serious side 
effects).  
Aminocyclitol antibiotics, such as spectinomycin, bind the 30S subunit of the bacterial 
ribosome, disrupting protein synthesis. Aminoglycosides, such as amikacin and gentamicin, 
act via the same mechanism. To do this, they must enter the cell through its cytoplasmic 
membrane – a process that requires energy dependent active bacterial transport24. This in 
turn requires oxygen and an active proton motive force; therefore these drugs are only 
typically effective for bacteria capable of aerobic respiration24. Aminocyclitols and 
aminoglycosides are considered inactive against anaerobic bacteria, which have adapted to 
survive without oxygen and do not have the usual required components to transport these 
drugs into their cells24. Therefore, these drugs are considered broad-spectrum but only for a 
range of aerobic bacteria. Although these antibiotics are known to be toxic to humans and can 
cause hearing loss, they are considered first line treatments for respiratory infections in cystic 
fibrosis patients26. They are also used to treat multiple-drug resistant (MDR) infections, often 
as part of combination therapy with beta-lactams, since these classes of antibiotics have a 
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synergistic effect when used together26. Aminoglycoside resistance is mediated by ribosomal 
mutations, enzymes that modify the antibiotic, or enzymes that modify the target27. 
Chloramphenicol, an amphenicol, is considered a broad-spectrum antibiotic and interacts 
with the 23S rRNA of the 50S ribosomal subunit, preventing protein synthesis24. It is a first line 
option for eye infections such as conjunctivitis, which can be caused by bacteria including 
Haemophilus influenzae, Streptococcus pneumoniae and Moraxella catarrhalis28. 
Chloramphenicol resistance is mediated by ribosomal mutations or chloramphenicol-
modifying enzymes. It can also be due to efflux-mediated resistance29. Mutations in 
components of efflux systems can increase the affinity for certain molecules including 
antibiotics, resulting in increased resistance29. 
Beta-lactams are a diverse group of antibiotics with several sub-classes. This includes 
penicillins, cephalosporins, carbapenems and monobactams. Beta-lactam antibiotics have a 
chemical structure that is similar to that of D-Alanyl-D-Alanine (D-Ala-D-Ala), a ‘building block’ 
of bacterial cell walls30. This means the beta-lactams can interact with the enzymes that 
catalyse the cell wall synthesis, preventing proper cell wall synthesis and resulting in osmotic 
instability and bacterial cell death30. The different sub-classes of beta-lactams are categorised 
by the modification to the standard beta-lactam structure that defines that particular group. 
Penicillins and 1st generation cephalosporins are on the Access list of antibiotics. Both these 
sub-classes of beta-lactam are typically considered narrow spectrum. However, the spectrum 
varies from drug to drug: for example, amoxicillin is considered broad-spectrum or extended-
spectrum compared to the original penicillin31. Penicillins, especially amoxicillin, are the first 
line drug of choice for common bacterial infections, such as dental, ear, respiratory and throat 
infections32, hence their position as the most used drugs in the world33. Genes that encode 
beta-lactamase enzymes, which degrade beta-lactam antibiotics, are some of the most 
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common antibiotic resistance genes (ARGs): over 1000 different beta-lactamase genes are 
described29. Beta-lactams can be given alongside a beta-lactamase inhibitor, such as 
amoxicillin with clavulanate, to prevent a beta-lactamase enzyme from functioning properly24. 
This combination increases the efficiency of the amoxicillin. First generation cephalosporins, 
such as cefalexin and cefazolin, have often been used as second-line options as an alternative 
to penicillin, in the case of resistance or allergies21. Beta-lactam resistance can also be 
mediated by mutations or modifications in the antibiotic target (penicillin-binding proteins 
(PBPs) in the cell wall) or in porins, which allow the beta-lactam antibiotics to enter the cell29. 
The folic acid metabolism inhibitor combination of sulphamethoxazole and trimethoprim is 
active against many different bacterial infections24. Bacteria must synthesise de novo folates 
that can act as cofactors for various other biosynthetic pathways; without these cofactors 
their growth is inhibited34. Sulphonamides, such as sulphamethoxazole, and trimethoprim, a 
diaminopyrimidine antibiotic, inhibit enzymes involved in different stages of the folic acid 
biosynthetic pathway and thus this combination is considered synergistic24. It is a common 
first-line treatment for infections including urinary tract infections (UTIs), traveller’s 
diarrhoea, methicillin-resistant Staphylococcus aureus (MRSA) skin infections, respiratory 
tract infections, and cholera35. Resistance to trimethoprim is mediated by mutations that 
increase the expression of trimethoprim targets so that the antibiotic is outnumbered and its 
effect limited29. Mutations that alter the targets themselves or the acquisition of genes that 
encode less sensitive targets are also known to result in trimethoprim resistance29. 
Sulphonamide resistance is common and mainly due to plasmid-borne genes encoding 
alternative enzymes that are less sensitive to the antibiotic36. This is a method of horizontal 
gene transfer (HGT): the movement of genes between bacterial cells that bypasses vertical 
transmission. 
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The nitroimidazole, metronidazole, inhibits DNA synthesis and causes DNA damage in 
anaerobic bacterial cells35. Strict aerobic bacteria lack electron-transport proteins with 
sufficient negative redox potential to activate the prodrug form once it is inside the cell, thus 
metronidazole has the opposite spectrum to aminoglycosides37. It is the first-line option for 
infections caused by anaerobic bacteria, such as dental abscesses (e.g. by Prevotella or 
Streptococcus)38 or bacterial vaginosis caused by Gardnerella vaginalis37. Resistance is 
mediated by decreased uptake or altered reduction efficiency (that also leads to decreased 
uptake)37. Efflux and drug inactivation are also possible, as is the acquisition of nim genes from 
other bacteria via HGT. These nim genes encode alternative reductase enzymes to convert the 
prodrug into a non-toxic alternative37. 
The nitrofuran, nitrofurantoin, has multiple antibacterial properties – none of which are fully 
understood yet39. Like nitroimidazoles, it is a prodrug, and is activated inside the bacterial cell 
by the action of nitroreductases39. The intermediate metabolites produced bind to bacterial 
ribosomes and enzymes involved in DNA and RNA synthesis, plus other metabolic processes39. 
It is broad-spectrum with activity against both Gram-negatives and Gram-positives, though 
some Klebsiella and Pseudomonas species are intrinsically resistant39, and it is a first-line 
treatment for uncomplicated, lower UTIs39. Resistance is thought to be mediated by mutations 
in nitroreductases39. 
Tetracyclines such as doxycycline are another type of protein synthesis inhibitor that act upon 
conserved sections of the 16S rRNA in the 30S subunit, preventing translation24. It has broad 
spectrum and is commonly used to treat sexually transmitted infections (STIs), Lyme disease, 
skin infections and MRSA40. Resistance is mediated by tetracycline-specific efflux pumps or 
target-protection proteins that dislodge tetracycline when it is bound to the ribosome29. 
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1.3.2 Watch antibiotics: first or second line of defence with high resistance potential 
Watch antibiotics have higher resistance potential and may be of broader spectrum21. These 
antibiotics are also featured on the Highest Priority Critically Important Antimicrobials (CIA) 
list41, which is intended to ensure that these antibiotics are prioritised for stewardship 
strategies and used prudently. 
Piperacillin with tazobactam is another penicillin/beta-lactamase inhibitor combination, as 
described earlier. Pseudomonas aeruginosa is an opportunistic, Gram-negative pathogen that 
can cause infections in humans, but is intrinsically resistant to penicillin antibiotics caused by 
the production of a beta-lactamase enzyme42. Piperacillin with tazobactam has anti-
pseudomonal activity and therefore is a common option for the treatment of P. aeruginosa 
infections. This bacterium has become a major contributor to infections that are hospital-
acquired and/or in immunocompromised or critically ill patients43. It is important then that 
antibiotics capable of treating these infections are only used when appropriate to limit the 
development of resistance and conserve their utility. 
There are two other sub-classes of beta-lactams that are on the Watch list: third generation 
cephalosporins and penems. Third generation cephalosporins have a specific type of 
modification to the basic beta-lactam structure that increases their specificity to binding cell 
wall proteins44. They have a broader spectrum than previous generations, although again it 
varies between drugs. For example, cefotaxime and ceftizoxime have the best Gram-positive 
coverage of third generation cephalosporins44, though they are typically used to treat Gram-
negative infections in hospitals associated with meningitis and sepsis44. Penems, including 
carbapenems, have the broadest spectrum of activity of the beta-lactams and are relatively 
resistant to most types of beta-lactamases45; hence why they are often used to treat beta-
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lactam resistant or MDR infections45. Carbapenem resistance can be conferred by single 
nucleotide polymorphisms (SNPs) that affect PBPs in the cell wall46 or in the porin that enables 
carbapenem import into the cell46, or by increased activity of efflux pumps46. The most 
clinically important cause of carbapenem resistance is carbapenemases enzymes29. 
Fluoroquinolone antibiotics, such as ciprofloxacin, are highly active against both Gram-
negatives and Gram-positives47. Newer fluoroquinolones in particular, such as moxifloxacin, 
have very broad spectrums of activity, including against anaerobes47. They work by inhibiting 
DNA gyrase, an enzyme involved in DNA replication and transcription24. Fluoroquinolones are 
very commonly prescribed drugs, including for ear, gastrointestinal (GI) and respiratory 
infections and UTIs47. Resistance is commonly mediated by mutations in the target enzymes, 
as well as over-expression of efflux pumps and production of Qnr, a protein encoded by 
plasmids that competes for the fluoroquinolone binding site29. 
Glycopeptides are similar to beta-lactams in that they inhibit cell wall synthesis, however they 
do this by binding to the D-Ala-D-Ala molecules rather than the enzymes that process 
synthesis24. These antibiotics target Gram-positive organisms only; due to their size, they are 
typically unable to cross the outer membrane (OM) of Gram-negatives48. Teicoplanin is more 
potent than vancomycin, but both are crucial antibiotics used to treat infections caused by 
Gram-positive bacteria such as Enterococcus or Clostridioides difficile48. Resistance to 
vancomycin is mediated by the acquisition of a van gene cluster, which act to replace the final 
D-Alanine in the cell wall molecules with D-lactate or D-serine, preventing vancomycin 
binding29. The normal D-Ala-D-Ala molecules are also destroyed by the function of the van 
gene operon29. 
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Lincosamides, such as clindamycin, and macrolides, such as azithromycin, have similar 
mechanisms of action. They inhibit translocation, an early stage in protein synthesis, by 
targeting the conserved sequences of the 23S rRNA in the 50S ribosomal subunit24. 
Lincosamides target Gram-positives and anaerobes, but typically not Gram-negative or strictly 
aerobic organisms49. They are often used to treat head, neck, respiratory, bone, soft tissue, 
abdominal, and pelvic infections50. Macrolides have a similar broad spectrum of activity, plus 
some Gram-negative aerobes or facultative anaerobes, but Enterobacteriaceae tend to be 
resistant due to having relatively impermeable cell walls51. They are also used for respiratory 
tract, skin and soft tissue infections51. Resistance to lincosamides and macrolides can be 
mediated by mutations in the ribosome, modifications of the ribosome (e.g. methylation), or 
by efflux pumps29. 
 
1.3.3 Reserve antibiotics: last resort 
Reserve antibiotics are those that should only be used as a last resort; that is, in the case of a 
serious or life-threatening multi-drug resistant infection that is not responding to first or 
second line treatments41.  
There are three types of beta-lactam included on the reserve list: fourth and fifth generation 
cephalosporins and monobactams. Fourth and fifth generation cephalosporins have a 
broader spectrum of, and higher, activity52 and are more resistant to extended-spectrum beta-
lactamases53 than previous generation cephalosporins. The fifth generation cephalosporin 
ceftaroline also has activity against Methicillin-Resistant Staphylococcus aureus (MRSA) and is 
now a vital drug in the treatment of MRSA infections54. In contrast, monobactams such as 
aztreonam have a narrow spectrum and are only active against Gram-negatives capable of 
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aerobic respiration, including P. aeruginosa55. These synthetic antibiotics are highly resistant 
to beta-lactamases and are used to treat multi-drug resistant Gram-negative infections55. 
However, there are certain beta-lactamases, such as TEM-3, that are capable of degrading 
aztreonam29.  
Daptomycin is a synthetic cyclic lipopeptide antibiotic first reported in 200256 with a unique 
mechanism of action. It inserts into the bacterial cytoplasmic membrane, where it disrupts 
the membrane functional integrity to trigger the release of intracellular ions and cause rapid 
cell death57. It has antibiotic activity against Gram-positive bacteria, such as vancomycin-
resistant enterococci (VRE), MRSA and penicillin-resistant streptococci – for which there are 
few alternative treatments57. Daptomycin resistance is complicated but thought to be 
mediated by mutations in genes that alter the target or the entry of daptomycin into the 
cytoplasmic membrane58. Daptomycin-degrading enzymes exist in environmental bacteria but 
are not currently considered clinically relevant59. 
Fosfomycin (a simple form of phosphonic acid) was discovered from Streptomyces in 1969 
and is unique in its mechanism of inhibiting the first step in bacterial cell wall synthesis60. It is 
active against both Gram-negative and Gram-positive bacteria and though it was uncommonly 
used for several decades, in recent years it has been revived to treat antibiotic-resistant UTIs60. 
UTIs account for a significant burden of hospital admissions and are increasingly resistant to 
first or second line antibiotics61, and so reserving fosfomycin for use only when absolutely 
necessary is vital to continue treating these cases. Fosfomycin resistance is rare as there 
appears to be an associated fitness cost, but mutations in murA, the gene encoding the protein 
that initiates cell wall synthesis, can occur62. In addition, mutations that alter membrane 
transporters can prevent fosfomycin entering the cell, and bacteria can acquire plasmid-
encoded genes that inactivate the drug62. 
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Tigecycline is the first of the synthetic class of glycylcycline antibiotics, developed in the 
2000s63. Glycylcyclines feature a modified tetracycline structure; tetracycline resistance is 
now rife since this antibiotic is relatively old and very widely-used64. The glycylcycline 
structure binds to the bacterial 30S ribosome, blocking tRNA entry and preventing protein 
synthesis63. Tigecycline is broad spectrum, including activity against drug-resistant Gram-
positive infections and even some resistant to tetracycline, despite any presence of 
tetracycline-specific resistance mechanisms65. However, efflux pumps involved in MDR and 
point mutations can sometimes cause tigecycline resistance29. 
The oxazolidinone linezolid is another synthetic antibiotic, from the late 1980s, which 
interferes with protein synthesis in two separate stages: by binding the 23S rRNA in the 50S 
ribosomal subunit and by interacting with tRNAs to prevent protein synthesis initiation66. Like 
daptomycin, it is used to treat antibiotic-resistant Gram-positive infections such as VRE and 
MRSA but also has activity against Gram-negative anaerobes67. Gram-negative aerobic or 
facultative anaerobic bacteria can contain efflux pumps that are able to pump out linezolid 
and resist its action67. Resistance is also mediated by ribosomal mutations29. 
Polymyxins are non-ribosomal cyclic lipopeptides, originally discovered in 1947 during “the 
golden age of antibiotic discovery” before falling out of use due to nephrotoxicity. They have 
been revisited more recently due to the increasing cases of MDR infections68. Polymyxins bind 
to the lipopolysaccharide in the OM of Gram-negative bacteria, causing outer and 
subsequently inner membrane destabilisation68. They are also reported to induce osmotic 
imbalance and oxidative stress, resulting in cell lysis68. Polymyxins are not susceptible to the 
activity of efflux pumps24, hence why they are such good options to selectively treat serious 
Gram-negative aerobic or facultative anaerobic infections that are resistant to other 
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antibiotics69. Colistin resistance is mediated by chromosomal mutations or acquisition of 
genes that alter the lipopolysaccharide27. 
From this information discussed so far, we can make two important conclusions: firstly, beta-
lactam antibiotics feature in all three categories of antibiotics, encompass a large number of 
drugs, are among the oldest clinically-used antibiotics and are still the most prescribed drugs 
in the world. This underlines their critical importance in modern human medicine. Secondly, 
that resistance to all these clinically relevant antibiotics among bacterial pathogens has 
emerged5, including to last resort antibiotics. This means that cases are arising where an 
infection cannot be treated with any available antibiotics – sometimes resulting in the 
patient’s death70. For example, a woman died in the United States in 2017 following a 
carbapenem-resistant Enterobacteriaceae infection: the strain of K. pneumoniae she was 
infected with was resistant to 26 antibiotics available in the country at the time70. This 
highlights the increasing severity of antibiotic resistance. 
 
1.4 Bacterial genetics and antibiotic resistance 
There are three main ways in which bacteria can be resistant to antibiotics that are explained 
by their genetics: intrinsic resistance, where the bacteria are naturally resistant; DNA 
mutations, where mutations in the genome lead to increased resistance; and antibiotic 
resistance genes, where entire genes can explain increased resistance. These will now each 
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1.4.1 Intrinsic resistance 
There are a number of biological differences between bacteria that mean not all antibiotics 
are effective against all bacteria; this natural resistance is also described as intrinsic resistance. 
For example, Gram-negative bacteria have an OM, which Gram-positives do not possess71. 
The OM prevents access of glycopeptide antibiotics such as vancomycin to Gram-negative 
bacteria such as Proteobacteria71. Moreover, metabolic differences (e.g. aerobic versus 
anaerobic) can explain intrinsic resistance. For example, efflux pumps, that can pump out 
antibiotics from bacterial cells, are common in aerobic and facultatively anaerobic bacteria 
such as Proteobacteria29. As they require oxygen and active transport to function, they are 
uncommon in anaerobic bacteria. The decision of which antibiotic to prescribe must take 
these differences into consideration, along with a number of other factors relating to the 
disease-causing bacterium, the antibiotic and the patient. However, these intrinsic resistances 
are not involved in the development or spread of antibiotic resistance as they occur naturally; 
instead, these processes are caused by changes in the bacterial genome72. 
 
1.4.2 DNA mutations 
One key way in which antibiotic resistance can develop is by changes in the DNA sequence, or 
mutations. Mutations occur naturally: when cells replicate and divide, DNA must also be 
replicated, but the process is not error-free73. If incorrect nucleotides are incorporated into 
the new DNA strand being synthesised, this could have an impact on the function of that 
particular DNA sequence. For example, a bacterial cell with a mutation in a gene that encodes 
the target of an antibiotic may have a reduced affinity for how the antibiotic binds to said 
target72. In the presence of that antibiotic, that cell is less likely to be killed by the antibiotic 
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and can divide to produce more cells featuring the same DNA mutation. In this way, a more 
resistant strain can replace and take over the previous population of bacterial cells; thus, 
antibiotics select for bacteria that are more tolerant of or resistant to the antibiotic being 
used. The problem is magnified when we consider the short generation times of bacteria: E. 
coli can divide in approximately 20 minutes, leading to millions of cells in a matter of hours74. 
This allows antibiotic-resistant bacteria to be selected for in a short time period and also for 
mutations to accumulate and potentially become fixed in the population73. Mutations can 
impact antibiotic resistance in several ways: they can alter the target of the antibiotic so that 
the two can no longer interact; they can alter an efflux pump to have increased activity and 
reduce the concentration of antibiotic in the cell; they can increase the amount of the target 
protein in the bacterial cell so the impact of the antibiotic is reduced; or increase the 
expression and production of antibiotic-degrading enzymes. Using sufficiently high antibiotic 
dosing regimens can prevent a sub-population of cells with antibiotic resistance-conferring 
mutations from surviving75,76.  
 
1.4.3 Antibiotic resistance genes and horizontal gene transfer 
In addition to DNA mutations, bacteria can harbour antibiotic resistance genes (ARGs): genes 
that encode proteins that are capable of modifying or degrading antibiotics or their targets72. 
One of the most common examples is a beta-lactamase, an enzyme capable of degrading beta-
lactam antibiotics (the class that includes penicillins). There are both different sub-classes of 
beta-lactam antibiotics and beta-lactamase enzymes. Different beta-lactamases can have 
differing levels of activity against sub-classes of beta-lactam antibiotics25. This means that 
beta-lactam antibiotics belonging to a different sub-class (e.g. a cephalosporin) could be used 
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to treat infections that are resistant to penicillin via a penicillin-degrading beta-lactamase. 
Modifying and degrading enzymes exist for different types of antibiotics, as outlined in section 
1.3 and Table 1.2. 
The critical issue with ARGs is that they can be transferred by HGT; there are three main 
processes through which this can take place. Firstly, there is transformation, where bacteria 
that are “competent” can take in DNA from their environment that is self-replicable or is 
incorporated into their genome72. Competence can vary between species and even within a 
single bacterial cell depending on its replication cycle72. Secondly, there is transduction, which 
involves the packing of bacterial DNA into bacteriophages (viruses that infect bacteria)72. 
When the phage infects another bacterium it inserts the bacterial DNA inside it into the new 
host bacterium, where it can be incorporated into the bacterial chromosome72. Thirdly, there 
is conjugation, involving the direct cell-cell contact or bridge-like connections between 
bacteria, allowing for DNA to be transferred from the donor cell to the recipient cell72. 
The movement of ARGs is therefore a major contributing factor to the spread of antibiotic 
resistance. ARGs are not always transferred alone but can reside in mobile genetic elements 
(MGEs)77; regions of DNA that contain more than a single gene and even elements responsible 
for their own replication or movement. Such MGEs include: 
• Integrative and Conjugative Elements (ICEs): also known as conjugative transposons – 
DNA sequences that are integrated into the host bacterial genome and encode their 
own functional conjugation systems 
• Integrons: sections of DNA that easily recombine to capture new DNA 
• Plasmids: self-replicating, circular extra-chromosomal DNA transferred by conjugation 
• Phages: bacterial viruses that can integrate into the host bacterial genome 
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• Transposable elements: transposons and insertion sequences are DNA sequences that 
can move position within a genome 
The conjugative MGEs are especially relevant to the spread of antibiotic resistance as they aid 
the transfer between unrelated bacteria. A single MGE can contain multiple ARGs, meaning 
that a bacterium can acquire resistance to multiple antibiotics at once, even in the absence of 
selective pressure from those antibiotics. Furthermore, not only does antibiotic use introduce 
a selective pressure that selects for mutations conferring antibiotic resistance, but it also 
promotes mutations and HGT78. Antibiotic exposure can induce the SOS DNA damage 
response in bacteria, which arrests the cell cycle and allows any DNA damage to be repaired79. 
SOS-induced DNA damage repair is especially error prone, resulting in an increased mutation 
rate79. In addition, the SOS response is linked to increased rates of conjugative transfer79. 
Thus, antibiotic therapy both promotes and selects for a variety of antibiotic-resistance 
conferring changes in bacterial genomes.  
 
1.5 Antibiotic resistance is a major global issue 
Antibiotic resistance is an ancient strategy used by bacteria to survive competition from other 
microorganisms that produce antibiotics5. It is, therefore, a perfectly natural biological 
occurrence. However, it is problematic when it occurs in clinical isolates of bacterial infections. 
Antibiotic resistance is a global threat to human health that is increasing in both prevalence 
and severity, and is considered one of the most pressing issues of the 21st Century80. Some 
estimates place the mortality rate of drug-resistant infections (DRIs) at 10 million deaths per 
year by 205080. The highest burden of DRIs is in developing countries, where antibiotics are 
becoming increasingly more accessible and are often available without a prescription81. In 
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these countries, proper sanitation (e.g. clean water, basic toilets, good hygiene practises and 
waste disposal) and strict antibiotic guidelines are often lacking82. South-East Asia in particular 
is a global hotspot for emerging infectious diseases due to these reasons, plus small-scale 
animal production and high livestock densities83. As a result, infections are more easily 
transmitted and there is a strong selective pressure for the evolution of resistant bacteria82. 
For example, enteric pathogens isolated from Vietnamese children suffering from Acute 
Watery Diarrhoea (AWD) are often MDR84. The issue is also important in developed countries: 
in the USA, 23,000 people die of DRIs annually85.  
Of particular concern are hospital-acquired infections (HAIs), infections acquired whilst 
receiving other medical treatments that total over 1.7 million cases and almost 99,000 related 
deaths per year86. The leading causes of these are the ESKAPE pathogens: Enterococcus 
faecium, Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter baumannii, 
Pseudomonas aeruginosa and Enterobacter spp.. These contribute significantly to healthcare 
and economic burdens and are often reported as resistant to multiple drugs87. The latter four 
of these (“KAPE”) are all members of the phylum Proteobacteria; of 538 species of bacterial 
pathogens88, 43 % (236) belong to Proteobacteria – the biggest contribution of any phyla (Fig. 
1.3). Antibiotic resistance in pathogenic Proteobacteria is therefore especially relevant and 
understanding the spread of antibiotic resistance, plus discovering alternative or novel 
treatments for MDR pathogenic bacteria, is of high priority89. Indeed, the top three microbial 
infections of critical priority for new treatment R&D according to the World Health 
Organisation (WHO) involve three of the KAPE Proteobacteria pathogens: A. baumannii, P. 
aeruginosa, and Extended-Spectrum Beta-lactamase (ESBL)-producing Enterobacteriaceae 
(and specifically isolates that are resistant to carbapenems)90.  
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Carbapenems are typically reserved for infections that are resistant to multiple other 
antibiotics, including other beta-lactams. As mentioned, beta-lactam antibiotics are some of 
the most commonly used drugs in the world, and beta-lactamases are some of the most 
common and well-studied types of ARGs91. These often exist on MGEs, and have contributed 
significantly to the burden of DRIs. For example, the aminopenicillin amoxicillin is one of the 
Figure 1.3. Proportions of 538 species of bacterial pathogens belonging to particular phyla. The list of bacteria 
species was taken from Taylor 200188 and the phyla they belong to identified with the online NCBI taxon identifier 
tool (https://www.ncbi.nlm.nih.gov/Taxonomy/TaxIdentifier/tax_identifier.cgi). The bacterial pathogens belong 
to nine different phyla, with over 40 % belonging to Proteobacteria and 20 % to Firmicutes. The numbers above 
the phyla names refer to the number of species observed in each phyla to be bacterial pathogens according to 
Taylor 200188. The four coloured phyla highlight the four key phyla of the human gut microbiota. 
 
most prescribed antibiotics globally due to its role as a first-line drug in the treatment of otitis 
media ear infections33. These infections are the most frequent reason doctors in the USA 
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facultatively anaerobic, Proteobacteria E. coli92. Nowadays, up to 95 % of E. coli isolates in 
national collections are resistant to amoxicillin (Fig. 1.4). Although there are a wide range of 
enzymes that confer extended-spectrum beta-lactam resistance93, the highly mobilisable CTX-
M genes are the most common and important types of ESBL due to their ease of dissemination 
and prevalence in human, animal and environmental isolates94. ESBLs were originally defined 
as enzymes that could hydrolyse the beta-lactam ring in most beta-lactam sub-classes except 
carbapenems93. However, some ESBLs, such as OXA-23, OXA-40 and OXA-48, have been 
reported as conferring resistance to carbapenems95. 
 
Figure 1.4. Global aminopenicillin (including amoxicillin) resistance in Escherichia coli. Map created at 
https://resistancemap.cddep.org/ on 02/03/2018. Data curated by the Center for Disease Dynamics, Economics 
and Policy and includes aggregated resistance rates for isolates (includes intermediate resistance) from blood 
and cerebrospinal fluid (i.e., invasive) from inpatients of all ages. Because of differences in scope of collections 
and testing methods, caution should be exercised in comparing across countries. Full data available online: The 
Center for Disease Dynamics Economics & Policy. ResistanceMap: Antibiotic Resistance. 2018. 
https://resistancemap.cddep.org/AntibioticResistance.php. Data accessed: March 02, 2018. 
 
Carbapenem-resistant Enterobacteriaceae (CRE) infections have increased by 3 % in the USA 
between 2001 and 201090 and have high mortality rates of up to 48 %96 due to the limited 
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treatment options. In addition, carbapenem-resistance conferred by mobile carbapenemases 
is especially important clinically due to their specific ability to hydrolyse the beta-lactam ring 
in carbapenems and propensity to spread97. One treatment option in these cases is colistin, 
but even resistance to this drug is rapidly spreading. It was previously thought that colistin 
resistance only involved chromosomal DNA mutations98. However, the first plasmid-mediated 
colistin resistance gene mcr-1 was identified in 201599. MCR-1 is an enzyme that modifies the 
colistin target and thus reduces the drug-target interaction, first discovered in E. coli isolates 
from China99. Eight mcr variants have now been identified100, at least two of which are globally 
distributed101. Therefore, treatment options are severely limited and emerging colistin 
resistance in carbapenem-resistant infections is one of the most pressing concerns for global 
health. The emergence and global spread of mobile carbapenemases and mcr genes in clinical 
isolates of pathogenic bacteria highlights the extent and severity of horizontal antibiotic 
resistance gene transfer (HGT). 
 
1.6 Antibiotic misuse and overuse: a One Health problem 
Many antibiotic treatments are unnecessary, unregulated, or do not correctly follow 
guidelines102, leading to increased opportunities for bacteria to develop or spread antibiotic 
resistance. Underdosing is a particular problem, where bacteria are exposed to a 
concentration of antibiotics too low to kill them. This can occur if the concentration required 
to kill the infectious bacterial cells is underestimated, or if the person prescribing, selling or 
purchasing antibiotics is doing so without consulting official guidance. Antibiotics are now 
available over-the-counter, without prescription, in countries across the world, meaning 
someone can choose to self-medicate with antibiotics who may not understand or receive 
instructions on the correct dosage to take. In addition, some people stop taking antibiotics 
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once they start to feel better, instead of finishing the advised course of therapy, which may 
lead to sub-optimal doses of antibiotic that could select for bacterial cells more tolerant to or 
better able to resist the antibiotic75. This ‘underdosing’ phenomenon was even warned about 
by Fleming in his Nobel Prize acceptance speech in 1945103: 
‘It is not difficult to make microbes resistant to penicillin in the laboratory by exposing them 
to concentrations not sufficient to kill them, and the same thing has occasionally happened in 
the body. The time may come when penicillin can be bought by anyone in the shops. Then 
there is the danger that the ignorant man may easily underdose himself and by exposing his 
microbes to non-lethal quantities of the drug make them resistant.’ – Alexander Fleming, 
1945. 
However, there is uncertainty over the guidelines for prescription doses and length of 
treatments and how important it is to adhere to these rules75. Indeed, there is evidence that 
taking antibiotics for longer is more likely to result in increased resistance than shorter 
treatment durations75,104. Clinical trials investigating end points such as fever resolution105 as 
a guide for when to stop antibiotic treatment are recommended to better understand and 
develop antibiotic prescribing guidelines that reduce the risk of bacteria developing 
resistance. 
The overuse of antibiotics is also problematic – for example in the USA, up to 50 % of antibiotic 
use is reportedly unnecessary106. Reasons for overuse include: prescribing antibiotic therapy 
despite lack of evidence of bacterial infection or suspected non-bacterial infection; lack of 
prescription required to obtain antibiotics; easy access to antibiotics (e.g. over-the-
counter)107. The contribution of these issues varies from country-to-country, leading to 
variable rates of antibiotic use between nations. Antibiotic use can be measured in defined 
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daily doses (DDD), which represents assumed average maintenance dose per day for a drug 
used for its main indication in adults108. For example, the DDD for amoxicillin administered 
orally is 1.5 g per day109. DDD can be compared across a number of factors such as inpatients 
in a hospital, or population per country, e.g. DDD per 1000 people per day. In the UK 
antibiotics can only legally be obtained with a prescription from a licensed medical 
practitioner, and there are national campaigns to reduce the unnecessary or inappropriate 
use of antibiotics. In 2015, the UK had a total 8696 DDDs per 1000 people per day across all 
antibiotics measured (Fig. 1.5) – this is equivalent to 8.696 DDDs of antibiotics per person per 
day.  
In contrast, Turkey is one of the heaviest users of antibiotics in the world110, and had 18,095 
DDDs per 1000 people per day (18.095 DDDs of antibiotics per person per day). The reasons 
for such high usage are much the same as already described: poor medical education 
regarding antibiotics, pharmaceutical industry pressure and promotions, and lack of antibiotic 
policy or guidelines111. Thankfully Turkey, and most other countries, have brought in measures 
to reduce the overuse and misuse of antibiotics112. These measures, such as national 
campaigns to increase awareness and understanding of antibiotic resistance or more strictly 
regulate antibiotic use, are known as antibiotic stewardship113. This stewardship is designed 
to limit the development and spread of antibiotic resistance113 and therefore conserve our 
antibiotics and prolong their lifespan as much as possible. Despite this, antibiotic use has 
generally increased over the last fifteen years (Fig. 1.5) and broad-spectrum penicillins such 
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Figure 1.5. Usage of antibiotics in the United Kingdom and Turkey. The UK is the location of the current study 
and Turkey has the highest use of antibiotics of any country. Antibiotic use data are shown in defined daily doses 
(DDD) per 1,000 individuals (population, pop) per day. The Center for Disease Dynamics Economics & Policy. 
ResistanceMap: Antibiotic Use 2018. https://resistancemap.cddep.org/AntibioticUse.php. Date accessed: 
01/03/2018. 
 
However, it is not just antibiotic use in people that contributes to the problem of antibiotic 
resistance. It is a One Health problem, linking human health to the health of animals and the 
environment, where ensuring optimal health for all these components requires a collaborative 
effort across scientific disciplines and geography (e.g. locally, nationally, internationally and 
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and the presence of antibiotic resistance – in animals and the environment, alongside humans. 
For example, antibiotic use in agricultural animals is widespread18,113,115. Whilst often for 
medical purposes, antibiotics are also commonly misused in agriculture as growth 
promoters116 – the exact mechanism is not well understood, but antibiotics are thought to 
reduce the amount of bacteria in the gut microbiome of livestock animals, reducing 
competition for energy derived from the animal’s feed116. The doses used for these “medically 
unnecessary” purposes is typically not controlled115 and so animals can receive sub-inhibitory 
concentrations117, creating conditions that select for antibiotic-resistant bacteria.  
Clinical cases of antibiotic-resistant infections have been acquired from agricultural animals: 
for example, drug resistant Salmonella infections from poultry date back to the 1960s118. This 
“farm-to-fork” hypothesis proposes that livestock carry antibiotic-resistant bacteria that 
spread to humans through e.g. direct contact or contaminated animal products99,119. If these 
resistant bacteria enter a human’s GI tract, they may potentially cause an infection requiring 
antibiotic treatment, where the first-line drug of choice may not work. In addition, several 
important ARGs were first identified in animal associated bacterial strains and have since 
spread to human-associated strains – including the mcr-1 colistin resistance gene in colistin-
resistant E. coli from pigs99. Therefore, antibiotic use in agricultural animals should also be 
monitored and reduced to what is only necessary for proper veterinary medicine. In some 
countries, such as Sweden, Denmark, the Netherlands and the UK, the use of antibiotics as 
growth promoters in agriculture is banned115. However, other countries (for example, China) 
continue to use antibiotics critical to human medicine – including the last-resort antibiotic 
colistin – for this purpose113. Clearly, there is still work to be done in reducing the unnecessary 
use of antibiotics in both humans and animals. 
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Since antibiotic resistance is a natural phenomenon, antibiotic-resistant bacteria are found in 
the environment. However, humans have increased the selective pressure on environmental 
bacteria to promote the development or spread of antibiotic resistance. This can be linked to 
agricultural use of antibiotics: faeces from livestock may contain antibiotic-resistant bacteria 
or antibiotic compounds themselves. Areas exposed to agricultural run-off can therefore 
contain concentrations of antibiotics that promote the development of antibiotic resistance 
in bacteria that should not have received antibiotic exposure117. Again, these may cause 
antibiotic-resistant infections – if someone ingests vegetables grown in contaminated 
soil99,119, for example. Additionally, hospital waste can contaminate local water sources with 
antibiotics or antibiotic-resistant bacteria120,121 – if someone went swimming in this water, 
they may also acquire an antibiotic-resistant infection122. Environments containing antibiotic-
resistant bacteria and ARGs – which could be harboured by pathogenic and non-pathogenic, 
environmental bacteria that do not typically cause disease – are referred to as reservoirs of 
antibiotic resistance. In reservoirs of antibiotic resistance, it is possible that ARGs can move 
between diverse and multiple bacteria via HGT. Since HGT has contributed to the global 
dissemination of antibiotic resistance, it is important to understand its mechanisms and the 
environments in which it occurs. For example – where do pathogenic bacteria acquire ARGs 
from, and what other bacteria do they donate ARGs to? 
 
1.7 The gut microbiome as a reservoir of antibiotic resistance  
The gut microbiome, the complement of commensal microorganisms and their genes that live 
in the GI tract, was first proposed as a reservoir for antibiotic resistance in 2004123. The 
intestinal microbiota refers specifically to the microorganisms, including bacteria that reside 
within the GI tract. They make up part of the total human microbiome, along with the skin 
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microbiome, vaginal microbiome, and microbiomes of other organs and tissues. Humans first 
become colonised by microbiota during birth, for example from the vagina and faeces if born 
via the birth canal. Caesarean-born babies are less exposed to these sources of bacteria and 
are more likely to first be colonised by through skin-skin contact and contact with the 
environment124. We continue to be colonised as we age, from our diets and our environments, 
and our microbiome matures from its initial form into a mature, relatively stable state124. In 
the healthy adult, there is estimated to be approximately 300 species of commensals in the 
GI tract125, of which the majority and most abundant belong to the Firmicutes and 
Bacteroidetes respectively126. Proteobacteria and Actinobacteria are two other common 
intestinal microbiota phyla, though typically less abundant and diverse in the gut microbiome 
than Bacteroidetes and Firmicutes126. These phyla vary in their respiration physiology: 
Actinobacteria are typically considered aerobic, with two genera described as anaerobic or 
facultatively anaerobic127; Bacteroidetes are typically considered anaerobic, though two 
families are thought to be strict aerobes128; Firmicutes includes taxa described as aerobic and 
others described as anaerobic; Proteobacteria are described as facultative anaerobes129. Since 
the gut contains a very low concentration of oxygen and is generally considered an anaerobic 
environment, most gut bacteria taxa are adapted to these conditions and are considered 
strictly anaerobic130. Facultatively anaerobic or microaerophilic bacteria are much less 
abundant in the gut than strict anaerobes130. 
Our intestinal microbiota are very important to our health: they help train our immune 
system131, digest food and produce energy, metabolise waste products, and protect from 
certain diseases132. One particular example is providing colonisation resistance against 
bacterial infections such as C. difficile133; the gut microbiota can prevent this pathogen from 
colonising the gut and producing toxins which causes severe diarrhoea in 
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immunocompromised patients. Unfortunately antibiotic use, to treat or prevent bacterial 
infections including C. difficile, can also negatively affect our gut microbiota. This is because 
antibiotics, especially those considered broad-spectrum and delivered orally, can have a direct 
impact on our indigenous gut microbiota. This impact may vary at different life stages: for 
example, in a new-born baby to prevent infection, antibiotics can disrupt the normal 
colonisation process134. This is associated with the later development of immunological 
conditions such as asthma134. As an adult, antibiotic therapy can alter the colonisation 
resistance of the gut microbiota and leave the person at risk of a C. difficile infection135.  
We are exposed to antibiotics throughout our lives: during birth to prevent infection; during 
childhood to treat common infections such as ear or throat infections; more rarely in 
adulthood (perhaps for a wisdom tooth infection or a more severe but relatively rare infection 
such as bacterial meningitis); to prevent infection during labour, in immunocompromised 
Intensive Care Unit patients or the elderly, amongst others. Due to the use and overuse of 
orally-administered broad-spectrum antibiotics, our gut microbiota are also often under 
selective pressure to evolve antibiotic resistance136. There is a strong positive correlation 
between antibiotic consumption and proportions of antibiotic resistant bacteria and antibiotic 
resistance gene abundance in gut microbiomes137: for example, southern Europe consumes 
more antibiotics than Denmark and accordingly human faecal samples from Denmark have 
lower carriage of antibiotic resistance genes than samples from Spain or France137. In addition, 
due to the density and diversity of commensal bacteria, the potential for exposure to food-
borne pathogens such as members of Enterobacteriaceae is high. It is possible transient 
intestinal pathogens transfer ARGs to the resident gut microbiota, rendering these ARGs 
theoretically accessible to any other pathogen that passes through123, or vice versa. As just 
one example, conjugation events of plasmids carrying antibiotic resistance genes between 
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commensal E. coli and pathogenic Salmonella can occur138. Therefore, not only can gut 
microbiota acquire ARGs from pathogens, but they also harbour their own ARGs that can be 
transferred to other bacteria123.  
Indeed, many studies have identified the presence of ARGs in commensal gut bacteria137,139-
144 including genes with over 90% similarity to known ARG sequences from pathogenic 
bacteria in human stool and saliva samples139. Even in healthy infants under one month of age 
who had not been treated with antibiotics, ARGs conferring resistance to up to 14 antibiotics 
have been identified141. Tetracycline genes, such as tetO, tetQ and tetW, are particularly 
prevalent in gut microbiome samples collected from across the world139,142; this is thought to 
be due to the historical high usage of tetracycline in agriculture (now banned in the EU and 
USA)137 and therefore associated with the farm-to-fork hypothesis. Macrolide and 
sulphonamide resistance genes (e.g. ermB and sul2 respectively) are also reportedly common 
in gut microbiomes137,141,142; macrolides have also been used as agricultural growth 
promoters137, whereas sulphonamides are very old types of antibiotics and so selective 
pressure for sulphonamide resistance in the gut has existed for a comparatively long period 
of time137. Clearly then, antibiotic resistance can occur in the gut even in the absence of 
antibiotic treatment, although antibiotic usage is associated with increase abundance or 
diversity of resistance genes and mutations. 
Moreover, gut bacteria have been found to contain novel ARGs that have not previously been 
detected in pathogenic bacteria139,144. For example, ten novel beta-lactamase genes with 
between 35 and 61 % similarity to known beta-lactamases at the time were identified from 
human stool and saliva139,144. More recently, novel beta-lactamases have been detected in 
sewage sludge containing human faecal matter145, including one found on a mobile element 
that is considered likely to be highly mobilisable between bacteria145. Thus, despite the 
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increasing evidence that the human gut microbiome harbours diverse ARGs, it is unlikely we 
have discovered all ARGs or mutations that cause antibiotic resistance. In addition, with 
studies typically focussing on Western or industrialised communities, antibiotic resistance in 
other communities is less well understood. Finally, since gut microbiome studies have often 
depended on culture-independent techniques, rare or lowly abundant members of the gut 
microbiota are less well studied than more abundant bacteria. As a result, the incidence, 
distribution and dissemination of ARGs within the gut microbiota is still not fully understood.  
 
1.8 Studying antibiotic resistance in bacteria  
Studying antibiotic resistance involves determining the sensitivity of particular bacterial taxa 
(e.g. isolate, strain, species, genus, family, order, class and phylum) to an antibiotic. This can 
involve measuring the physical response through culture and phenotyping an isolate-
antibiotic combination, or studying the presence and prevalence of antibiotic resistance-
conferring mutations or genes (genetic determinants of antibiotic resistance) in bacterial 
genomes or metagenomes. How these methods have been used to study antibiotic resistance, 
particularly in gut microbiota, will now be discussed in turn. 
 
1.8.1 Phenotyping 
Microbiology has its foundations in culturing bacteria and studying their physical 
characteristics (i.e., phenotypes). Pathogenic bacteria have come under much scrutiny 
because of their propensity to cause disease. As described earlier, the majority of clinical 
pathogens tend to be Gram-negative, facultatively anaerobic bacteria that are amenable to 
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culture, allowing their antibiotic resistance phenotypes to be measured and recorded on a 
large scale. This has resulted in huge quantities of data being collected regarding the variation 
in antibiotic resistance and susceptibility to various antibiotics in common pathogenic 
bacteria. This data can be used to can define cut off points of susceptibility or resistance, such 
as those by the European Committee on Antibiotic Susceptibility Testing (EUCAST), the Clinical 
Laboratory Standards Institute (CLSI) or the British Society of Antimicrobial Chemotherapy 
(BSAC). These consider bacteria as resistant if they require over a certain concentration of 
antibiotic to be killed, and bacteria that are killed with lower concentrations are considered 
susceptible. For example, the EUCAST guidelines (version 7.1, valid from March 2017) list the 
amoxicillin breakpoint MIC for Enterobacteriaceae as 8 mg/L: Enterobacteriaceae isolates 
with an amoxicillin MIC equal to or less than 8 mg/L are considered susceptible and those with 
MICs over 8 mg/L are considered resistant. This type of data also allows for antibiotic 
resistance over time and space and between related isolates to be monitored. This is critical 
for prescribing practices – if there is an increasing trend in resistance to an antibiotic by a 
bacterial pathogen in a particular area, then the local doctors can include this in their 
consideration when choosing which antibiotics to prescribe.  
The situation is very different for bacteria that are typically considered non-pathogenic, such 
as gut bacteria, which until recently have been comparatively under-studied. Due to their 
adaption to conditions in the gut, including the requirement for anaerobic conditions146, they 
have also been hard to culture and study physically. The spectrum of antibiotics is therefore 
often only based upon the testing of Gram-negative, facultatively anaerobic or aerobic 
pathogens plus a select few Gram-positive or anaerobic species147, such as Enterococcus 
faecalis or Bacteroides fragilis (both opportunistic pathogens)147. Therefore, antibiotic 
breakpoints of resistance/susceptibility in commensal gut bacteria are not defined. Moreover, 
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it means we do not fully understand the impact of different antibiotics across the diversity of 
our gut microbiota. However, since gut bacteria can sometimes act as opportunistic 
pathogens (like B. fragilis, a common cause of post-operative infections148) and in combination 
with their role as an ARG reservoir, it is important to understand their variation in antibiotic 
sensitivity. In particular, it would be useful to know which antibiotics might be useful for 
treating infections caused by opportunistic pathogenesis by our commensal gut bacteria, 
which antibiotics we should avoid if we wish to limit harm to out gut microbiota, and what 
types of antibiotic resistance these organisms might contribute to spreading. Fortunately, 
with recent developments in culturing of gut bacteria146,149-151, we can now culture over 90 % 
of species of gut bacteria found in an individual146. This offers an exciting opportunity to 
investigate phenotypic antibiotic resistance in gut bacteria at an unprecedented scale. 
 
1.8.2 Genome sequencing 
In addition to phenotypic antibiotic resistance, antibiotic resistance genotypes can also be 
studied. Genomic-based predictions of resistance is typically relied upon for the surveillance 
of antibiotic resistance in non-pathogenic bacteria, including intestinal microbiota152. 
Databases and tools designed for this purpose (summarised in Table 1.3) have been used to 
study antibiotic resistance genotypes of whole genomes, either from raw sequence reads or 
assembled contigs. These types of methods have become popular for monitoring or tracking 
antibiotic resistance genes in bacterial isolates over time and/or space. This is largely used for 
clinical isolates to see trends in increasing or more widespread antibiotic resistance; such as 
the Global Pneumococcus Project studying 20,000 isolates of Streptococcus pneumoniae that 
found resistance genotypes for five antibiotics of different classes were strongly associated 
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with the country of isolation153. Relatively few studies of this type have been performed in gut 
microbiota, due to a proportionate lack of multiple cultured isolates and thus whole genomes 
for a particular species: for example, a study of the genus Bifidobacterium, a dominant 
component of the early-life microbiome, assessed ten classes of antibiotic resistance 
genotypes and phenotypes of 91 isolates from 54 subspecies154. 
In addition, these described tools have been used in combination with whole genome shotgun 
metagenomics (sequencing all the DNA in a sample) to study the resistome155 (the collection 
of antibiotic resistance genes, mutations and their precursors) in diverse microbiome 
environments – such as soils, wastewater or sludge, smog and sediments156. These whole 
genome shotgun metagenomic studies have demonstrated that antibiotic resistance genes 
are widespread throughout natural and human-associated environments156. However, the 
databases are often based upon knowledge from clinically relevant pathogens – which as 
demonstrated earlier in Figure 1.2 are predominantly Gram-negative, facultatively anaerobic 
Proteobacteria. Since the majority of commensal gut bacteria are strictly anaerobic Gram-
positives126,157, they are distantly related to clinically relevant pathogens and may harbour 
currently unknown antibiotic resistances139. These have the potential to become clinically 
relevant either through direct opportunistic pathogenesis of commensal species158 or through 
the transfer of ARGs to pathogens152.  
  
Table 1.3. Summary of databases and tools for predicting antibiotic resistance genotypes from sequence data. A brief summary of each database and/or tool is provided alongside 
an overview of the advantages and disadvantages. 
Resource Type Advantages Disadvantages 
Antibiotic Resistance Database 
(ARDB)159 




• Large number of sequences 
• Extensive metadata 
• Last updated 2009 
• Redundancy 
Antibiotic Resistance Identification 
by Assembly (ARIBA)160 
• Tool • Tool uses sequence reads 
• Detailed, customisable, easily interpretable output 
• Removes redundancy from databases used 
• Can identify resistance mutations including new variants 
• Relies on input databases 
• Not really suited for metagenomic data 
ARG-ANNOT161 • Database • Extensive list of resistance gene sequences combined 
from multiple sources 
• Can be used to identify mutations 
• Redundancy  
• Last updated 2017 
• Data no longer appears to be available on 
website 
Bacterial Antimicrobial Resistance 
Reference Gene Database 
 
• Database of 
antibiotic 
resistance genes 
• Combines data from several sources 
• Regularly updated 
• Redundancy  
• Does not include resistance mutations 
Bush-Jacoby Database162 • Database of 
beta-lactamases 
• Highly curated database of sequences and metadata 
associated with beta-lactamases 
• Website no longer appears to work 
Comprehensive Antibiotic 
Resistance Database (CARD)163,164 
• Database of 
resistance genes 
• Tools to identify 
resistance 
genes/mutations  
• Regularly updated 
• Includes both genes (including all ARDB sequences) and 
mutations 
• Online tool to apply methods and command-line tool 
available 
• Extensive metadata 
• Can account for gene or mutation conferring resistance 
to multiple antibiotics 
• Tool has built in option to look for candidate novel 
resistance genes 
 
• Redundancy  
• Ontology complex 






Type Advantages Disadvantages 
DeepARG165 • Database of 
resistance genes 






• Online and command-line tool 
• Can be applied to sequence reads (e.g. for metagenomic 
samples) and assembled genomes 
• Highly curated database 
• Does not just rely on best-hit 
• Database last updated 2017 
• Does not account for mutations 
Lactamase Engineering Database166 • Database of 
beta-lactamases 
• Highly curated database of sequences and metadata 
associated with beta-lactamases 
• Only two families of beta-lactamases 
included 
• Unsure when last updated, website does not 
appear up to date or completely functional 




• Tool to identify 
resistance genes 
• Simple ontology and metadata 
• Good for population level analysis (e.g. count-based 
analyses in metagenomic samples) 
• Easy to interpret results 
• Tool uses sequence reads 
• Non-redundant 
• Does not include resistance mutations 
• Cannot account for gene or mutation 
conferring resistance to multiple antibiotics 
• Last updated 2016 




• Tool to identify 
mutations 
• Good for chromosomal point mutations 
• Online or command-line tool, can be run together with 
ResFinder 
• Regularly updated 
• Focuses on small range of species and genes 
• Difficult to analyse many samples at once 
ResFams169 • Database of 
profile HMMs of 
resistance genes 
• Combines resistance genes from multiple sources 
• Includes HMMs based on resistance genes identified in 
functional metagenomic screens 
• Can be used to identify candidate novel resistance genes 
• Last updated 2015 
• Mainly intended for use for functional 
metagenomic screens, rather than 







Type Advantages Disadvantages 
ResFinder170 • Curated 
database of 
resistance genes 
• Tool to identify 
resistance genes 
• Regularly updated 
• Online tool, can be run together with Pointfinder 
• Add-on function for functional metagenomic screens 




• Database of 
resistance genes 
• Highly curated database 
• Non-redundant 
• DNA and protein sequences 
• Does not account for mutations 
• Focuses only on genes that can be 
transferred horizontally 
• Database does not appear to be publicly 
available 
• Last updated 2013 
SRST2_ARG-ANNOT171 • Curated 
database of 
resistance genes 
• Tool to identify 
resistance genes 
or mutations in 
genomes 
• Uses sequence reads 
• Removes redundancy from ARGANNOT 
• Can identify mutations 
• Relies on ARGANNOT database 
• Last updated 2017 
• Can only identify pre-defined mutations or 
variants 
Structured ARG database172 • Database of 
resistance genes 
• Tool to identify 
resistance genes 
• Nucleotide sequences and profile HMMs 
• Online analysis pipeline and command-line tools 
• Good for metagenomic samples 
• Claims to frequently update 
• Redundancy 
• Does not account for mutations 
• Last updated 2018 
• Not designed for whole genomes 
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Functional metagenomic studies, such as Sommer et al. 2009139, have shown that ARGs unlike 
those seen in pathogens exist in gut bacteria. This technology clones DNA fragments that have 
been extracted directly from an environmental sample, such as a stool sample, into another 
bacterium, often E. coli, and screened for antibiotic resistance phenotypes by plating on agar 
containing antibiotics. This bypasses the issue of culturing gut microbiota, making functional 
metagenomics a very powerful tool for studying a community in a relatively unbiased way. 
Indeed, this method has been important in understanding antibiotic resistance genes in a 
range of microbiomes and environments, including but not limited to: chicken guts173; 
uncontacted Amerindians174; faeces from domesticated animals as well as soil, water and 
sanitation facilities of rural villages and “shanty” towns in Peru143; seawater175; and Alaskan 
soil176. From functional metagenomic studies, we have learned that antibiotic resistance genes 
not currently found in pathogenic bacteria are both diverse, abundant and widely distributed. 
In addition, bacteria do not have to have been exposed to clinical antibiotics to harbour 
antibiotic resistance genes, even ones that have been found in pathogenic bacteria. However, 
these studies tend to rely on cloning of genes into E. coli143 and may miss genetic determinants 
that cannot be expressed in this organism; plus, there is extensive bacterial diversity across 
the planet that has not been studied in depth177. This leaves the possibility that there are still 
more unknown antibiotic resistance determinants waiting to be discovered – not just in the 
gut, but in the Earth’s total microbiome. 
Genomic methods can be combined for more in-depth analyses of antibiotic resistomes. An 
important study of reservoirs of antibiotic resistance used 16S rRNA gene sequencing 
(amplification and sequencing of variable regions in the 16S rRNA gene, used as markers for 
bacterial species or genera), functional metagenomics and whole genome shotgun 
metagenomic sequencing to explore the similarity of resistomes between different 
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environments143. This included the human gut, domesticated animal gut microbiomes, soil, 
water, and sanitation facilities143. This multi-genomics approach allows antibiotic resistance 
genes to be quantified in terms of their relative abundance and associated with particular 
taxa, rather than just observing their presence. The resistomes of the different samples 
correlated with the phylogenetic diversity of each sample across an ecological gradient but 
certain antibiotic resistance genes were able to move between more diverse habitats and 
were linked to mobile genetic elements143. For example, the sulphonamide resistance gene 
sul2 was found in 50 % of samples from six of seven environments studied and appeared to 
be localised in integrons – indicating it has the potential to transfer between bacteria143. 
Combining next-generation sequencing methods is therefore a powerful tool for 
understanding resistomes.  
In addition to using genomics to discover or monitor ARGs, it has been used to assess the 
impact of antibiotics on communities of bacteria. For example, 16S rRNA gene sequencing of 
gut bacteria following antibiotic treatment in humans has shown that diverse gut taxa are 
impacted by antibiotic therapy; however, the extent varies between individuals178. Moreover, 
16S rRNA gene-based studies have revealed the long-lasting impact of antibiotics on the gut 
microbiota, where often the gut microbiome does not fully return to its pre-antibiotic 
treatment state179. However, 16S rRNA gene sequencing only allows for species- or genus-
level resolution, meaning detailed analysis of species or strains is not possible. Whole genome 
shotgun metagenomics adds more resolution, and has been used to identify that the initial 
state of the gut microbiome determines the impact antibiotics will have180. However, both 16S 
rRNA gene sequencing and whole genome shotgun metagenomics depend on reference 16S 
rRNA gene or genome sequences181. Therefore, the effect of antibiotics on bacteria for which 
reference genomes are not available cannot be readily detected. As previously discussed, 
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there are uncharacterised organisms without reference sequences, meaning there is still 
much to be learned about the development of antibiotic resistance following antibiotic 
therapy in humans. 
1.9 Thesis aims 
Clearly antibiotic resistance is a global issue and whilst the gut has been described as an 
antibiotic resistance reservoir, the full capacity for antibiotic resistance and which antibiotics 
are effective against gut bacteria are not well defined. This thesis therefore sets out to 
characterise the antibiotic resistance potential of human gut bacteria. To do this, I will exploit 
recent developments in culturing of gut bacteria and characterise the genotypic and 
phenotypic resistance profiles of intestinal microbiota. Moreover, I will seek direct 
experimental evidence of the selection of antibiotic resistance within communities of 
commensal human microbiota to help understand the dynamics of antibiotic resistance in the 
gut microbiota. The thesis can be broken down into three key parts: 
• Characterisation of genomic antibiotic resistance in commensal gut bacteria: 
Determine a comprehensive overview of antibiotic resistance genes and mutations 
in commensal human gut bacteria representing the phylogenetic diversity of the 
human gut microbiome. 
• Determination of phenotypic antibiotic resistance in commensal gut bacteria and 
the accuracy of genotypes: Measure antibiotic sensitivity phenotypes in 
commensal human gut bacteria representing the phylogenetic diversity of the 
human gut microbiome and compare this to antibiotic genotypes. 
• Modelling the development of antibiotic resistance in vivo: Assess the impact of 
amoxicillin therapy on amoxicillin resistance in mice with human-derived gut 
microbiota at both community- and strain-level. 
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Chapter 2: Materials and Methods 
All analysis was performed by me, unless otherwise stated. 
2.1 Anaerobic gut bacteria culture collection  
The human commensal gut microbiota used in this thesis belong to the Human 
Gastrointestinal Bacteria Culture Collection (HBC)151 that I helped to develop (published in 
2019). The HBC contains 737 gut bacteria isolated from 20 humans, 8 from the UK and 12 from 
North America151. Any 16S rRNA gene sequences of less than 98.7 % similarity to known 
sequences are considered to belong to novel species, < 94.5 % to novel genera, < 86.5 % to 
novel families, < 82.0 % novel orders, < 78.5 % novel classes and 75.0 % novel phyla182. 
Genomic DNA was extracted from the 737 HBC isolates using a phenol:chloroform 
procedure146,151 by Dr Hilary Browne. DNA was sequenced by the Sanger Sequencing Pipelines 
(Wellcome Sanger Institute, WSI) team using the Illumina HiSeq platform, generating paired-
end reads of 125 or 150 bp; these reads were assembled using the pipeline described by Page 
et al. 2016146,151,183. The amino acid sequences of forty core genes were extracted from each 
genome using FetchMG184, concatenated and aligned using MAFFT v7.0185,186.  A phylogeny 
was inferred using FastTree v2.1.3 SSE3187,188 and the JTT+CAT model of amino acid evolution.  
 
2.2 Genome-based predictions of antibiotic resistance in the HBC 
Raw paired-end sequencing reads for each genome were used as input for the Antibiotic 
Resistance Identification By Assembly (ARIBA) algorithm160, which performs local assemblies 
and maps them against a database of antibiotic resistance genes and mutations (genetic 
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resistance determinants). In this study, the Comprehensive Antibiotic Resistance 
Database163,164 (CARD; version 2.0.2 June 2018) was used with default ARIBA parameters: 90% 
nucleotide identity for clustering sequences (ARIBA prepareref task), plus minimum 90 % 
alignment identity, minimum 20 % alignment length, minimum 50 reads assembly coverage 
and 95 % of gene cluster sequence must be assembled to call a gene cluster present (ARIBA 
run task). The observed determinants were grouped by the class of antibiotics they are 
reported to confer resistance to, using the CARD ontology. If a determinant was described as 
conferring resistance to more than one antibiotic, it was classified as ‘nonspecific’ antibiotic 
resistance. The exception is for resistances to Macrolide, Lincosamide, Pleuromutilin and 
Streptogramin (MLPS) antibiotics, as resistance determinants against these antibiotics can 
have cross-resistance to each other and are grouped together in a single, separate category. 
The grouping of these determinants was visualised using Krona189. The proportion of identified 
genetic antibiotic resistance determinants that belonged to a particular antibiotic class were 
calculated and visualized using Krona189. The proportion of isolates with at least one resistance 
determinant was calculated. The interquartile range (determined using the Tukey method190) 
and mean number of predicted antibiotic resistance determinants in an individual isolate was 
plotted according to the bacterial phyla of each isolate. This was repeated for the number of 
antibiotic classes isolates were predicted to be resistant to. 
In addition, the presence of predicted resistance to a particular antibiotic class was visualised 
against a core genome phylogeny (generated as described in section 2.1) using the online 
interactive Tree of Life (iTOL) tool191. To identify which antibiotic resistances were enriched in 
certain phyla, the proportion of isolates with at least one resistance determinant in each phyla 
was compared to the proportion of the overall HBC with Fisher exact tests192 and corrected 
using two-stage linear step-up procedures of Benjamini, Krieger and Yekutieli193. These 
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analyses were repeated in bacterial families containing more than five HBC isolates and in 
novel versus characterised isolates, plus the proportion of predicted resistances were 
determined for each antibiotic in novel versus characterised genomes.  
ARIBA was also implemented with the MegaRes167, ResFinder170 and SRST2-ARGANNOT161 
databases, plus the CARD-RGI164 tool was applied, with default parameters to predict 
antibiotic resistance in the HBC genomes.  
 
2.3 Genome-based predictions of antibiotic resistance in pathogenic genomes 
PATRIC194 was searched for genomes for the ESKAPE pathogens (E. faecium, S. aureus, K. 
pneumoniae, A. baumannii, P. aeruginosa and Enterobacter species). E. coli and C. difficile 
were also included as both are important causes of gut-related bacterial infections, and there 
are commensal isolates of these species in the HBC. I filtered for bacteria isolated from 
humans in clinical settings to ensure they were definitely pathogenic isolates. In addition, I 
chose bacteria isolated from 2010 or after, and from Canada, the US or the UK, to be 
consistent with the HBC isolates. From this list, I selected isolates that were considered to 
have ‘good’ quality genomes and with a high level of completeness (CheckM195 completeness 
score equal to or greater than 98 %). PATRIC considers genomes good or poor quality based 
on summary annotation statistics and from comparisons with other PATRIC genomes after 
they have been through the PATRIC comprehensive genome analysis service194. There were 
no E. faecium isolates with post-2010 dates in the official isolation date meta-data column, 
but looking at other meta-data columns I identified 37 isolates from 2012 or later, two from 
2001, one from 2000 and one from 1997; these were all included in the subsequent analyses. 
From the resultant list of genomes, I downloaded paired-end short read sequences and 
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predicted the presence of genetic antibiotic resistance determinants in CARD using ARIBA as 
in section 2.2. I then repeated the analyses of the proportion of isolates with predicted 
resistance, the interquartile range and mean number of resistance determinants per isolate, 
and the proportion of predicted resistances per antibiotic as in section 2.3 for each of the eight 
pathogenic species and between the pathogenic isolates and HBC isolates. 
 
2.4 Phenotypic antibiotic sensitivity in commensal gut bacteria 
HBC isolates were streaked out from glycerol stocks onto modified YCFA146,151,196 agar (Table 
2.1) plates in anaerobic conditions in a Whitley DG250 workstation at 37°C and left for 48 
hours. Single colonies were sub-cultured and left to grow for another 48 hours; this was 
repeated once more, then a single colony for each isolate was used to inoculate 1ml of YCFA 
broth in a 96 well plate. Three separate inoculations were performed per isolate to allow three 
biological replicates to be tested. After 48 hours in broth, a cotton swab was dipped in each 
culture and streaked on a YCFA agar plate three times, turning 60° each time. An Oxoid 
antibiotic disk dispenser was used to place single-concentration antibiotic disks onto the 
inoculated agar plates. Mr Mark Stares assisted with these phenotypic tests.  
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Table 2.1 Modified YCFA media. Volumes are to make 500 ml of YCFA broth or agar. The solutions and mixes are 




Amount  Components of solutions and mixes 
(part number) 
 Amount 
Before autoclaving   Resazurin Solution  
Agar (optional) 8 g  Resazurin (10269990) 0.1 g 
Tryptone (84610.0500) 5.0 g  d.H2O 100 ml 
Yeast extract (LP021B) 1.25 g    
NaHCO3 (10583381) 2.0 g  Mineral Solution I  
(D)+Glucose (G8270) 1.0 g  K2HPO4 (10677623) 3 g 
(D)+Maltose (CHE1900) 1.0 g  d.H2O 1 L 
(D)+Cellobiose (10207603) 1.0 g    
L-cysteine (30089) 0.5 g  Mineral Solution II  
Mineral Solution I 75 ml  KH2PO4 (P9791) 3 g 
Mineral Solution II 75 ml  (NH4)2SO4 (A4418) 6 g 
Resazurin Solution 0.5 ml  NaCl (10616082) 6 g 
Haemin Solution  5 ml  MgSO4 (CHE2458) 0.6 g 
Vitamin Solution I 0.5 ml  CaCl2 (dry) (10704492) 0.6 g 
d.H2O Up to 500 ml  d.H2O 1 L 
VFA mix 3.1 ml    
NaOH (CHSO0041) pH to 7.45  VFA mix  
   Acetic acid (10304980) 17 ml 
After autoclaving   Propionic acid (15658000) 6 ml 
Vitamin Solution II 0.5 ml  n-Valeric acid (10686584) 1 ml 
   Iso-valeric acid (129542) 1 ml 
   Isobutyric acid (11366766) 1 ml 
     
   Haemin Solution  
   KOH (8143530100) 0.28 g 
   Ethanol 95 % 25 ml 
   Haemin (10506591) 0.1 g 
   d.H2O Up to 100 ml 
     
   Vitamin Solution I  
   Biotin (B4501) 5 mg 
   Cobalamin (Vitamin B12) (47869) 5 mg 
   PABA (4-Aminobenzoic Acid) (A9878) 15 mg 
   Folic acid (F7876) 25 mg 
   Pyridoxine (P5669) 75 mg 
   d.H2O Up to 500ml 
     
   Vitamin Solution II  
   Thiamine hydrochloride (T4625) 25 mg 
   Riboflavin (R4500) 25 mg 
   d.H2O Up to 500 ml 
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Disk concentrations were selected based on advice for Enterococcus from CLSI, EUCAST and 
BSAC as a Gram-positive, facultative anaerobic Firmicute (Table 2.1). Though Bacteroidetes 
are Gram-negative, the same concentration disks were used for consistency. Zone of inhibition 
diameters were measured using a digital caliper after 48 hours and averaged across the 
biological replicates. The identity of each culture was confirmed using full-length PCR of the 
16S rRNA gene (7F forward primer (5ʹ-AGAGTTTGATYMTGGCTCAG-3ʹ) and 1510R reverse 
primer (5ʹ-ACGGYTACCTTGTTACGACTT-3ʹ)) with the following program: 95 °C 15 mins; 35 
cycles of 95 °C 30 s, 58 °C 30 s, 72 °C 2 mins; 72 °C 8 mins. DNA purification and capillary 
sequencing was performed by Eurofins Genomics (Germany). The forward and reverse 
sequences were trimmed and those shorter than 400bp discarded. The remaining forward and 
reverse reads were merged using Merger (Emboss: 6.3.1197) and BLASTn was used to identify 
a closest taxonomic match against the 16S rRNA gene sequences of the HBC151. 
Table 2.2. Single-concentration antibiotic disks used for phenotypic susceptibility testing. Antibiotics were 




Antibiotic class Oxoid Disk 
Concentration (μg) 
Based on guidelines 
Amoxicillin 
(11952962) 





10 Enterococcus; EUCAST 2018 
Ciprofloxacin 
(11499838) 
Fluoroquinolones 10 Enterococcus; CLSI 2015 
Erythromycin 
(10280243) 
Macrolides 15 Enterococcus; CLSI 2015 
Gentamicin 
(10299772) 
Aminoglycosides 30 Enterococcus; EUCAST 2018 
Metronidazole 
(11913972) 
Nitroimidazoles 5 Miscellaneous; BSAC 2015 
Tetracycline 
(11963872) 





5 Enterococcus; EUCAST 2018 
Vancomycin 
(11974012) 
Glycopeptide 30 Enterococcus; CLSI 2015 
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Density curves of average zone of inhibition diameters for each phylum and antibiotic was 
plotted using R198 and ggplot2199. In addition, the interquartile range of average zone sizes in 
isolates with and without genetic determinants of resistance were determined using the 
Tukey method190. 
 
2.5   Defining a scale for categorising resistant/susceptible phenotypes 
Guidelines for defining resistance and susceptibility exist for a range of pathogens, though are 
less well-characterised in anaerobes and Gram-positive bacteria. Moreover, they are used for 
categorising closely related taxa, usually at the species level. In this thesis I wanted to compare 
at higher taxonomic levels, therefore I used the phenotypic data that I generated to create a 
scale, considering isolates ‘resistant’ if the zone size was in the lower quartile or smallest 25 
% of all zone sizes for a particular antibiotic. Similarly, isolates were considered ‘susceptible’ 
if the zone size was in the upper quartile or largest 25 % of all zone sizes for a particular 
antibiotic. Isolates with zone sizes in the middle 50 % require further testing to determine 
whether or not they should be considered susceptible or resistant (see Fig. 4.4, Table 4.1 and 
Table 4.3 in Chapter 4). In combination with the genotypic data, there are four key 
genotype/phenotype combinations of confirmed or unpredicted susceptibility or resistance. 
These genotype/phenotype combinations were then converted to a four-number system and 
visualised as a heatmap in iTOL191 against the phylogeny of the 73 isolates (generated as 
described in section 2.1). In addition, the proportions of these categories were determined 
for both the antibiotics tested and in each phylum. The enrichment of each combination in 
antibiotics or phyla was determined using Fisher exact tests192 and corrected using the 
Benjamini, Hochberg, and Yekutieli method193 (q significant < 0.05). The proportion and 
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enrichment of Unpredicted Resistances per phylum was determined for each antibiotic in the 
same way. Proportions of genotype/phenotype combinations were compared between 
databases or prediction methods as described in section 2.2. to the proportions first 
calculated using ARIBA160 with CARD163,164 with two-proportion z tests plus Yates correction (q 
value significant < 0.05). 
 
2.6 Further investigations of Unpredicted Resistance 
All phenotyped HBC isolates were ranked from most ceftriaxone-resistant to least ceftriaxone-
resistant (i.e., from smallest to largest mean ceftriaxone zone of inhibition). Each average 
ceftriaxone zone of inhibition size was then plotted next to each isolate in this ranked order. 
Isolates in the top five most ceftriaxone-resistant isolates without beta-lactam resistance 
genes or mutations and with unexpectedly large average ceftriaxone zones of diameter 
(determined as described in section 2.4 using the Tukey method190) were investigated further 
(Bacteroides faecis 18048_2#66 and Lachnospiraceae nov. 20287_6#18). The HBC core gene 
phylogeny visualised in iTOL191 from section 2.1 was used to identify the most closely related 
isolates in the HBC to Bacteroides faecis 18048_2#66 and Lachnospiraceae nov. 20287_6#18. 
Average Nucleotide Identity (ANI) between the isolates of interest and close relatives was 
performed using FastANI200 with default parameters. The Minimum Inhibitory Concentration 
(MIC) for ceftriaxone was determined using Biomerieux Etest strips. Isolates were purified, 
grown in YCFA broth culture and used to inoculate YCFA agar plates as described for disk 
testing in section 2.4. Etest strips (ceftriaxone gradient 0.016-256 μg/mL; Biomerieux part 
number 506618) were placed on the plates and MIC measured after 48 hours growth in 
anaerobic conditions as for disk tests described in section 2.4. The most closely related isolate 
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to Lachnospiraceae nov. 20287_6#18 that was susceptible to ceftriaxone was only 81 % similar 
by ANI and so these isolates were excluded from subsequent analyses. 
Roary201 was used to identify genes unique to the resistant B. faecis isolates (MIC > 256 μg/mL) 
and genes unique to the susceptible B. faecis isolates (MIC < 48 μg/mL) as well as genes shared 
by both sets. The NCBI Protein database was searched for “beta-lactamase” and the amino 
acid sequence of all results was downloaded. ShortBRED194 was used to group these 
sequences into unique amino acid markers. ShortBRED was also used to search the genes 
unique to the resistant isolates for the amino acid markers of beta-lactamase related 
sequences. A range of similarity cut offs from 90 % to 25 % were tested. The highest cut off, 
90 %, represents a high level of similarity that can be used to infer function. A single beta-
lactamase was identified in the B. faecis isolate (“Group 2384”) with 90 % identity. The 
presence of this gene in the 737 HBC isolates was predicted using ARIBA160 as in section 2.2 
and was found in 16 additional HBC isolates. Five of those isolates also contained other beta-
lactam resistance genes or mutations and so were excluded from downstream analyses. The 
MIC of ceftriaxone for the remaining 11 additional Group 2384-positive isolates and their most 
closely related Group 2384-negative isolates in the HBC was determined using Etests as 
before. ANI analysis was also performed for these isolates as above. The nucleotide sequence 
for the Group 2384 gene was extracted from each phenotyped Group 2384-positive isolate, 
aligned using Muscle202,203 (visualised in SeaView204) and a phylogenetic tree inferred using 
the General Time Reversible model with FastTree187,188. 
The Group 2384 candidate beta-lactamase was synthesised in a plasmid vector containing a 
chloramphenicol resistance gene using GeneArt (ThermoFisherScientific, plasmid 
pACYC184205, construct ID 18ADVNOP). The construct was transformed into 
electrocompetent ElectroMAX DH10B T1 Phage-Resistant Competent E. coli Cells 
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(ThermoFisherScientific, part number 12033015, via electroporation according to the 
manufacturer’s instructions and with assistance from Mr Matthew Dorman). The ceftriaxone 
MIC of the recipient E. coli strain was determined using Etests as earlier described. The 
transformed cells were grown on LB agar plates containing chloramphenicol (12.5 μg/mL ) and 
ceftriaxone at a concentration of 256 μg/mL (representing the observed B. faecis phenotype) 
or 4 μg/mL (slightly above the E. coli’s initial MIC).  
Bacteroides faecis 18048_2#66 and Lachnospiraceae nov. 20287_6#18 isolates with 
unpredicted ceftriaxone resistance were purified and Mr Mark Stares isolated genomic DNA 
using phenol:chloroform extractions. The genomic DNA was separated by size using a 1 % low-
melting point agarose gel and fragments of approximately 40kb extracted using the Copy 
Control Fosmid Cloning Kit (Lucigen part number CCFOS059) according to manufacturer’s 
instructions. These fragments were cloned into ceftriaxone susceptible E. coli using the Copy 
Control Fosmid Cloning Kit (Lucigen part number CCFOS059) according to manufacturer’s 
instructions. The vector contains a chloramphenicol resistance gene; clones were selected for 
on LB agar containing  chloramphenicol (12.5 μg/mL). The ceftriaxone MIC of the recipient E. 
coli strain was determined using Etests as earlier described. The transformed E. coli were 
screened for gain of ceftriaxone resistance by growth on LB agar containing ceftriaxone at a 
concentration of 256 μg/mL (representing the observed B. faecis phenotype) and 4 μg/mL 






2.7 Humanised microbiota mouse experiments 
A mouse line with microbiota derived from a healthy human had been established previously 
by Dr Simon Clare, Dr Sam Forster, Dr B. Anne Neville and colleagues in the Wellcome Sanger 
Institute Research Support Facility, by oral gavage of homogenised stool into germ-free (GF) 
mice (“Donor 2 humanised microbiota mice”). A second mouse line with microbiota derived 
from a different healthy human had also previously been established using the same 
techniques (“Donor 7 humanised microbiota mice”) by the same persons. Full details are 
described in section 5.2.1. 
Mice were given a theoretically therapeutic dose (approximately 45 mg/kg/day), based on the 
concentration required to adequately exceed the MIC of sensitive organisms in otitis media 
infections206 and assuming that the average mouse weighs 30 g and consumes approximately 
5 ml of water per day (according to John Hopkins University, 
http://web.jhu.edu/animalcare/procedures/mouse.html, accessed June 2015 and June 2019, 
and as advised by Dr Simon Clare). Amoxicillin sodium (TOKU-E part number A059) was 
dissolved in water, sterilized using a 0.2 μm filter and given to the mice via drinking water for 
seven days by Dr Simon Clare and his team. Faecal pellets were collected from each mouse at 
various time points before and after treatment by Dr Simon Clare and his team. At each time 
point, I weighed each individual faecal pellet and homogenised them in 100 mg/ml in sterile 
PBS; faecal homogenates were pooled per cage. An aliquot of the undiluted pooled 
homogenate was treated with ethanol for 30 minutes (1:3 volumes of 70 % v/v ethanol) to 
select for ethanol-resistant and spore-forming organisms146, and washed by centrifugation for 
13200 g for five minutes at room temperature, before removal of the supernatant and 
resuspension in four volumes PBS. The wash was repeated twice more and after the third 
wash and removal of supernatant, the sample was resuspended in the original volume of PBS. 
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Untreated and ethanol-treated pooled homogenates were serially diluted 1 in 10 from 10-1 to 
10-7.  Untreated dilutions were plated on modified complex, broad-range YCFA188 (Table 2.1), 
with or without amoxicillin added, under aerobic conditions (37 °C in a New Brunswick 
Scientific Innova 42 incubator) and anaerobic conditions (37 °C in a Whitley DG250 
workstation. Amoxicillin was included in the agar at a concentration representative of clinical 
resistance according to EUCAST and CLSI guidelines for anaerobic bacteria (8 mg/L). Ethanol-
treated dilutions were plated as above except that the agar plates also contained the bile salt 
sodium taurocholate (STC; Fisher Scientific UK Ltd part number 10629452) to promote 
germination of spores146. 
 
2.8 Colony count data 
At each time point, the number of colonies growing in each condition from each cage was 
counted and converted to colony forming units (CFU) per gram of stool. CFU/g values were 
averaged across both experiments for each culture condition: aerobic plates without 
amoxicillin, anaerobic vegetative plates without amoxicillin, anaerobic spore-forming plates 
without amoxicillin, aerobic plates with amoxicillin, anaerobic vegetative plates with 
amoxicillin and anaerobic spore-forming plates with amoxicillin. Standard deviation was 
determined for each of these six conditions. The colony count data was then tested for normal 
or log-normal distribution using the Anderson-Darling, D’Agostino and Pearson, Shapiro-Wilk, 
and Kolmogorov-Smirnov tests. As many of the conditions did not pass the normality tests, a 
non-normal distribution was assumed for performing Kruskal-Wallis (One-way ANOVA of non-
parametric data) tests to determine statistically significant changes in bacterial load over the 
time course of the mouse experiments (comparisons were performed between time points). 
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The two-stage step-up method of Benjamini, Krieger and Yekutieli193 was used to correct for 
multiple comparisons. 
 
2.9 Isolation of individual isolates and analysis 
Non-confluent colonies were picked from culture plates, after 24-hour and 48-hours of growth 
in aerobic and anaerobic conditions respectively, directly into 300 μl YCFA broth. This was 
done with the assistance of Dr Hilary Browne, Dr Sam Forster, Dr Elisa Viciani and Dr Ana Zhu 
alongside other members of the Host-Microbiota Interactions Laboratory. The aerobic 
colonies were left to grow in broth for another 24 hours; anaerobic colonies were left for 48 
hours. Half a millilitre of each broth culture was mixed with 0.5ml of 50 % glycerol to create 
glycerol stocks and stored at -80 °C. The full-length 16S rRNA gene was amplified from each 
isolate using PCR and sequenced by Eurofins as described in section 2.4. Reads were aligned 
using ssu-align v0.1.1207 and the STK alignment converted to MSA. Consensus OTU sequences 
were aligned with Mafft185,186 and a phylogeny inferred using FastTree187,188 for visualisation 
with ITOL191. The tree leaves were annotated based on the BLASTn results and Operational 
Taxonomic Units (OTUs) were assigned with Mothur v1.35.1208 with a defined cutoff of 0.01 
(i.e., 99 % similarity).  The number of isolates in each OTU was visualised using Krona189. 
Isolates of interest were purified and genomic DNA extracted using phenol:chloroform by Mr 
Mark Stares. Sequencing was performed by the Sanger Sequencing Pipelines (WSI) team using 
Illumina X10 technology, generating 150 bp paired-end reads. 
Paired-end sequence reads were filtered and assembled using the pipeline as earlier 
mentioned183. To perform phylogenetic analyses, the amino acid sequences of 40 core genes 
were extracted, aligned and visualised as for the HBC184-188,191 in section 2.1. Each genome was 
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searched for the presence of known antibiotic resistance determinants described in 
CARD163,164 using ARIBA160 with default parameters, as for the HBC in section 2.2. The ARIBA 
results were compared between genomes from isolates cultured on agar with amoxicillin after 
the mice received amoxicillin and genomes of the same strain (>99 % 16S identity) from agar 
without amoxicillin before treatment. The sequence of the cfxA beta-lactamase was identified 
in isolates of one OTU, Odoribacter splanchnicus 99.556 %, after amoxicillin therapy but was 
not present in isolates of the same OTU from before therapy. The nucleotide sequences of 
cfxA were extracted from all the whole genomes generated in this study (where present) and 
aligned using Muscle202,203. The amoxicillin MIC was determined for four isolates of 
Odoribacter splanchnicus 99.556 %, as described in section 2.6 (amoxicillin gradient 0.016-256 
μg/mL; Biomerieux part number 500918). 
For each candidate OTU, Roary201 was used to identify genes found in the isolates from culture 
plates containing amoxicillin after mice were treated with amoxicillin but absent from isolates 
in the same candidate OTU from culture plates without amoxicillin before the mice received 
treatment. Genes meeting this criteria were searched for sequences with 90 % similarity to 
the ShortBRED209 beta-lactamase markers developed in section 2.6. In addition, paired-end 
sequencing reads from bacteria isolated after amoxicillin treatment were mapped against 
assembled contigs from an isolate of the same OTU cultured before amoxicillin treatment 
using Smalt (https://www.sanger.ac.uk/science/tools/smalt-0). Variant bcf files were 
produced and used to identify SNPs in coding sequences (open reading frames annotated as 
such if over 100 bases) in Artemis210. Coding sequences containing SNPs were compared to 




2.10 Metascrape and metagenomic analysis 
The total growth on a culture plate was mixed with 1 ml sterile PBS and scraped off 
(“metascrape”) for total DNA extraction using the FastDNA Spin Kit for Soil (MP Biomedicals 
part number 1149200) according to manufacturer’s instructions. Metagenomic sequencing 
was performed by the Sanger Sequencing Pipelines (WSI) team using Illumina HiSeq 4000 
technology, generating paired-end reads of 150 bp. Metagenomic samples were multiplexed 
at 32 samples per lane. Metagenomic data was analysed using Kraken211 with default 
parameters to compare the sequence reads to databases of reference genomes and assign 
taxonomy. Raw read counts per species were used to determine alpha and beta diversity using 
R scripts developed by Dr Kevin Vervier at each experimental time point for three culture 
conditions (aerobic, anaerobic vegetative and anaerobic spore-forming), on agar plates with 
or without 8 mg/L amoxicillin added. Statistical significance was determined by Mann-
Whitney U tests212, adjusted for multiple-testing with the Benjamini, Hochberg, and Yekutieli 
method193; q value significant < 0.05. Read counts were normalised per sample and the 
normalised values were averaged across samples for each of the three conditions (aerobic, 
anaerobic vegetative and anaerobic spore-forming) from plates containing amoxicillin. The 
species were then ranked by their mean relative abundance in each culture condition and the 
mean relative abundance of the top 10 most abundant species plotted as stacked bar charts, 
with the relative abundances of the remaining species grouped as “Other”. Relative 
abundance of species was compared between consecutive time points and the start and end 
of the experiment using two-proportion z tests with Yates correction (q value significant when 
q < 0.05). Finally, the whole genome sequences generated in this study were searched for in 
the metascrape data to confirm the presence or absence of candidate OTUs of increased 
amoxicillin resistance on plates containing amoxicillin using Mash213 with default parameters. 
 
 62 
An identity cut off of 0.99 (99 %) was used to conclude that a particular strain was present in 




Chapter 3: Characterisation of genomic antibiotic resistance 




The gut microbiome is considered a reservoir of antibiotic resistance214 through the sharing of 
antibiotic resistance genes (ARGs) amongst autochthonous, commensal gut bacteria. In 
addition, these ARGs may be shared with allochthonous, transient bacteria passing through 
the gastrointestinal tract, which can include bacterial pathogens123. This is evidenced by 
studies that have identified both known, clinically relevant antibiotic resistance genes in 
samples collected from the gut microbiome as well as ‘novel’ antibiotic resistance genes (not 
previously identified or seen in pathogenic bacteria). For example, the functional 
metagenomics study by Sommer, Dantas and Church in 2009139 identified ARGs identical at 
the nucleotide level to genes previously identified in clinical isolates of disease-causing 
bacteria, proving that the gut microbiota do harbour clinically relevant ARGs. However, the 
majority of antibiotic resistance-conferring inserts (82 %) were distantly related to known 
antibiotic resistance genes from pathogens (nucleotide identity 60.7 % on average)139. These 
results highlight both the diversity of genetic antibiotic resistance determinants in the gut but 
also their potential to be shared between commensal and pathogenic bacteria. 
Another interesting study of the gut as a reservoir of antibiotic resistance used whole genome 
shotgun metagenomic sequencing to examine the resistomes of 180 healthy individuals from 
11 different countries across Europe, Asia, North and South America representing 
industrialised, low-income and remote societies215. In total, 507 different ARGs were 
identified, including eight shared by all 180 individuals215. This further highlights how 
antibiotic resistance appears to be widely distributed across gut microbiomes. If those ARGs 
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are acquired by pathogenic bacteria passing through the gut, or if the gut bacterium hosting 
the ARG moves outside of its usual location in the gut and causes an infection elsewhere in 
the body, then gut microbiota are part of the antibiotic resistance problem.  
These types of metagenomic studies investigate the entire community but not individual 
bacteria, therefore it is essentially impossible to say exactly which bacterium a particular 
antibiotic resistance determinant might have come from. Antibiotic resistance genes are often 
located on mobile genetic elements; since mobile genetic elements can be shared between 
different bacteria, it is hard to place the nucleotide sequence of a mobile genetic element 
identified from a mixed sample into its original genomic context. It can also be difficult to 
validate the results, as without knowing the host or having an isolate of the suspected host a 
phenotype cannot be measured and correlated with the presence or absence of the ARG in 
question. Therefore, these studies are good for observing the presence and abundance of 
known or putative ARGs in an environment, but not determining exactly which bacteria they 
belong to. This means that we do not necessarily fully understand the taxonomic placement 
of antibiotic resistance determinants among the bacterial community in a mixed sample, such 
as a stool sample that represents the gut microbiome. Combined with the fact that we are still 
discovering new members of the gut microbiota through metagenome-assembled genomes 
and high-throughput culturing146,151,216 the full potential of the gut microbiome as an antibiotic 
resistance reservoir remains to be understood. 
With recent developments in culturing of anaerobic commensal gut bacteria146,151, there is 
now the opportunity to use these methods to determine a comprehensive map of antibiotic 
resistance determinants in these diverse and relatively uncharacterised microorganisms. It is 
important to determine which commensal gut bacteria harbour antibiotic resistance genes as 
this information will help understand which ones are of concern for acting as donors to spread 
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antibiotic resistance. In this chapter, I use a unique collection of reference genomes to study 
the presence of known antibiotic resistance determinants in diverse commensal human gut 
bacteria.  
 
3.2 Results  
3.2.1 Summary of resources used in this chapter 
To determine the presence of antibiotic-resistant determinants in diverse commensal human 
gut bacteria, I have used the genomes from the Human Gastrointestinal Bacteria Culture 
Collection (HBC)151. Each isolate has been whole genome sequenced using Illumina short-read 
paired-end sequencing, assembled and annotated183, and the physical isolates are held in 
glycerol stocks at -80 °C allowing for phenotypic validation and characterisation (Chapter 4). 
The HBC contains 737 gut bacteria isolated from healthy adult humans, who had not taken 
antibiotics in the six months prior to sampling, using broad range culturing and targeted 
phenotype culturing for spore-forming bacteria146,151 (Fig. 3.1). The collection contains 273 









Figure 3.1 Phylogeny of the HBC commensal gut bacteria. The Human Gut Bacteria Culture Collection contains 
737 isolates of human gut bacteria151. The amino acid sequences of 40 core genes were extracted from these 
genomes and used to infer a phylogeny to illustrate the taxonomic diversity of this culture collection. The stars 
mark which genomes are considered novel based on the similarity of their 16S rRNA gene sequence to known 









Table 3.1. Taxonomic information for the HBC. The number of total or novel isolates, species and families is 
summarized for the four phyla of the HBC and the HBC overall. 
 
 
Species were defined by considering the sequence identity of each genome’s full length 16S 
rRNA gene. 16S rRNA gene sequences at least 97.8 % identical to each other are considered 
the same species182. In addition, the HBC 16S rRNA gene sequences were compared to RefSeq 
16S rRNA sequences to assign taxonomic classification. Any 16S rRNA gene sequences of less 
than 94.5 % similarity to known sequences are considered to belong to novel genera, < 86.5 
% to novel families, < 82.0 % novel orders, < 78.5 % novel classes and 75.0 % novel phyla182. 
In total, there are 276 isolates that belong to novel taxonomic groups in the HBC. This unique 
collection offers extensive and novel phylogenetic diversity, compared to the six ESKAPE 
pathogenic species (E. faecium, S. aureus, K. pneumoniae, A. baumannii, P. aeruginosa and 
Enterobacter spp.) that represent just six species from two orders within the Firmicutes and 
Proteobacteria. ESKAPE pathogens are included later as a comparator as they have been the 
focus of most antibiotic resistance gene and mutation research. 
Sequence reads for each genome were searched against the Comprehensive Antibiotic 
Resistance Database (CARD)163,164 as it is one of the largest resistance determinant databases, 
contains both ARGs and resistance-associated mutations, and is updated regularly. It is also 
commonly used as a reference database for studying antibiotic resistance genes and 
 
Actinobacteria Bacteroidetes Firmicutes Proteobacteria All HBC 
Total isolates 53 143 496 45 737 
Novel isolates 0 18 253 5 276 
Total species 16 40 203 14 273 
Novel species 0 13 91 1 105 
Total families 6 4 18 3 31 
Novel families 0 1 0 0 1 
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mutations (e.g.143,215,217,218). Version 2.0.2 of CARD (from June 2018, analysis performed in July 
2018), contains 2426 antibiotic resistance determinants. The CARD ontology describes which 
antibiotics each determinant confers resistance to; these descriptions were further grouped 
by the major antibiotic class – for example all sub-classes of beta-lactams were combined (Fig. 
3.2; see Appendix 1 for Table A1.1 describing groupings). In total, there are 29 different 
antibiotic classes or categories represented in CARD. Determinants conferring resistance to 
Macrolide, Lincosamide, Pleuromutilin and Streptogramin antibiotics were grouped together 
(MLPS) as resistance determinants against these antibiotics can have cross-resistance each 
other219 and are grouped together in a single, separate category. Any other determinants 
described as conferring resistance to more than one class of antibiotics were grouped under 
“non-specific antibiotic resistance” for the purpose of this study.  
Figure 3.2. The proportions of antibiotic categories in the Comprehensive Antibiotic Resistance Database. 2426 
antibiotic resistance determinants are described in CARD. The CARD ontology describes which antibiotics each 
determinant confers resistance to. If determinants were described as conferring resistance to multiple classes of 
antibiotics, these were grouped under “non-specific” antibiotic resistance. The exception is for resistances to 
Macrolide, Lincosamide, Pleuromutilin and Streptogramin (MLPS) antibiotics, as resistance determinants against 
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3.2.2 Computational predictions of antibiotic resistance in 737 whole genome sequences of 
anaerobic gut bacteria 
Approximately 60 % of the determinants in CARD are associated with beta-lactam resistance 
(Fig. 3.2). The CARD database includes redundancy, therefore I used ARIBA160 (Antibiotic 
Resistance Identification By Assembly) to predict the presence of CARD determinants in the 
HBC genomes. ARIBA clusters gene sequences from CARD by similarity, so that only the 
presence of “unique” non-redundant antibiotic resistance determinants are considered. 
Following the ARIBA ‘prepareref’ command, which performs the clustering of determinants, 
1024 clusters were created. ARIBA then performs local assemblies of sequence reads, in this 
case for each individual genome, against the reference sequence for each antibiotic resistance 
determinant cluster. If an assembled gene was 90 % similar to a reference antibiotic resistance 
determinant cluster sequence at the nucleotide level, that cluster was reported as present in 
that genome.  
In total, 178 unique clusters of genetic antibiotic resistance determinants were observed in 
the HBC (Fig. 3.3, see Appendix 2, Table A2.1 for full description and 
https://docs.google.com/spreadsheets/d/1zwmhUicOW3JVW_9y6P6LssbavW47EFiRq4_ww
nS9CMg/edit?usp=sharing for Table A2.2), with a combined total of 1434 occurrences across 
the 737 genomes. The determinants were grouped as described before: 19 of the 29 possible 
categories of antibiotics were represented by the HBC genomic resistances. The largest 
proportion of identified resistance determinants (29 %) were those considered “non-specific” 
determinants (Fig. 3.3). Beta-lactam antibiotic resistance determinants were the second most 
common type (13 %) to be observed. All antibiotic classes from the WHO List of Essential 
Medicines21 are represented in these observations, with the exception of oxazolidinone; it is 
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possible oxazolidinone resistance may be present via non-specific determinants if they alter 
the 23S and 30S rRNA subunits targeted by this antibiotic.  
Figure 3.3. Proportions of 178 antibiotic resistance determinants identified in 737 isolates of human gut 
bacteria. The determinants were grouped by the antibiotic class that they are described as conferring resistance 
to according to the CARD ontology. MLPS = Macrolide, Lincosamide, Pleuromutillin and Streptogramin A. 
 
Approximately half of the HBC genomes (390/737; 52.9 %) were predicted to contain at least 
one antibiotic resistance determinant (Fig. 3.4A). The number of unique determinants in a 
single genome ranged from 1 to 56 (including non-specific resistance determinants; Fig. 3.4B), 
although approximately three-quarters of the genomes were observed to contain just one or 
two antibiotic resistance determinants. Individual isolates carried resistances to 10 different 
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though again approximately three quarters of the HBC only harboured resistance to two or 
fewer antibiotic categories. Overall, the majority of this phylogenetically diverse collection of 
human commensal gut microbiota contain antibiotic resistance determinants, despite not 
having been exposed to antibiotics for at least six months. In addition, the range in number of 
resistance determinants, and the number of antibiotic classes resistance is predicted to, per 
isolate indicates variability in antibiotic resistance genotypes across the HBC.  
Figure 3.4. Summary of genetic determinants of antibiotic resistance in the HBC.  
A) The proportion of the 737 genomes with genetic determinants of resistance identified using CARD and ARIBA. 
B) The range in the number of genetic determinants of resistance predicted in an individual genome.  
C) The range in different antibiotic classes an individual genome was predicted to be resistant against (excluding 
non-specific antibiotic resistance). 
For B) and C), the boxes show the interquartile range determined using the Tukey method; the black circles 
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3.2.3 Variation of predicted genomic resistance across the four key gut bacteria phyla 
The presence of a resistance determinant to a particular antibiotic is assumed to confer 
phenotypic resistance to that antibiotic (e.g., the presence of a beta-lactam resistance gene 
predicts that isolate to be resistant to beta-lactam antibiotics). Therefore in this thesis these 
observations are considered “predicted resistance”. The distribution of predicted resistances 
belonging to the 19 categories of antibiotic among the 737 genomes is demonstrated in Figure 
3.5. This shows that antibiotic resistance is predicted throughout all four phyla in the HBC, and 
that predicted resistances vary, even between closely related isolates. However, 
Proteobacteria, and certain members of the Firmicutes, have more predicted antibiotic 
resistances than other isolates. These isolates belong to species known to be able to act as 
opportunistic pathogens such as Enterobacter cloacae220, Klebsiella oxytoca221, K. 
pneumoniae221 (Proteobacteria) and E. faecalis222 and E. faecium222 (Firmicutes). These initial 
findings support the role of the gut microbiota as a reservoir of antibiotic resistance and its 




Figure 3.5. Observations of predicted antibiotic resistance in the HBC isolates against the core genome 
phylogeny. The phylogeny represents the core genomes of 737 whole genome sequences of gut microbiota 
isolated from healthy human faecal samples. Antibiotic resistance genes and mutations described in CARD were 
identified in these genomes, which were grouped by the corresponding class of antibiotic. If more than one, then 
these were classified as ‘non-specific resistances’ or MLPS if Macrolide, Lincosamide, Pleuromutillin or 
Streptogramin A. The outer rings of coloured bars show the presence of at least one resistance determinant to 
a particular antibiotic class. Proteobacteria isolates appear to have the highest number of resistances to different 
antibiotic classes. 
 
Having determined the overall occurrence of known antibiotic resistance determinants in the 
HBC and gained a broad idea of their distribution, I next sought to understand the prevalence 
of antibiotic resistance predicted in each of the four main gut microbiota. From the phylogeny 
in Figure 3.5, Proteobacteria have the highest number of resistances to different antibiotic 
classes. Looking more specifically at the proportion of isolates within phyla (Fig. 3.6) further 





























to 82.5 % of Bacteroidetes, 43.5 % of Firmicutes and just 24.5 % of Actinobacteria. 
Proteobacteria and Bacteroidetes also have a significantly higher proportion of predicted 
resistant isolates than expected based on the HBC proportion overall (q values of < 0.0001, 
determined by Fisher exact tests and corrected for multiple testing; significant < 0.05).  
 
Figure 3.6. Proportions of isolates with at least one genetic antibiotic resistance determinant in each phyla, 
compared to the overall HBC. The numbers of genomes with at least one genetic antibiotic resistance 
determinant were counted for the complete HBC and for each of the four HBC phyla. HBC 52.9 %; Actinobacteria 
24.5 %; Bacteroidetes 82.5 %; Firmicutes 43.5 %; Proteobacteria 95.6 %. Proteobacteria and Bacteroidetes had 
significantly more isolates with predicted resistance than expected based on the overall HBC collection. Statistical 
significance determined by Fisher exact tests, and corrected using the Benjamini, Hochberg, and Yekutieli 
method; q = significant < 0.05. n = total number of isolates in that group. 
 
Moreover, Proteobacteria showed a bigger range and higher maximum number of antibiotic 
resistance determinants per isolate than the other three phyla (Fig. 3.7) and again, this was 
found to be statistically significant (q < 0.0001). Overall, the data from Figures 3.5 to 3.7 so far 
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phyla: more Bacteroidetes isolates are found to contain resistance determinants than 
expected, but the number of determinants per isolate was not significantly different to the 
HBC overall. The Proteobacteria phylum is significantly enriched for the number of isolates 
with resistance and the number of resistance determinants per isolate.  
Figure 3.7. Interquartile range of number of antibiotic resistance determinants per isolate in each phyla, 
compared to the overall HBC. The total number of antibiotic resistance determinants was calculated for each 
isolate and the interquartile range in this number plotted for all 737 HBC genomes and for each of the four HBC 
phyla. Actinobacteria had the smallest range (0-2) and lowest total number of antibiotic resistance determinants 
per isolate of all the phyla. In contrast, Proteobacteria had the biggest range (0-56) and highest total number of 
antibiotic resistance determinants per isolate. Interquartile range was determined using the Tukey method; the 
black circles indicate outlier observations and the thick black line represents the median. The red dashed line 
represents the mean. The mean number of determinants per isolate was statistically higher in Proteobacteria 
than the HBC. Statistical significance determined by Mann-Whitney U test; p = significant < 0.05. n = number of 
isolates in that group with predicted resistance (i.e., excluding isolates without resistance). 
 
Similarly, Proteobacteria display a bigger range in the number of specific antibiotic categories 
resistance is predicted to (i.e., excluding non-specific antibiotic resistances; Fig. 3.8): the 
Proteobacteria isolates are on average predicted to be resistant to four different antibiotics 
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Firmicutes are only predicted to be resistant to 1.0 or 1.5 antibiotics on average respectively. 
Again, these results were found to be statistically significant (p < 0.0001). This analysis 
excludes the non-specific antibiotic resistances. That the range in number of predicted 
resistances appears similar to the range in number of antibiotic resistance determinants per 
isolate suggests that non-specific antibiotic resistance is not a major factor for Actinobacteria, 
Bacteroidetes and Firmicutes. There is a bigger difference in the Proteobacteria, indicating 
that these isolates contain more non-specific resistances.  
Figure 3.8. Interquartile range of number of antibiotic classes resistance is predicted to per isolate in each 
phylum, compared to the overall HBC. After grouping the determinants by the antibiotic class they are described 
as conferring resistance against by CARD, the total number of specific antibiotic classes a single isolate was 
predicted to harbor genetic resistances against was counted (i.e., excluding non-specific resistances), Again, 
Proteobacteria had the biggest range and highest maximum number of antibiotic classes per isolate. Interquartile 
range was determined using the Tukey method; the black circles indicate outlier observations and the thick black 
line represents the median. The red dashed line represents the mean. The mean number of different antibiotic 
classes per isolate was statistically higher in Proteobacteria than the HBC. Statistical significance determined by 
Mann-Whitney U test; p = significant < 0.05. n = number of isolates in that group with predicted resistance (i.e., 
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Next, I considered whether certain phyla were enriched for particular antibiotic resistances. 
Fisher exact tests were performed to compare the proportion of isolates with resistance 
determinants for a particular antibiotic category within phyla compared to the proportion of 
all HBC isolates; p-values were adjusted for multiple testing using the Benjamini, Hochberg, 
and Yekutieli method (Table 3.2). Overall, every phylum except Actinobacteria is enriched for 
resistance to specific antibiotic classes. Bacteroidetes were enriched for beta-lactam 
resistance and tetracycline resistance (q values both < 0.001, significant < 0.05) and Firmicutes 
were enriched for diaminopyrimidine antibiotic resistances (q value 0.001). Proteobacteria 
were statistically enriched for determinants belonging to nine different classes of antibiotics, 
as well as non-specific antibiotic resistance determinants (q values all < 0.001). In several 
cases, resistance to antibiotic classes was observed significantly less often than expected – for 
example, beta-lactam resistance in Actinobacteria. This further indicates that genetic 
determinants of resistance are unevenly distributed between phyla. Overall, Proteobacteria 
are enriched for the most antibiotic classes and known resistance determinants, thus 
appearing to harbour more clinically relevant antibiotic resistance determinants than the 
other three key gut microbiota phyla.  
  
Table 3.2. The proportion of isolates with resistance to particular antibiotic categories is compared between phyla and the overall HBC. Percentage represents proportion of 
predicted resistances for an antibiotic in the HBC or individual phyla. The individual phylum proportions were compared to the HBC proportion to determine the direction of statistical 
significance. The arrows denote the direction of significance; ↑ indicates that antibiotic resistance was observed more than expected and ↓ that antibiotic resistance was observed 
less than expected. No arrow means that any change in the proportion was not statistically significant. Q values significant < 0.05 (Fisher exact tests and adjusted using the Benjamini, 
Hochberg, and Yekutieli method).  
  Phylum (number of genomes) 
    Actinobacteria (53) Bacteroidetes (143) Firmicutes (496) Proteobacteria (45) 
Antibiotic HBC % Phylum % q-value* Direction Phylum % q-value* Direction Phylum % q-value* Direction Phylum % q-value* Direction 
Acridine Dye 0.3 0.0 1.000   0.0 1.000   0.4 1.000   0.0 1.000   
Aminocoumarin 1.6 0.0 1.000   0.0 1.000   0.0 < 0.001* ↓ 26.7 < 0.001* ↑ 
Aminoglycoside 5.2 0.0 1.000   1.4 0.227   3.4 0.096   33.3 < 0.001* ↑ 
Beta-lactam 12.1 0.0 0.023* ↓ 31.5 < 0.001* ↑ 1.4 < 0.001* ↓ 82.2 < 0.001* ↑ 
Chloramphenicol 0.5 0.0 1.000   0.0 1.000   0.8 1.000   0.0 1.000   
Diaminopyrimidine  5.2 1.9 1.000   0.0 0.007* ↓ 7.3 0.001* ↑ 2.2 1.000   
Elfamycin 1.1 0.0 1.000   0.0 1.000   0.0 0.002* ↓ 17.8 < 0.001* ↑ 
Fluoroquinolone 1.6 0.0 1.000   0.0 1.000   0.0 < 0.001* ↓ 26.7 < 0.001* ↑ 
Fosfomycin 3.5 0.0 1.000   0.0 0.066   0.4 < 0.001* ↓ 53.3 < 0.001* ↑ 
Glycopeptide 1.5 0.0 1.000   0.0 1.000   2.2 0.227   0.0 1.000   
MLPS 9.4 0.0 0.087  11.9 1.000   14.1 1.000   6.7 1.000   
Mupirocin 0.1 1.9 0.767   0.0 1.000   0.0 1.000   0.0 1.000   
Nitrofuran 1.5 0.0 1.000   0.0 1.000   0.0 < 0.001* ↓ 24.4 < 0.001* ↑ 
Nitroimidazole 1.6 0.0 1.000   0.0 1.000   0.0 < 0.001* ↓ 26.7 < 0.001* ↑ 
Non-specific 11.8 5.7 1.000   0.0 < 0.001* ↓ 8.7 0.004* ↓ 91.1 < 0.001* ↑ 
Nucleoside 1.2 0.0 1.000   1.4 1.000   1.2 1.000   2.2 1.000   
Peptide 4.2 0.0 1.000   0.0 0.026* ↓ 3.8 1.000   26.7 < 0.001* ↑ 
Sulphonamide 0.5 0.0 1.000   1.4 1.000   0.0 0.140   4.4 0.227   
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3.2.4 Variation of predicted genomic resistance across different human commensal bacterial 
Families 
Having identified significantly more antibiotic resistance overall in Proteobacteria so far, I 
wanted to see whether this was also true at the family level. Families with more than 5 isolates 
were selected to be analysed to allow a certain degree of robustness. Those 14 families were 
ranked by the proportion of isolates with predicted resistance (Fig. 3.9). 
Figure 3.9. Proportions of isolates with at least one genetic antibiotic resistance determinant in taxonomic 
families. The numbers of genomes with at least one genetic antibiotic resistance determinant were counted for 
families in the HBC. The two families with the highest average number of resistance determinants per isolate or 
with more than five isolates are shown for each phylum. 
 
This shows that as for phyla, families vary in their proportion of isolates with predicted 















































































































































































































resistance occur in Enterobacteriaceae, Streptococcaceae, Enterococcaceae, and 
Bacteroidaceae. These families are known to contain opportunistic pathogenic species. 
However, so is the family Peptostreptococacceae (namely, the diarrhoea-causing 
Clostridioides difficile), yet this family has a much lower proportion of isolates with predicted 
resistance. If we consider the number of genetic determinants per isolate between families 
(Fig. 3.10), even though Streptococcaceae and Bacteroidaceae have high proportions of 
isolates with predicted resistance, they only harbour relatively few resistance determinants 
per isolate. In comparison, Enterococcaceae and Enterobacteriaceae both have significantly 
more resistance determinants per isolate on average compared to Bacteroidaceae and 
Streptococcaceae. However, Enterobacteriaceae did not have significantly more resistance 
determinants on average than Enterococcaceae. Together so far, this data suggests that gut 
microbiota taxa known to contain isolates of species that can act as opportunistic pathogens 




Figure 3.10. Interquartile range of number of antibiotic resistance determinants per isolate in commensal gut 
bacterial families. The total number of antibiotic resistance determinants was calculated for each isolate and 
the distribution in this number plotted at the family level. This included non-specific antibiotic resistance 
determinants. Interquartile range was determined using the Tukey method; the points show outlier observations 
and the thick black line represents the median. The red line represents the mean. n = number of isolates in that 
group with predicted resistance. Only families with more than five isolates were included. Statistical significance 
was determined between families known to contain pathogenic bacteria (Bacteroidaceae, Enterococcaceae, 
Peptostreptococacceae, Streptococcaceae and Enterobacteriaceae) by Kruskal-Wallis tests and corrected using 
the Benjamini, Hochberg, and Yekutieli method; q = significant < 0.05. Only significant results are shown. 
 
3.2.5 Distribution of predicted genomic resistance between known and novel isolates 
So far, I have identified that families containing species that can act as opportunistic 
pathogens are enriched for genetic determinants of antibiotic resistance. Having such a 
diverse and novel collection of gut bacteria has also allowed me to investigate whether 
clinically relevant antibiotic resistance determinants are harboured not just by bacteria 
belonging to previously published or described (“known”) taxa, but those considered to be 
novel and thus uncharacterised. As we do not have novel isolates for many of the families in 
_ _ _ _ _ _



























































































































































































































































































































the HBC, I performed this analysis at the phylum level. Fewer novel genomes overall harbour 
clinically relevant antibiotic resistances (Fig. 3.11); this is also true for the Bacteroidetes 
phylum. There were no novel Actinobacteria in this dataset so the rates in this phylum could 
not be compared. In Proteobacteria and Firmicutes (which has the most novel genomes at 
253), it is the novel genomes that harbour more clinically relevant antibiotic resistances. 
However, the only statistically significant results were that the HBC overall and Bacteroides 
phyla had more known isolates with resistance than novel isolates; the observations in the 
Firmicutes were not significantly different. Nonetheless, these results indicate that 
uncharacterised bacteria contribute to the intestinal reservoir of known antibiotic resistance.  
Figure 3.11. Proportions of resistant isolates in known versus novel isolates. The numbers of isolates that were 
novel were counted for all 737 HBC genomes and for each of the four HBC phyla. For each sub-group (known or 
novel), isolates with at least one genetic antibiotic resistance determinant were counted as before. 47.4 % of the 
novel genomes in the HBC were predicted to have at least one genetic antibiotic resistance determinant overall. 
There were no novel Actinobacteria genomes; the majority (91.7 %) of novel genomes belong to Firmicutes, with 
46.6 % of novel Firmicutes predicted to have at least one genetic antibiotic resistance determinant overall. 
Overall, the HBC had significantly more known isolates with predicted resistance than novel isolates; within phyla 
only Bacteroides showed a significant difference. Statistical significance determined by Fisher exact tests, and 
corrected using the Benjamini, Hochberg, and Yekutieli method; q = significant < 0.05. n = total number of isolates 


















































n = 461 n = 276 n = 53 n = 0 n = 125 n = 18 n = 243 n = 253 n = 40 n = 5
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Overall, the known genomes of the HBC harboured resistances to all 19 categories of 
antibiotics, whereas the novel genomes only harboured resistances to 12 categories of 
antibiotics (Figure 3.12, showing the proportion of predicted resistances). Known and novel 
Bacteroidetes genomes harboured resistances to the same six antibiotics, although there was 
proportionately more diversity in the resistances of novel Bacteroidetes. Similarly, novel 
Firmicutes harboured resistances to the same 11 categories of antibiotic as known Firmicutes, 
though there were more tetracycline resistances in the novel Firmicutes compared to known 
Firmicutes. The proportion of resistances in known and novel Bacteroidetes and Firmicutes 
appears broadly similar, largely dominated by tetracycline resistance. In contrast, the 
Actinobacteria and Proteobacteria have different patterns in predicted resistances: the known 
Actinobacteria have resistances to all 19 classes of antibiotics and known Proteobacteria to 
14 classes of antibiotics, whereas the novel Proteobacteria only have eight classes of antibiotic 
resistance predicted. In addition, the novel Proteobacteria have different classes of antibiotic 
resistance predicted (i.e., acridine dye, diaminopyrimidine, glycopeptide) than the known 
Proteobacteria. Together, these observations make it clear that although Proteobacteria is 
enriched for antibiotic resistance, non-Proteobacteria and uncharacterised gut microbiota 
harbour diverse antibiotic resistances, underlining the importance of understanding this 














Figure 3.12. Proportions of antibiotic categories that resistances are predicted against in HBC genomes. The 
number of predicted resistance phenotypes in known and novel genomes per antibiotic class was calculated for 
the HBC and each phylum. The majority of predicted resistances in those novel Firmicutes were against 
tetracycline antibiotics. r = total number of predicted resistance phenotypes for that group; g = genomes with 
predicted resistance in that group. 
 
3.2.6 Comparison of predicted genomic resistance in commensal versus pathogenic isolates 
I next compared the presence of antibiotic resistance in commensals of the HBC to pathogens. 
To do this, I searched PATRIC194 for genomes for the ESKAPE pathogens (E. faecium, S. aureus, 
K. pneumoniae, A. baumannii, P. aeruginosa and Enterobacter species). E. coli and C. difficile 
were also included as both are important causes of bacterial infections, and there are 
commensal isolates of these species in the HBC for comparisons. I filtered for bacteria isolated 
from humans in clinical settings to ensure they were definitely pathogenic isolates. In addition, 




































































n = 0n = 13 n = 8n = 110 n = 118n = 98 n = 5n = 38
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contemporaneous with the HBC isolates. From this list, I selected isolates that were 
considered to have ‘good’ quality genomes and with a high level of completeness (CheckM195 
completeness score equal to or greater than 98). PATRIC considers genomes good or poor 
quality based on summary annotation statistics and from comparisons with other PATRIC 
genomes after they have been through the PATRIC comprehensive genome analysis service194. 
There were no Enterococcus faecium isolates with official isolation dates post-2010, but 
looking at other meta-data identified 37 isolates from 2012 or later, two from 2001, one from 
2000 and one from 1997; these were all included in the subsequent analyses. For the 1725 
genomes, I predicted the presence of genetic antibiotic resistance determinants in CARD using 
ARIBA as for the HBC. 
Importantly, 97 % of these pathogenic genomes had at least one predicted resistance. 
However, there is more variation in the number of resistance determinants per isolate 
between species (Fig. 3.13) than was seen for the commensal isolates in section 3.2.4. This 
shows that although resistance is predicted in the majority of pathogenic isolates, different 
pathogenic species of bacteria have different antibiotic resistance potential. Pathogenic E. coli 
has the highest maximum, median and mean number of determinants per genome; this is 






Figure 3.13. Interquartile range of number of antibiotic resistance determinants per isolate in pathogenic 
bacterial species. The total number of antibiotic resistance determinants was calculated for each pathogenic 
genome studied and the distribution in this number plotted at the species level. This included non-specific 
antibiotic resistance determinants. n = number of isolates in that group with predicted resistance. Interquartile 
range was determined using the Tukey method; the points show outlier observations and the thick black line 
represents the median. The red line represents the mean. 
 
In addition, different pathogenic species have different profiles of predicted resistances (Fig. 
3.14). Thus, not all of these pathogen groups are equal in their predicted propensity to 
harbour antibiotic resistances. The Proteobacteria species and S. aureus appear broadly 
similar, with eight or more different resistances predicted. In contrast, C. difficile and E. 






























































































Figure 3.14. Proportions of antibiotic categories that resistances are predicted against in pathogenic bacterial 
genomes. The percentage of predicted resistance phenotypes in pathogenic genomes per antibiotic class was 
calculated for each species. r = total number of predicted resistance phenotypes for that group; g = genomes 
with predicted resistance in that group. 
 
Having assessed the frequency and proportions of genomic resistance in certain pathogenic 
species, I wanted to directly compare between pathogenic and commensal (from the HBC) 
genomes of related species. I have performed this analysis at the family level for 
Enterococcaceae (includes pathogenic E. faecium), Peptostreptococacceae (includes 
pathogenic C. difficile), Staphylococcaceae (includes pathogenic S. aureus), and 
Enterobacteriaceae (includes pathogenic Enterobacter, E. coli and K. pneumoniae) due to 
limitations in numbers of HBC genomes for certain species. Comparing the number of 



























































































r = 104 r = 170 r = 5613 r = 1002 r = 62 r = 3494 r = 918 n = 289
g = 99 g = 39 g = 872 g = 207 g = 17 g = 305 g = 139 g = 42
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same families, we can see that the pathogenic isolates have significantly more determinants 
per genome on average, except for Peptostreptococcaceae (Fig. 3.15).  
Figure 3.15. Interquartile range of number of antibiotic resistance determinants per isolate in commensal 
versus pathogenic isolates. The total number of antibiotic resistance determinants was calculated for each 
genome studied and the distribution in this number plotted at the family level, where families were represented 
by more than one isolate in both datasets. n = number of isolates in that group with predicted resistance. 
Interquartile range was determined using the Tukey method; the black circles show outlier observations and the 
thick black line represents the median. The red line represents the mean. Statistical significance determined by 
Mann-Whitney U test; p = significant < 0.05. 
 
 
However, we can also see that Enterococcaceae and Enterobacteriaceae each have broadly 
similar resistance profiles in both commensal HBC and pathogenic isolates of these families 
(Fig. 3.16). In contrast, pathogenic Staphylococacceae have more categories of antibiotic 
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different pattern again: the pathogenic isolates are dominated by non-specific resistances, 
whereas the commensal isolates have more tetracycline and MLPS resistances predicted. This 
data shows that although pathogenic isolates of Enterococcaceae and Enterobacteriaceae 
carry more resistance determinants, overall commensal and pathogenic isolates in these 
families are predicted to be resistant to similar antibiotics. In contrast, commensal isolates of 
Peptostreptococacceae and Staphylococcaceae are predicted to be resistant to different 
antibiotics than pathogenic isolates. 
 
Figure 3.16. Proportions of antibiotic categories that resistances are predicted against in commensal HBC 
versus pathogenic bacterial genomes. The number of predicted resistance phenotypes in genomes per antibiotic 
class was calculated for each family. r = total number of predicted resistance phenotypes for that group; g = 
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3.3 Discussion  
In this chapter, I aimed to determine the presence of known antibiotic resistance 
determinants in pure isolates of commensal gut bacteria and see if the whole gut microbiome 
may contribute to the problem of antibiotic resistance or only certain members. I therefore 
screened a collection of 737 phylogenetically diverse human gut bacterial genomes for known 
antibiotic resistance determinants described by CARD. This identified 178 unique antibiotic 
resistance determinants across the HBC, predicted to confer resistance against 19 antibiotic 
categories (including a category for non-specific antibiotic resistance). This included all but 
one of the antibiotics on the WHO Essential Medicines List, oxazolidinone. As in previous 
studies140,142, tetracycline resistance genes were some of the most prevalent across the 
diversity of the HBC. 
There were nine other antibiotics described in CARD to which there were not any predicted 
specific resistances: rifamycin, polyamine, triclosan, isoniazid, para-aminosalicylic acid, 
antibacterial free fatty acids, bicyclomycin and pyrazinamide (listed in order of the number of 
resistance determinants against these antibiotics in CARD). Rifamycin has broad-spectrum 
activity against Gram-negatives and Gram-positives, but is mainly used to treat TB 
infections223. There are no Mycobacterium isolates in the HBC, which we would expect given 
the criteria for the human donors for the HBC study to be healthy and without any bacterial 
infections. Rifamycin resistance develops by mutations in the RNA polymerase gene, and if 
the donors had not received rifampicin treatment recently then this may explain the absence 
of rifamycin-conferring resistance mutations in genomes of gut bacteria isolated from those 
people. Isoniazid224, para-aminosalicylic acid and pyrazinamide are also used to treat TB and 
so a similar explanation may apply. However, there were non-specific determinants present 
in these genomes that included rifamycin as one of the antibiotics they are described as 
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conferring resistance to (Appendix II). Similarly, triclosan and oxazolidinone were included in 
some non-specific determinant descriptions. Bicyclomycin is an old antibiotic with weak 
activity that is being revived for combinatorial therapy of drug resistant infections225. 
Polyamine is a compound that can increase the susceptibility of bacteria to other 
antibiotics226, such as beta-lactams, that is also being developed as an option combinatorial 
therapy227. Antibacterial free fatty acids are another experimental alternative to antibiotics228. 
Since these antibiotics are not currently commonly used as treatment of bacterial infections, 
resistance is less likely to have had the chance to develop or spread as often as resistance to 
other, more commonly used antibiotics. This could explain the absence of resistance 
determinants to these three antibiotics in the HBC. 
Overall, resistances were enriched among the Proteobacteria, and particularly the 
Enterobacteriaceae, in terms of diversity of resistance determinants, abundance of resistance 
determinants per isolate, and the number of isolates with predicted resistance. Isolates of 
Enterobacteriaceae harboured between 1 and 31 non-specific resistance determinants; this 
means the Proteobacteria could be resistant to more antibiotics than assumed when just 
considering the specific antibiotic resistance determinants. Since the HBC isolates were 
isolated from the guts of healthy adults who had not taken antibiotics in at least six months, 
and the microbiome is a diverse population of microorganisms, it is unlikely that the 
Enterobacteriaceae isolates have been more exposed to antibiotics than non-Proteobacteria 
isolates. As many of the most important bacterial pathogens are Gram-negatives – often 
Enterobacteriaceae or other Proteobacteria – some of the most commonly used antibiotics 
are those that target Gram-negatives. Therefore, it is possible that when taking antibiotics the 
commensal Enterobacteriaceae are theoretically more likely to be impacted and thus under 
more selective pressure to develop antibiotic resistance. If this were maintained long-term 
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(beyond the period of antibiotic treatment), this may explain the observations in this chapter. 
This is plausible, however there is often a fitness cost associated with antibiotic resistance229, 
implying that any acquired antibiotic resistance genes or mutations are not likely to be 
maintained in the absence of antibiotic selective pressure.  
Alternatively, it is possible that the HBC Enterobacteriaceae acquired resistance genes from 
bacteria in the environment or diet, in line with the “One Health” concept discussed in the 
Introduction to this thesis, and that this has happened more commonly in this taxon. However, 
horizontal gene transfer is not necessarily more common in Proteobacteria than other phyla: 
a recent study found that phylogeny did not have a significant impact on genome fluidity230. 
Conversely, and more likely, these results may reflect how the databases are predominantly 
created from information generated by studying bacterial pathogens; throughout this chapter 
it is the families of bacteria known to contain pathogenic species that have the most antibiotic 
resistance predicted. The databases would therefore be biased towards predicting antibiotic 
resistance genes or mutations in bacterial genomes more similar to those studied for the 
creation of said databases. This bias could explain the enrichment of resistance in 
Enterobacteriaceae over more distantly related bacteria, such as the Firmicutes. 
Despite the apparent enrichment in Proteobacteria, there is still a diverse range of antibiotic 
resistance predicted in large proportions of the other phyla in the HBC. For example, 
Firmicutes were enriched for diaminopyrimidine (trimethoprim) resistance; dfr trimethoprim 
resistance genes have been described in both Gram-negative and Gram-positive bacteria, but 
are thought to be intrinsic to enterococci231. Moreover, Bacteroidetes were enriched for beta-
lactam resistance; beta-lactamases are often endogenously produced by these bacteria232. 
Finally, tetracycline resistance was enriched in Bacteroidetes, and was the most common type 
of resistance in the HBC. Tetracycline resistance has been reported as increasingly common in 
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Bacteroidetes233 and the gut microbiota generally123, and serves to highlight how antibiotic 
resistance can become widespread in commensal bacteria. Whilst tetracyclines are now 
infrequently used in human medicine for this reason, there is a possibility of cross resistance 
with the last resort glycylcycline antibiotic tigecycline, and so the presence of tetracycline 
resistance determinants remains relevant. There were also instances of resistance to 
antibiotic classes being observed significantly less often than expected, such as to beta-
lactams in the Actinobacteria isolates; this would suggest either the isolates of those phyla are 
all susceptible to that antibiotic, or that there are alternative resistance mechanisms not 
identified using the methods applied here. 
Many of the predicted resistances in novel HBC genomes, most of which belong to the phylum 
Firmicutes, were to tetracycline. Other resistances were also predicted such as MLPS, beta-
lactams and diaminopyrimidine (trimethoprim). If known resistance genes were not identified 
in novel isolates, then the fact there are still gut bacteria to be discovered216 does not 
necessarily have serious consequences for the problem of antibiotic resistance. However, 
almost half of the novel HBC isolates did contain antibiotic resistance genes or mutations. 
Since there are uncharacterised gut bacteria, this emphasises that we do not yet fully 
understand the gut microbiota and the extent of their contribution to antibiotic resistance. 
Overall, significantly more known HBC genomes contained resistance determinants than novel 
HBC genomes; the same statement is true for the Bacteroidetes phylum specifically. There 
was no significant difference between the numbers of known or novel Firmicutes or 
Proteobacteria with resistance determinants. For the Proteobacteria, it is possible that this is 
due to sample bias, as there were only five novel Proteobacteria isolates, whereas in 
Firmicutes it is almost a 50:50 division of novel and known genomes. This suggests that known 
bacteria, which are more likely to be more closely related to known pathogenic bacteria, are 
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more likely to contain antibiotic resistance, and that more distantly related (novel and 
uncharacterised) bacteria are less likely to contain antibiotic resistance. However, it is possible 
that again database bias is impacting these results, and that known bacteria are more likely 
to be predicted to contain antibiotic resistance than more distantly related bacteria. Overall 
though, this data emphasises that commensal gut microbiota do harbour clinically relevant 
antibiotic resistances and that this reservoir, much of which remains uncharacterised, is more 
extensive than currently realised. 
Antibiotic resistances were commonly predicted throughout the HBC and there was variation 
observed even between closely related isolates; these statements are known to be true for 
pathogens as well as commensals. The commensal families most enriched for genetic 
determinants of antibiotic resistance are those known to contain opportunistic pathogenic 
species or isolates, such as Enterobacteriaceae and Enterococcaceae. In the last part of this 
chapter, I studied the differences in antibiotic resistance genotypes between commensal and 
pathogenic bacteria. I found that resistance determinants were observed more frequently in 
pathogenic isolates, and again especially in Proteobacteria.  
As mentioned, antibiotics are often targeted towards these bacteria since many pathogenic 
species are Gram-negative Proteobacteria (Fig. 1.3); it is possible then that these bacteria are 
more exposed to antibiotics and thus more likely to develop antibiotic resistance. This may be 
partially true, but antibiotics can have “off-target” effects on other bacteria; other antibiotics 
are broad-spectrum and thus designed to target several types of bacteria, including Gram-
positives. This means that other members of the gut microbiome will also be impacted by 
antibiotic use and thus also under selective pressure to develop resistance. Potentially, 
Proteobacteria might be more genetically capable of developing antibiotic resistance: 
Gammaproteobacteria (which includes Enterobacteriaceae) are known to have super-
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integrons as an integral component in their genomes234, allowing for multiple-drug resistance 
to develop rapidly. However, this concept of increased HGT in particular taxa was discussed 
earlier in this section and is unlikely to be the case. Alternatively, the enrichment of antibiotic 
resistance determinants in Proteobacteria may be due to efflux pumps being more common 
in Gram-negative bacteria than in Gram-positives235. Here, the majority of resistance 
determinants in the Proteobacteria were non-specific, of which efflux mechanisms 
dominated. This confirms that these non-specific mechanisms are a major contributor to the 
antibiotic resistance potential in Proteobacteria and may explain why pathogenic 
Proteobacteria are so prone to cause multi-drug resistant infections. 
However, the average number of determinants per genome was lower in Enterobacter spp. 
than in E. faecium and S. aureus. Since Enterobacter spp. are Proteobacteria, this is perhaps 
unexpected based on my earlier findings, but could be explained by the fact that these 
bacteria have only relatively recently been described as an emerging multi-drug resistant 
threat236. In addition, pathogenic E. faecium and C. difficile genomes had resistances predicted 
to fewer antibiotic categories than pathogenic S. aureus or the Proteobacteria species. 
Pathogenic Gram-negative Proteobacteria are known for having mobile genetic elements that 
can contain several resistance genes at once that can confer resistance to different 
antibiotics237. In addition, pathogenic S. aureus is well-known for being resistant to multiple 
antibiotics238, despite being Gram-positive. This may explain the difference in predicted 
resistance profiles observed.  
When I compared the pathogenic versus commensal genomes, pathogenic isolates were 
generally found to have more genetic resistance determinants per genome on average than 
commensal isolates, particularly Enterobacteriaceae. The exception was for 
Peptostreptococcaceae, although it is possible that this is due to the number of genomes 
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studied (five commensals versus 99 pathogens) and studying additional genomes of 
commensal Peptostreptococcaceae will determine whether this pattern continues to be seen. 
In general for the comparisons between commensals and pathogens, the sample bias means 
these results should be treated with caution.  
Finally, I found that for Peptostreptococacceae and Staphylococacceae, commensal genomes 
had different profiles of predicted antibiotic resistances to pathogenic isolates, whereas 
Enterobacteriaceae and Enterococcaceae shared similar predicted resistance profiles 
between commensal and pathogenic isolates. It is possible that this could be explained by 
more frequent horizontal sharing of resistance determinants within Enterobacteriaceae or 
Enterococcaceae than other bacterial families, though as discussed above phylogeny has not 
been observed to impact this process230. However, that study was performed at the species 
level, and so in the future it would be interesting to more specifically estimate and compare 
the frequency of horizontal gene transfer at other taxonomic levels, such as within and 
between bacterial families. This will also help to understand the spread of antibiotic resistance 
better. Yet again, it is important to consider the potential bias of the database of antibiotic 
resistance genes and mutations. This bias could also explain the observed higher proportions 
of pathogenic species with predicted resistance (and the high numbers of resistance 
determinants per genome) compared to commensal HBC isolates: the pathogenic isolates will 
be more similar to the isolates studied and used to create the database. 
It is important to acknowledge that this study has only used one collection of commensal gut 
bacteria and one database of antibiotic resistance determinants; repeating these analyses 
with additional genomes and alternative databases will help confirm these findings. However, 
since the CARD database is a regularly updated and extensive collection of antibiotic 
resistance determinants, and the HBC is a recent and diverse collection of gut bacteria, these 
 
 97 
new findings add to current knowledge regarding the gut microbiome as a reservoir of 
antibiotic resistance. The most important message from this chapter is that antibiotic 
resistance genotypes are common in commensals and often share similar predicted resistance 
profiles to related pathogens. In addition, many of the resistance genotypes are to antibiotics 
on the WHO list of essential medicines21, emphasising the potential clinical relevance of these 
observations. 
As the findings in this chapter are based purely on predicted genotypes using known antibiotic 
resistance determinants, this does not necessarily preclude that the isolates studied here are 
not resistant to other antibiotics – or even that they are resistant to the ones predicted. As 
discussed, there may be a database bias that makes it more likely to predict antibiotic 
resistance in bacteria more closely related to pathogenic species. Only phenotypic testing of 
antibiotic sensitivity of HBC isolates will confirm whether or not the observations in this 
chapter are accurate predictions of phenotypic antibiotic resistance. I will investigate this in 







Chapter 4: Determination of phenotypic antibiotic resistance 





In the previous chapter, I identified the presence of a range of clinically relevant genetic 
antibiotic resistance genes and mutations in the 737 genomes of the HBC. This analysis 
identified a significant enrichment of ARGs in the Proteobacteria members of the HBC. In this 
chapter I investigate whether Proteobacteria are phenotypically enriched for antibiotic 
resistance using the HBC culture collection, or whether CARD is biased towards identifying 
resistance genotypes in this phylum. In addition, I assess how accurate these predictions of 
antibiotic resistance in commensal gut bacteria are by determining phenotypic susceptibility 
and resistance to a range of clinically relevant antibiotics in a subset of the HBC. 
The gold-standard method for determining isolate-specific and phenotypic antibiotic 
susceptibility is culture-based antibiotic susceptibility testing (AST). Developed mainly for 
clinical isolates of pathogenic bacteria, AST involves culturing the bacterium of interest in the 
presence of an antibiotic and observing its ability to grow. One common method is measuring 
the size of a zone of inhibition: this features a paper disk containing a single concentration of 
the antibiotic that is placed on an agar plate that has been inoculated all over with the isolate 
of interest – after 24 hours incubation this produces a bacterial lawn. The sensitivity of the 
isolate to that antibiotic determines how close to the disk it can grow: the more sensitive the 
isolate, the less close to the disk it will be able to grow. The diameter of the zone where no 
growth occurs (the zone of inhibition) is measured. The antibiotic disks are 0.5cm in diameter, 
 
 100 
allowing several disks to be placed on a single inoculated plate and many antibiotic and isolate 
combinations to be tested using few resources239. Another method includes measuring the 
minimum inhibitory concentration (MIC). This involves exposing a bacterial isolate to a 
stepwise increasing range of antibiotic concentrations. This can be performed using broth 
microdilution (a series of prepared liquid culture mediums each with a different antibiotic 
concentration is inoculated with the isolate of interest) or using antibiotic gradient strips. 
These are small rectangular paper strips that contain a gradient of an antibiotic and are placed 
on top of an agar plate that has been inoculated to produce a bacterial lawn. The antibiotic 
diffuses into the agar – the more concentrated end will diffuse further – and then after 24 
hours incubation the antibiotic concentration at which the isolate is no longer able to grow 
alongside the strip (the MIC), is measured.  
 
4.1.2. Defining isolates as antibiotic-susceptible or -resistant 
The zone of inhibition or MIC is compared to guidelines provided by the European Committee 
on Antimicrobial Susceptibility Testing (EUCAST) or the Clinical and Laboratory Standards 
Institute (CLSI); international agencies who study and determine zone of inhibition 
breakpoints that categorise a certain isolate as resistant, susceptible or having intermediate 
sensitivity. This depends on having culturable, purified isolates of the bacteria of interest – 
which, until recently has been difficult to achieve for the majority of gut bacteria. Therefore, 
these breakpoint guidelines are only available for a small number of pathogenic bacteria 
species. 
As the costs of DNA sequencing decrease, whole genome sequencing antibiotic susceptibility 
testing (WGS-AST) is being investigated as an alternative method to culture-based AST to 
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determine antibiotic sensitivity. For example, the genome of a disease-causing bacterium 
isolated from a patient is sequenced and then searched for known antibiotic resistance 
determinants; any found are assumed to confer phenotypic resistance to the corresponding 
antibiotic. This approach is considered a rule-based WGS-AST method: the presence of 
antibiotic resistance determinant A in the genome confers resistance to antibiotic B. 
Therefore, rule-based methods rely on databases that contain information regarding the 
nucleotide or amino acid sequence of resistance determinants and which antibiotics they 
confer resistance to240. These methods are attractive as they offer the potential for results to 
be available in a matter of hours rather than days and to screen many more bacteria than 
culture-based methods. Moreover, rule-based approaches offer easily interpretable results 
and are currently the most popular methods for translation of WGS-AST into a clinical setting. 
However, the reliance on databases of known resistance determinants can introduce 
problems; as discussed in the previous chapter, these databases may introduce bias towards 
certain bacteria. This can lead to a “false negative” result: no genetic resistance determinant 
is present in an isolate, but the isolate is phenotypically resistant to a particular antibiotic. 
These rule-based methods therefore vary in their accuracy for antibiotic/taxon 
combinations241; to my knowledge, how accurate they are for gut bacteria has not yet been 
assessed. 
In this chapter, I generate and study the in vitro phenotypes of a diverse set of human 
commensal gut bacteria in the HBC against nine clinically relevant antibiotics (all of which 
belong to classes on the WHO List of Essential Medicines). As previously discussed, phenotypic 
data can be used to determine breakpoints of antibiotic concentrations where isolates are 
considered susceptible or resistant. Since published breakpoints are limited for gut bacteria, I 
defined a system for determining whether the isolates I studied should be considered 
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susceptible or resistant. I then determined the enrichment of phenotypic resistance in isolates 
representing the four main gut phyla of bacteria: Actinobacteria, Bacteroidetes, Firmicutes 
and Proteobacteria242. I also combined this phenotypic data with the genotypic data from the 
previous chapter to determine whether a rule-based prediction method of antibiotic 
resistance inferred from the presence of known resistance determinants can be accurately 
applied to human commensal gut bacteria. I then applied a comparative genomics and 
phenotype approach to identify and study candidate novel antibiotic resistance genes. 
 
4.2 Results 
4.2.1 Phenotypic screening of antibiotic resistance in a subset of 73 HBC isolates 
Having identified the presence of genetic antibiotic resistance determinants using CARD, I 
leveraged our ability to culture anaerobic gut bacteria146,151 to assess the phenotypic response 
to antibiotics. 73 phylogenetically diverse isolates from the HBC (Fig. 4.1) were selected, 
representing all four phyla, approximately 10 % of the culture collection and 14 % of the 
number of different species (39/273) contained in the HBC: 16 isolates of Proteobacteria 
(seven species in two families); 21 isolates of Bacteroidetes (11 species in two families); 11 
isolates of Actinobacteria (five species in two families); 25 isolates of Firmicutes (16 species in 
three families). These isolates have a total of 115 predicted resistance phenotypes against 16 
of the 17 antibiotic resistance classes discussed in Chapter 4 (acridine dye was not included 
since it is not a clinically relevant antibiotic243). Each isolate was tested for in vitro sensitivity 
against nine antibiotics that are clinically relevant and on the WHO list of essential 
medicines21: amoxicillin and ceftriaxone (two different sub-types of beta-lactams), 
ciprofloxacin (a fluoroquinolone), erythromycin (a macrolide), gentamicin (an 
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aminoglycoside), metronidazole (a nitroimidazole), tetracycline, trimethoprim (a 
diaminopyrimidine), vancomycin (a glycopeptide).  
 
Figure 4.1. A phylogeny of 73 isolates from the HBC selected for selective phenotypic screening of antibiotic 
sensitivity. The phylogeny was inferred from 40 core genes of 73 whole genome sequences of gut microbiota 
isolated from healthy human faecal samples. These samples are a subset of the 737 isolates in the Human 


















































































To measure antibiotic sensitivity, I performed zone of inhibition analysis, due to the benefits 
described and because it is easy to perform in the confines of an anaerobic cabinet, where 
culturing anaerobic gut bacteria must take place. This method places single-concentration 
antibiotic disks (Table 4.1) on agar plates inoculated with the isolate of interest and measures 
the diameter of the zone of inhibition (the area surrounding the antibiotic disk where the 
isolate does not grow). An average zone of inhibition diameter was calculated from three 
biological replicates of each isolate/antibiotic combination (73 isolates x 9 antibiotics = 657 
combinations). These phenotypic tests were set up by myself and Mr Mark Stares. 
 
Table 4.1. Single-concentration antibiotic disks used for phenotypic sensitivity testing. Disks were 
manufactured by Oxoid and the concentration chosen was based on CLSI or EUCAST or BSAC guidelines as 
indicated in the table. Disk concentrations are usually selected based on guidance from EUCAST or CLSI 
breakpoint information; however, information for anaerobes is lacking. Therefore, concentrations were mainly 
selected based on advice for Enterococcus, as a Gram-positive, facultative anaerobic Firmicute. Though 
Bacteroides are Gram-negative, the same concentration disks were used for consistency and to allow 
comparisons. 
 
Antibiotic Antibiotic class Disk Concentration 
(μg) 
Based on guidelines 
Amoxicillin Beta-lactam: 
penicillin 
10 Enterococcus; CLSI 2015 
Ceftriaxone Beta-lactam: 
cephalosporin 
10 Enterococcus; EUCAST 2018 
Ciprofloxacin Fluoroquinolone 10 Enterococcus; CLSI 2015 
Erythromycin Macrolide 15 Enterococcus; CLSI 2015 
Gentamicin Aminoglycoside 30 Enterococcus; EUCAST 2018 
Metronidazole Nitroimidazole 5 Miscellaneous; BSAC 2015 
Tetracycline Tetracycline 30 Enterococcus; CLSI 2015 
Trimethoprim Diaminopyrimidine 5 Enterococcus; EUCAST 2018 
Vancomycin Glycopeptide 30 Enterococcus; CLSI 2015 
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Density curves were plotted for average zone of inhibition diameter for each antibiotic (Fig. 
4.2), where each dot represents an average zone size for a particular isolate/antibiotic 
combination. These graphs therefore represent the proportions of isolates in each phylum 
with a certain zone size. Visualising the data in this way identifies trends in the range and 
frequency of zone of inhibition sizes for each antibiotic and each phylum. A larger zone of 
inhibition size (e.g. 60 mm) suggests that that isolate was very sensitive to that antibiotic; in 
contrast, a smaller zone of inhibition size (e.g. 5 mm) suggests that the isolate was less 
sensitive.  
A very narrow range of zone of inhibition sizes occurs several times: Actinobacteria with 
amoxicillin, gentamicin, tetracycline and vancomycin; Bacteroidetes with gentamicin; 
Proteobacteria with ciprofloxacin, gentamicin, metronidazole, tetracycline and vancomycin 
(Fig. 4.2) These narrow distributions generally appear around the mid-range of average zone 
of inhibition sizes (20-40 mm), suggesting that all the isolates tested in those categories were 
sensitive (i.e., the antibiotic had an effect on these isolates). The exception is for Bacteroidetes 
and gentamicin, where the majority of isolates were not sensitive at all (zone of inhibition = 0 
mm). Only two Bacteroidetes isolates were slightly sensitive with a zone of inhibition that was 
always smaller than 10 mm. This suggests that this phylum is particularly unaffected by 
gentamicin. Moreover, in some cases all isolates of a phylum were not sensitive to an 
antibiotic, such as Proteobacteria for metronidazole and vancomycin. Much bigger ranges in 
zone of inhibition size and thus sensitivity are also present: for example Actinobacteria with 
metronidazole; Bacteroidetes with amoxicillin, ceftriaxone, erythromycin and tetracycline; 
Firmicutes with ceftriaxone, erythromycin, tetracycline and trimethoprim. This indicates that 
some isolates in those phyla are more resistant to these antibiotics than other isolates. Since 
only eight bacterial families are represented by these 73 isolates, and the majority of isolates 
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in each phylum belong to a single family, the observed variation in antibiotic sensitivity also 
occurs within bacterial families as well as phyla.  
 
Figure 4.2. Density curves of zone of inhibition size among 73 isolates of the four main phyla of human gut 
bacteria. The isolates were screened for phenotypic antibiotic resistance against the following antibiotics: 
amoxicillin and ceftriaxone (beta-lactams), ciprofloxacin (a fluoroquinolone), erythromycin (a macrolide), 
gentamicin (an aminoglycoside), metronidazole (a nitroimidazole), tetracycline, trimethoprim (a 
diaminopyrimidine), and vancomycin (a glycopeptide) using disks containing a single concentration of an 
antibiotic. The screen was repeated in three biological replicates and zone of inhibition diameter averaged per 
isolate. Density curves for average zone of inhibition size was plotted for each phyla and antibiotic: each dot 
represents an average zone of inhibition size for a particular isolate/antibiotic combination. The x axis is the zone 
of inhibition size in millimetres: a larger average zone of inhibition means that isolate was more sensitive to an 
antibiotic than a smaller zone of inhibition. The y axis is the density or proportion of isolates with a particular 
zone size. Some phyla have a very narrow range of zone of inhibition sizes, e.g. Proteobacteria and ciprofloxacin 
or Actinobacteria and vancomycin. Other phyla have a much bigger range in zone of inhibition or susceptibility, 





4.2.2 Comparison of zone of inhibition sizes between isolates with and without genetic 
antibiotic resistance determinants 
Combining the phenotypic data for these 73 isolates with the genomic data generated in the 
previous chapter it is possible to assess whether the antibiotic resistance genotype (or 
predicted phenotype) corresponds with the actual antibiotic resistance phenotype. Thus, the 
accuracy of the proposed rule-based method of predicting antibiotic resistance in gut bacteria 
is determined. To my knowledge, this is the first time this comparison of genotypic and 
phenotypic antibiotic resistance data has been performed for a diverse collection of gut 
bacteria isolated from healthy humans. 
Initially, I used the Tukey method to study the range of zone sizes in isolates with and without 
predicted resistance and identify outliers with abnormally small zone diameters for each 
antibiotic (Fig. 4.3). This showed that there were isolates completely resistant (zone diameter 
= 0 mm) to an antibiotic despite not harbouring any resistance determinants from CARD to 
that drug. This occurs for all antibiotics and indicates that the CARD based predictions of 
genetic resistance determinants are not completely accurate for these gut bacteria. To 








Figure 4.3. Range of average zone of inhibition between isolates with and without the presence of genetic 
resistance determinants. The average zone of inhibition diameters in isolates with predicted genetic resistance 
determinants against a certain antibiotic were compared against those in isolates with no predicted resistance. 
The boxplots show the interquartile range, median and limits at 1.5IQR above and below. Overall, there was a 
large range in zone of inhibition size in isolates without predicted genetic resistance determinants, with some 
isolates completely resistant to each antibiotic studied even in the absence of genomic resistance.  
 
4.2.3 Defining a system for categorising gut bacteria as resistant or susceptible to antibiotics 
and considering the spectrum of antibiotics 
Guidelines for defining resistance and susceptibility exist for a range of pathogens, though are 
less well-characterised in anaerobes and Gram-positive bacteria. Moreover, they are used for 
categorising closely related taxa, usually at the species level. In this thesis I wanted to compare 
at higher taxonomic levels, therefore I defined a scale using the phenotypic data I generated. 
Where very narrow ranges in sensitivity occur, cut-off points (breakpoints) in zone of 
inhibition size for categorising isolates as susceptible or resistant will be closer together (e.g. 
zone > 7.5 mm = susceptible but zone < 2.5 mm = resistant). Where broad ranges in sensitivity 
occur, breakpoints will be further apart (e.g. zone > 45 mm = susceptible and zone < 15 mm = 
resistant). This makes it clear that breakpoints for susceptibility/resistance must be defined 
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done at the species level using thousands of clinical and sometimes environmental isolates. In 
this study, there are not enough isolates to be able to do that and a scale was defined using 
all 73 HBC isolates for each individual antibiotic. I determined the interquartile range of the 
zone of inhibition sizes and categorised isolates ‘resistant’ if the zone of inhibition size was in 
the lower quartile or smallest 25 % of all zone sizes for a particular antibiotic (Fig. 4.4, Table 
4.2). Similarly, isolates were categorised ‘susceptible’ if the zone size was in the upper quartile 
or largest 25 % of all zone sizes for a particular antibiotic. Isolates with zone sizes in the middle 
50 % require further testing to determine whether or not they should be considered 
susceptible or resistant and are referred to as intermediate sensitivity; these will be excluded 
from downstream analyses. 
Figure 4.4. Proposed scale to define antibiotic resistance and susceptibility in human gut microbiota. I 
measured antibiotic susceptibility using single-concentration antibiotic disks and zone of inhibition size for nine 
antibiotics in 73 isolates (657 phenotypes in total). I ordered the zone of inhibition sizes for an individual 
antibiotic from largest to smallest and determined the interquartile range. I considered isolates ‘resistant’ if the 
zone size was in the lower quartile or smallest 25 % of all zone sizes for a particular antibiotic. Similarly, isolates 
were considered ‘susceptible’ if the zone size was in the upper quartile or largest 25 % of all zone sizes for a 
particular antibiotic. Isolates with zone sizes in the middle 50 % require further testing to determine whether or 




Q3 ≤ x ≤ Q4 (max) = susceptible
Q1 ≤ z < 3 = intermediate
























Table 4.2. Zone of inhibition limits used to categorise isolates of human gut bacteria as antibiotic-resistant or 
-susceptible. Zone of inhibition sizes for nine antibiotics in 73 isolates of human gut bacteria were determined. I 
ordered the zone of inhibition sizes for an individual antibiotic from largest to smallest and determined the 
interquartile range. I considered isolates ‘resistant’ if the zone size was in the lower quartile (min ≤ z < q1, where 
z = average of zone of inhibition in millimetres) or smallest 25 % of all zone sizes for a particular antibiotic. 
Similarly, isolates were considered ‘susceptible’ if the zone size was in the upper quartile (q3 ≤ z ≤ q4 (max)) or 
largest 25 % of all zone sizes for a particular antibiotic. Isolates with zone sizes in the middle 50 % (q1 ≤ z < q3) 
require further testing to determine whether or not they should be considered susceptible or resistant. For 
gentamicin, metronidazole and trimethoprim, all isolates with no zone of inhibition (0.00 mm) were considered 
resistant; any zone larger than 0.00 mm but smaller than the q3 value was considered intermediate. 
 
With this data it is possible to comment on the spectrum of antibiotic efficacy against diverse 
human commensal gut microbiota. For example, ceftriaxone appears a good example of a 
broad-spectrum antibiotic (i.e., an antibiotic that impacts several different bacterial taxa): all 
four phyla contain isolates that are very sensitive to this antibiotic (zone of inhibition > 25 mm, 
the midpoint in the range of zone of inhibitions measured). However, the proportions of 
isolates vary: for Proteobacteria, only one in 16 isolates (6.3 %) was susceptible to ceftriaxone, 
with one isolate (6.3 %) being resistant and the other 14 of intermediate sensitivity (87.5 %). 
In Bacteroidetes, one in 21 isolates (4.8 %) was susceptible to ceftriaxone, 12 isolates were 
resistant (57.1 %), and eight isolates were of intermediate sensitivity (38.1 %). In 
Actinobacteria, three in 12 isolates (25 %) were susceptible, one isolate was resistant (8.3 %) 
and eight isolates were of intermediate sensitivity (66.7 %). In Firmicutes, 14 in 25 isolates (56 
%) were susceptible to ceftriaxone, four isolates were resistant (16 %) and seven were of 
intermediate sensitivity (28 %). On the other hand, gentamicin would be considered a more 
Antibiotic Resistant (min ≤ z < q1) Intermediate (q1 ≤ z < q3) Susceptible (q3 ≤ z ≤ q4 (max)) 
Amoxicillin 0.00 ≤ z < 11.09 11.09 ≤ z < 36.76 36.76≤ z ≤ 52.85 
Ceftriaxone 0.00 ≤ z < 25.88 25.88 ≤ z < 34.90 34.90 ≤ z ≤ 48.85 
Ciprofloxacin 0.00 ≤ z < 8.12 8.12 ≤ z < 25.61 25.61 ≤ z ≤ 30.98 
Erythromycin 0.00 ≤ z < 11.35 11.35 ≤ z < 37.19 37.19 ≤ z ≤ 49.45 
Gentamicin 0.00 ≤ z ≤ 0.00 0.00 < z < 19.92 19.92 ≤ z ≤ 25.21 
Metronidazole 0.00 ≤ z ≤ 0.00 0.00 < z < 35.72 35.72 ≤ z ≤ 56.80 
Tetracycline 0.00 ≤ z < 9.87 9.87 ≤ z < 30.31 30.31 ≤ z ≤ 45.80 
Trimethoprim 0.00 ≤ z ≤ 0.00 0.00 < z < 21.32 21.32 ≤ z ≤ 55.91 
Vancomycin 0.00 ≤ z < 6.85 6.85 ≤ z < 25.47 25.47 ≤ z ≤ 36.205 
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narrow spectrum antibiotic (i.e., an antibiotic that impacts only specific taxa): no 
Bacteroidetes isolates were susceptible, but 19 were resistant (90.5 %; the other two isolates 
were of intermediate sensitivity (9.5 %)). In addition, no Actinobacteria were susceptible to 
gentamicin; all Actinobacteria isolates were of intermediate sensitivity. Four Firmicutes 
isolates were resistant to gentamicin (16 %) and another four were susceptible, with 17 
isolates (68 %) of intermediate sensitivity. Overall, these observations suggest that sensitivity 
varies within bacterial families and phyla and that different antibiotics affect certain families 
and phyla to different extents.  
 
4.2.4 Comparison of genomic predictions of antibiotic resistance with bacterial phenotypes 
and identification of unpredicted resistances 
Four key genotype/phenotype combinations can be defined by comparing these two datsets 
(Table 4.3): Confirmed Resistance (genetic resistance and phenotypic resistance both 
observed); Confirmed Susceptibility (no genetic or phenotypic resistance); Unpredicted 
Susceptibility (genetic resistance predicted but phenotypically susceptible) and Unpredicted 
Resistance (no genetic resistance predicted but phenotypically resistant).  
Table 4.3. Genotype/phenotype combinations of antibiotic sensitivity. Genotypes were determined by 
predicting the presence of antibiotic resistance genes and mutations described in CARD in the genomes of 73 
isolates of human gut bacteria. Phenotypes were determined by zone of inhibition antibiotic susceptibility testing 
and categorized as resistant or susceptible. This produces four possible genotype/phenotype combinations. 
 
 
  Presence of genetic resistance determinant (genotype) 
  Yes (Predicted Resistance) No (Predicted Susceptibility) 
Phenotype 
Resistant Confirmed Resistance Unpredicted Resistance 
Susceptible Unpredicted Susceptibility Confirmed Susceptibility 
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The distribution of these genotype/phenotype combinations among the 73 isolates is 
visualized in Figure 4.5 against their core genome phylogeny. Each cell represents a 
genotype/phenotype combination for a particular isolate and antibiotic. Visualising the data 
in this way shows patterns that can be generalized to each phylum. For example, Confirmed 
Resistances appear most common in the Proteobacteria and Bacteroidetes, whereas 
Actinobacteria have the fewest Confirmed Resistances. In contrast, Firmicutes appear to have 
the most Confirmed Susceptible isolates. In addition, the Proteobacteria isolates have the 
most Unpredicted Susceptibility genotype/phenotype combinations. All phyla feature 
Unpredicted Resistances; in some cases, these occur in every isolate of a particular phylum. 
For example, Proteobacteria and vancomycin; Bacteroidetes and Gentamicin; Firmicutes and 
























Figure 4.5. Distribution of antibiotic sensitivity genotype/phenotype combinations in 73 phylogenetically 
diverse isolates of human gut bacteria reveals many “unpredicted” resistances. The phylogeny was inferred 
from 40 core genes of 73 whole genome sequences of gut microbiota isolated from healthy human faecal 
samples. Each isolate was screened for antibiotic resistance to 9 antibiotics; in total 657 phenotypes were 
determined. Each cell in the figure represents an isolate’s genotype/phenotype combination for a particular 
antibiotic. Dark blue = Confirmed Resistance (genetic resistance and phenotypic resistance both observed); Light 
blue = Confirmed Susceptibility (no genetic or phenotypic resistance); Mid-blue = Unpredicted Susceptibility 
(genetic resistance predicted, but phenotypically susceptible) and Unpredicted Resistance (no genetic resistance 



















































































































Examining the proportion of these genotype/phenotype combinations per phylum more 
closely (Fig. 4.6) showed that Confirmed Resistance is significantly higher in Bacteroidetes 
compared to the overall set of 73 isolates (q value < 0.0001; p-values determined by Fisher 
exact tests, adjusted using the Benjamini, Hochberg, and Yekutieli method for q-values, 
significant when q < 0.05) and Confirmed Susceptibility is significantly higher in Firmicutes (q 
value < 0.0001). Unpredicted Susceptibility mainly occurs in Proteobacteria, where it was 
significantly enriched (q value < 0.001), plus a very small amount in Firmicutes. All phyla 
demonstrate Unpredicted Resistance, but this occurs significantly more so than expected in 
Bacteroidetes (q value < 0.001). The proportion of Unpredicted Resistance 
genotype/phenotype combinations can be considered as the rate of False Negatives (i.e., the 
absence of CARD resistance determinants but phenotypic resistance indicates susceptibility 
was falsely predicted). In addition, the proportion of Unpredicted Susceptibility can be 
considered as the rate of False Positives (i.e., the presence of CARD resistance determinants 
but phenotypic susceptibility indicates resistance was falsely predicted). Thus, the overall 
False Negative rate for all genotype/phenotype combinations in all isolates was 38.6 %: the 
highest False Negative rate (Unpredicted Resistance, 51.9 %) occurs in Bacteroidetes, followed 
by 40.5 % in Actinobacteria, 39.6 % in Proteobacteria and 29.7 % in Firmicutes. The overall 
False Positive (Unpredicted Susceptibility) rate is 3.2 %: the highest False Positive rate occurs 
in Proteobacteria (11.0 %) and the lowest is 0.72 % in Firmicutes. There were no False Positives 
in Actinobacteria or Firmicutes. Therefore, antibiotic resistance seems to be more accurately 




Figure 4.6. The proportion of genotype/phenotype combinations for each phylum. The number of 
genotype/phenotype combinations overall for all 73 isolates and each phylum was counted: All – 352; 
Actinobacteria – 37; Bacteroidetes – 81; Firmicutes – 138; Proteobacteria – 96. The proportion of specific 
combinations e.g. Confirmed Resistance, Confirmed Susceptibility, Unpredicted Resistance and Unpredicted 
Susceptibility was also determined across all 73 isolates tested and in each phylum. Confirmed Resistance was 
significantly enriched in Bacteroidetes (q value < 0.0001) compared to the overall Confirmed Resistance rate and 
was significantly lower in Firmicutes (q < 0.0001). Confirmed Susceptibility was enriched in Firmicutes (q < 
0.0001) and occurred significantly less in Bacteroidetes than expected (q < 0.0001). Unpredicted Resistance was 
found in all phyla, but significantly more in Bacteroidetes (q = 0.0354). Unpredicted Susceptibility significantly 
occurs in Proteobacteria (q < 0.0001), with a very small amount in Firmicutes. P-values determined by Fisher 
exact tests, adjusted for multiple-testing using the Benjamini, Hochberg, and Yekutieli method; significant when 
q < 0.05. Unpredicted Resistance can also be considered a False Negative result and Unpredicted Susceptibility 
can be considered a False Positive result. 
 
Assessing the proportion of genotype/phenotype for each antibiotic (Fig. 4.7) reveals that 
resistance is also more accurately predicted for some antibiotics than others. For example, 
both amoxicillin and tetracycline have significantly more Confirmed Resistances (34.2 % and 
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(13.9 %) across all genotype/phenotype combinations (q values 0.035 and < 0.0001 
respectively; p-values determined by Fisher exact tests, adjusted using the Benjamini, 
Hochberg, and Yekutieli method for q-values; significant when q < 0.05). Confirmed 
Susceptibility was not significantly different for any antibiotic compared to the overall rate 
(45.2 % of genotype/phenotype combinations across all antibiotics, ranging from 33.3 % to 
50.0 % for individual antibiotics). Unpredicted Susceptibility is only observed for ceftriaxone, 
ciprofloxacin, gentamicin, and vancomycin, although was not significantly enriched in any of 
these antibiotics. The overall False Positive (Unpredicted Susceptibility) rate was 3.13 % of 
genotype/phenotype combinations, with the highest False Positive rate occurring for 
gentamicin (11.9 %), closely followed by ciprofloxacin (10.5 %), then dropping to 2.63 % for 
vancomycin; False Positives were not observed for amoxicillin erythromycin, metronidazole, 
tetracycline and trimethoprim. The overall False Negative (Unpredicted Resistance) rate was 
much higher, at 37.8 % of genotype/phenotype combinations. Whilst no antibiotic was 
enriched for more Unpredicted Resistances than expected, the False Negative rate was also 
highest for gentamicin (54.8 %), and similarly high for ciprofloxacin (50.0 %), vancomycin (50.0 
%), and trimethoprim (48.8 %). The lowest False Negative rates occurred for amoxicillin (15.8 
%) and tetracycline (5.26 %); indeed, False Negatives (Unpredicted Resistances) were 
observed significantly less often for tetracycline (q value < 0.0001) than expected, based on 
the overall rate. Overall, that all nine antibiotics have False Negative results (Unpredicted 
Resistances) further indicates that the isolates examined contain more antibiotic resistance 





Figure 4.7. The proportion of genotype/phenotype combinations for each antibiotic. The number of 
genotype/phenotype combinations overall for all antibiotics (“All”) and each antibiotic was counted: All – 352; 
Amoxicillin – 38; Ceftriaxone – 38; Ciprofloxacin– 38; Erythromycin – 37; Gentamicin – 42; Metronidazole – 42; 
Tetracycline – 38; Trimethoprim – 41; Vancomycin – 38. The proportion of specific combinations e.g. Confirmed 
Resistance, Confirmed Susceptibility, Unpredicted Resistance and Unpredicted Susceptibility was also 
determined across all and for each antibiotic. Confirmed Resistance is enriched in amoxicillin and tetracycline (q 
values = 0.035 and < 0.0001 respectively). Unpredicted resistance was observed significantly fewer times than 
expected for tetracycline compared to all antibiotics (q < 0.0001). P-values determined by Fisher exact tests, 
adjusted for multiple-testing using the Benjamini, Hochberg, and Yekutieli method; significant when q < 0.05. 
Unpredicted Resistance can also be considered a False Negative result and Unpredicted Susceptibility can be 






























































































4.2.5 Comparison of antibiotic resistance databases and prediction methods 
Having identified that the ARIBA with CARD rule-based method is not completely accurate, 
other databases and methods were applied to the 73 isolates to provide alternative 
predictions of resistance genotypes (Fig. 4.8): the CARD’s own Resistance Gene Identifier tool 
(CARD-RGI) and ARIBA with the MegaRes, ResFinder, and SRST2-ARGANNOT databases were 
used. I then compared the newly generated resistance genotypes to the phenotypic data 
generated for the nine antibiotics to determine proportions of each genotype/phenotype 
combination (Confirmed Resistance, Confirmed Susceptibility, Unpredicted Resistance and 
Unpredicted Susceptibility) for each method. The proportion of each combination in the four 
new methods was compared to the proportion from the initial ARIBA with CARD analysis 
performed in this thesis. This shows that the ResFinder and SRST2-ARGANNOT databases had 
significantly higher proportions of Confirmed Susceptibility, but no significant differences in 
the other three genotype/phenotype combinations. All databases perform similarly in terms 
of the rate of False Negatives (Unpredicted Resistances), though it was highest when using 
ARIBA with the MegaRes database (45.5 %, compared to 45.1 % for ARIBA with CARD, 39.8 % 
for CARD-RGI, 39.2 % for ARIBA with ResFinder, and 38.9 % for ARIBA with SRST2-ARGANNOT). 
Despite a significant increase in Confirmed Resistance genotype/phenotype combinations 
with CARD-RGI, this tool also had a higher rate of False Positives (Unpredicted Susceptibility; 
8.5 % compared to 3.1 % for ARIBA with CARD, 2.8 % for ARIBA with MegaRes, and 0.9 % for 
ARIBA with SRST2-ARGANNOT). Therefore, CARD-RGI in particular seems to overpredict 
resistance using genomic data (predicting resistance when the isolate is susceptible). For these 







Figure 4.8. The proportion of genotype/phenotype combinations for each resistance database or method 
tested. The proportion of specific combinations e.g. Confirmed Resistance, Confirmed Susceptibility, 
Unpredicted Resistance and Unpredicted Susceptibility was determined for each database and method (total 
combinations = 352 for each method). These proportions were compared to the original ARIBA+CARD 
proportions using a two-proportion z test with Yates correction (q value significant when q < 0.05). The CARD 
Resistance Gene Identifier (CARD-RGI) method had significantly lower proportion of Confirmed Susceptibility (q 
= 0.0385) and significantly higher proportions of Confirmed Resistance and Unpredicted Susceptibility (q values 
0.0103 and 0.0377 respectively). ARIBA with the RESFINDER and SRST2-ARGANNOT databases both had 
significantly higher proportions of Confirmed Susceptibility than ARIBA+CARD (q = 0.0147 and 0.0119 
respectively). Unpredicted Resistance can also be considered a False Negative result and Unpredicted 













































































4.2.6 Identifying enrichment of unpredicted resistance to certain antibiotics in particular 
phyla 
Determining which phyla have Unpredicted Resistances to certain antibiotics (Fig. 4.9) shows 
that Actinobacteria and Proteobacteria only have Unpredicted Resistance against three and 
four antibiotics respectively, whereas Firmicutes and Bacteroidetes demonstrate Unpredicted 
Resistance for six and eight antibiotics respectively. In particular, Actinobacteria were 
enriched in unpredicted metronidazole and trimethoprim resistance (q values 0.027 and 0.042 
respectively; p-values determined by Fisher exact tests, adjusted using the Benjamini, 
Hochberg, and Yekutieli method for q-values, significant when q < 0.05). Bacteroidetes were 
especially enriched in unpredicted gentamicin resistance (q < 0.0001). Firmicutes were 
enriched in unpredicted ciprofloxacin resistance (q value 0.014), but fewer unpredicted 
metronidazole and vancomycin resistances were observed than expected (q values both 
0.005). Proteobacteria were not enriched for any unpredicted resistances. Therefore, each 
phylum has different profiles of Unpredicted Resistances. In addition, this data supports the 
previous findings that Proteobacteria appears to have resistance more accurately predicted, 
and that unpredicted resistance overall was more common in non-Proteobacteria. However, 
as we previously saw that the Proteobacteria have large proportions of Unpredicted 







Figure 4.9. The percentage of Unpredicted Resistance antibiotic genotype/phenotype combinations by which 
phyla those combinations were observed in. Proteobacteria and Actinobacteria only demonstrate unpredicted 
resistance for three antibiotics, whereas Bacteroidetes and Firmicutes demonstrate unpredicted resistance for 
eight and six antibiotics respectively. Actinobacteria were enriched for Unpredicted Resistance to Metronidazole 
and Trimethoprim (q = 0.027 and 0.042 respectively). Bacteroidetes were enriched overall for Unpredicted 
Resistance (q = 0.042) but especially gentamicin Unpredicted Resistance (q < 0.0001). Firmicutes were enriched 
for ciprofloxacin Unpredicted Resistance (q = 0.014) but significantly fewer metronidazole and vancomycin 
Unpredicted Resistances were observed compared to the complete dataset (q values both 0.005). Proteobacteria 
were not enriched for any Unpredicted Resistances; significantly fewer Unpredicted Resistances were observed 
for ciprofloxacin (q = 0.042), gentamicin (q = 0.027), metronidazole (q = 0.042), trimethoprim (q = 0.042) and 
vancomycin (q < 0.0001). P-values determined by Fisher exact tests, adjusted for multiple-testing using the 

















































































Phylum: Actinobacteria Bacteroidetes Firmicutes Proteobacteria
n = 6 n = 12 n = 19 n = 15 n = 22 n = 18 n = 2 n = 20 n = 19
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Considering the data so far, it is clear that the ARIBA + CARD method used here to initially 
predict antibiotic resistance in these human commensal gut bacteria is not accurate. In 
addition, the isolates studied contain more antibiotic resistance than is predicted using a rule-
based method with the CARD database of known, clinically relevant antibiotic resistance 
determinants. In particular, the Bacteroidetes isolates were enriched for False Negatives 
(Unpredicted Resistance) and Proteobacteria isolates were enriched for False Positives 
(Unpredicted Susceptibility). 
 
4.2.7 Further investigations of unpredicted resistance 
Unpredicted Resistance genotype/phenotype combinations represent instances of a 
mismatch between two important methods for determining antibiotic sensitivity (culture-
based- and WGS-AST). Some of these unpredicted resistance observations are likely explained 
by intrinsic resistance; for example, where they occur in all isolates of a particular phyla, 
including gentamicin in the Bacteroidetes isolates studied or vancomycin in the 
Proteobacteria (Fig. 4.5). However, where these unpredicted resistances occur in isolates that 
are closely related to isolates susceptible to that same antibiotic, these may be explained by 
genetic resistance determinants that are novel, or not described in CARD. This offers the 
opportunity to look for candidate novel antibiotic resistance genes or mutations in isolates 
with unpredicted resistance. In particular, there are instances of unpredicted ceftriaxone 
resistances observed in Bacteroidetes and Firmicutes where closely related isolates 
demonstrate Confirmed Susceptibility or Confirmed Resistance. As ceftriaxone resistance is 
often mediated by beta-lactamase enzymes these examples may indicate the presence of 
novel beta-lactamases in these human commensal gut microbiota. 
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Two particular isolates appeared good targets for novel beta-lactamases: Bacteroides faecis 
18048_2#66 and Lachnospiraceae nov. 20287_6#18. These isolates both had ceftriaxone zone 
of inhibition sizes of 0 mm, indicating complete resistance to this beta-lactam antibiotic. They 
were also in the top five most ceftriaxone-resistant isolates (Fig. 4.10), but were the only two 
of those five without genetic determinants of beta-lactam resistance in their genomes. 
  
  
Figure 4.10. Ranking of isolates by ceftriaxone sensitivity. The average zone of inhibition sizes was used to rank the 73 HBC isolates by ceftriaxone sensitivity (bottom = most 
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4.2.8 Searching for novel antibiotic resistance determinants in human gut commensal 
microbiota 
A comparative phenotyping and genomics approach was used to identify candidate novel 
resistance genes from Bacteroides faecis 18048_2#66 and Lachnospiraceae nov. 20287_6#18. 
I determined the average nucleotide identity (ANI), a measure of genomic similarity between 
the coding regions of two genomes, for each isolate under investigation and its closest two 
relatives from the HBC (Fig. 4.11). The two related B. faecis isolates, B. faecis 13470_2#65 and 
B. faecis 12718_7#26 were both more than 99 % similar by ANI to B. faecis 18048_2#66. 
Lachnospiraceae nov. 20287_6#18 had a very close relative of 99.24 % ANI, Lachnospiraceae 
nov. 8080_1#94, but the second next most closely related isolate from the HBC (Coprococcus 
nov. 20298_3#65) was only 81 % similar by ANI. 
I determined the average Minimum Inhibitory Concentration (MIC) for ceftriaxone for each of 
the six isolates using Biomerieux Etests (antibiotic gradient strips) across three biological 
replicates (Figure 4.11). The average MIC for the two isolates with Unpredicted Resistance to 
ceftriaxone, B. faecis 18048_2#66 and Lachnospiraceae nov. 20287_6#18, was at least 256 
µg/ml. The maximum concentration of ceftriaxone in the Etest strip was 256 µg/ml; these 
results mean that those two isolates were completely resistant to ceftriaxone at the maximum 
concentration tested and so the MIC is greater than or equal to 256 µg/ml. For B. faecis 
18048_2#66, both related isolates B. faecis 13470_2#65 and B. faecis 12718_7#26 were more 
sensitive to ceftriaxone, with MICs under 60 µg/ml. The Lachnospiraceae nov. 8080_1#94 
isolate shared the same phenotype as Lachnospiraceae nov. 20287_6#18 with an MIC of at 
least 256 µg/ml, and the Coprococcus nov. 20298_3#65 was much more sensitive with an MIC 




Figure 4.11. Comparison of ceftriaxone sensitivity in two sets of isolates from the HBC. Bacteroides faecis 
18048_2#66 and Lachnospiraceae nov. 20287_6#18 were identified as having unpredicted ceftriaxone 
resistance. Their two closest relatives each were identified from the HBC using a 40 core gene phylogeny and 
Average Nucleotide Identity (ANI) was determined for the two closest relatives compared to the isolate in which 
unpredicted resistance was observed. The ceftriaxone Minimum Inhibitory Concentration (MIC, µg/ml) was 
determined for each isolate. 
 
This data offers the opportunity to identify genomic differences between those isolates that 
may explain phenotypic differences. The Lachnospiraceae nov. 20287_6#18 isolate will be 
excluded since its most closely related isolate shared a ceftriaxone resistant phenotype and 
the ceftriaxone-susceptible Coprococcus nov. 20298_3#65 is a different species making 
genomic identification impractical. The B. faecis isolates, however, represent an ideal 
situation of very closely related isolates with differing phenotypic ceftriaxone sensitivity. In 
the rest of this section, I will investigate genomic differences between these B. faecis isolates 
to identify potential candidate beta-lactamase genes or mutations that may confer the 
unpredicted ceftriaxone resistance observed in B. faecis 18048_2#66. 
Core genome analysis was performed using Roary201 on the three B. faecis isolates and 
identified 3652 genes shared by all three isolates (“shared core genes”) and 614 genes unique 
to the ceftriaxone resistant B. faecis 18048_2#66 (“resistant-unique genes”, absent from the 
two more sensitive B. faecis isolates). ShortBRED209 was used to reduce the amino acid 





















NCBI Protein database as of July 2018) into a database of reference amino acid markers. This 
includes beta-lactamase regulatory proteins so can possibly account for regulatory mutations 
too. These markers were used to search the translated amino acid sequences of the 614 
resistant-unique genes and the 3652 shared core genes with 90 % identity. Other cut offs were 
tested (Table 4.4); however for subsequent analyses the 90 % cut off was used as a high level 
of similarity is typically required to infer functionality. Seven of the shared core genes were 
found to have amino acid sequences 90 % similar to reference amino acid markers from beta-
lactamases (Table 4.5). A single gene labelled “Group 2384” was annotated as a candidate 
beta-lactamase.  
 
Table 4.4. Numbers of resistant-unique and shared core genes with similarity to beta-lactamase markers in 
the human gut bacteria isolate Bacteroides faecis 18048_2#66. ShortBRED194 was used to reduce the amino acid 
sequences of 235,009 proteins containing the phrase “beta-lactamase” in their name from NCBI Protein database 
(as of July 2018) into a database of reference amino acid markers. These markers were used to search the 
translated amino acid sequences of the 614 resistant-unique genes and the 3652 shared core genes with a variety 
of similarity cut offs. 
Identity cut off (%) No. of resistant-unique genes matched No. of shared core genes matched 
90 1 7 
80 1 15 
70 1 20 
60 2 30 
50 3 52 
25 23 244 
  
Table 4.5. A summary of candidate beta-lactamases that may explain an unpredicted ceftriaxone resistance phenotype observed in the human gut bacteria isolate Bacteroides 
faecis 18048_2#66. This isolate was phenotypically resistant to ceftriaxone in the absence of genetic determinants of beta-lactam resistance described in CARD. The closest two 
relatives from the HBC were identified and also phenotyped; they were both more sensitive to ceftriaxone. Roary core genome analysis was performed to identify genes unique to 
the resistant isolate (“resistant unique”) and genes shared by all three isolates (“shared core”). These genes were searched for sequences with 90 % similarity to amino acid markers 
derived from 230,009 beta-lactamase related proteins in the NCBI Protein database. The table describes the genes that were found to contain markers of these proteins, what the 
genes were annotated as by Roary and the protein that the observed marker is derived from. 
Category Gene Annotation NCBI Beta-lactamase marker hit 
Resistant unique Group 2384 Beta-lactamase domain-containing protein WP004329300 MULTISPECIES: MBL fold metallo-hydrolase [Bacteroidales] 
Shared core ampG1 Major Facilitator Superfamily NP812531 AmpG protein, beta-lactamase induction signal transducer [Bacteroides 
thetaiotaomicron VPI-5482] 
Shared core ampG2 Signal transducer NP809947 signal transducer [Bacteroides thetaiotaomicron VPI-5482] 
Shared core blaR1 Transcriptional regulator WP010538315 MULTISPECIES: M56 family metallopeptidase [Bacteroides] 
Shared core Group 106 TonB WP062695069 M56 family peptidase [Bacteroides thetaiotaomicron] 
Shared core Group 3492 Protein of unknown function (DUF2874) WP062695288 hypothetical protein [Bacteroides thetaiotaomicron]; Putative beta-
lactamase-inhibitor-like, PepSY-like; pfam11396 
Shared core Group 4547 Protein of unknown function (DUF2874) WP008766859 hypothetical protein [Bacteroides thetaiotaomicron]; Putative beta-
lactamase-inhibitor-like, PepSY-like; pfam11396 
Shared core Group 6146 Putative exported beta-lactamase protein WP008769828 DUF302 domain-containing protein [Bacteroides fragilis]; Beta-lactamase; 
pfam00144 
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Subsequently, I investigated whether any of these candidate beta-lactamases might explain 
the unpredicted ceftriaxone resistance in B. faecis 18048_2#66. Firstly, I determined whether 
the candidate beta-lactamase gene Group 2384 unique to the resistant isolates corresponded 
with increased ceftriaxone MIC. To do this, I looked for the presence of Group 2384 in the 
complete set of HBC genomes with 100 % sequence length and nucleotide identity. This gene 
was identified in 16 other HBC isolates, all in the Bacteroidetes phylum. Five of these 
Bacteroidetes isolates were excluded from further analysis due to the presence of other 
genetic beta-lactam resistance determinants (identified in the analyses discussed in Chapter 
3). For the 11 remaining Bacteroidetes isolates, I measured the ceftriaxone MICs for their 
closest relatives in the HBC (Fig. 4.12). In theory, if Group 2384 was responsible for the 
ceftriaxone-resistance phenotype in B. faecis 18048_2#66 and potentially other Bacteroidetes 
isolates, I would expect the presence of Group 2384 in an isolate’s genome to correspond with 
a higher ceftriaxone MIC. This correlation was not observed, suggesting that this candidate 
beta-lactamase may not be responsible for this phenotype, or that it is not functional in the 




Figure 4.12. Ceftriaxone MIC in isolates with and without the Group 2384 candidate beta-lactamase gene. 
Group 2384 is a candidate beta-lactamase first identified in the Bacteroides faecis 18048_2#66, an isolate with 
unpredicted ceftriaxone resistance (highlighted in yellow). The presence of the Group 2384 gene was searched 
for in the HBC (100 % sequence length and ID) and was identified in 16 isolates. 11 Group 2384-positive isolates 
without any other predicted beta-lactam resistance (determined using CARD) plus each of their two closest 
relatives from the HBC were selected. ANI analysis was used to determine how similar the Group2384-negative 
isolates were to their closest Group 2384-positive relative. Ceftriaxone MICs were measured using Etests in three 
biological replicates of ach isolate. The presence of Group2384 was not correlated with a lower MIC for 
amoxicillin and ceftriaxone. 
 
Although the presence of Group 2384 did not correlate with increased ceftriaxone MIC and 
thus resistance in other HBC isolates, this does not necessarily rule out its function as a 
ceftriaxone-resistance gene in B. faecis 18048_2#66. It is possible that it is not expressed in 
the other isolates or contains mutations that leave it non-functional. To rule out the latter 
hypothesis, I extracted and aligned the Group 2384 sequences from the twelve Group 2384-
positive isolates I tested for phenotypic ceftriaxone sensitivity to infer a phylogenetic tree (Fig. 
4.13). Whilst the Group 2384 genes were not identical, very few mutations were identified: 
Bacteroides vulgatus 18048 2#68 has base T at position 545 where the other eleven isolates 






























































base C at gene position 15, whereas the other five Group 2384-positive isolates have base T 
(Fig. 4.13). These mutations were all synonymous and did not alter the amino acid sequence. 
Therefore, it is unlikely that these mutations had any direct impact on the hypothetical 
function of Group 2384 as a ceftriaxone beta-lactamase, especially since six of the eleven 






































Figure 4.13. Group 2384 gene sequences from twelve HBC isolates. Group 2384 is a candidate beta-lactamase 
first identified in the Bacteroides faecis 18048_2#66, an isolate with unpredicted ceftriaxone resistance 
(highlighted in yellow). A: the nucleotide sequence for the Group 2384 gene was extracted from 11 other HBC 
isolates in which it was identified, aligned and used to infer a phylogeny and identify mutations (labelled at 
branch points). B: the alignment of nucleotides 1-40 and 521-560 are shown to illustrate the single nucleotide 




















                                            1         40
          Bacteroides finegoldii 13414_6#45 ATGAAAAAGA CATCCACAGT ACAATTGGTG CGCAATGCCA
           Alistipes onderdonkii 21673_4#13 ATGAAAAAGA CATCCACAGT ACAATTGGTG CGCAATGCCA
           Alistipes onderdonkii 21673_4#9  ATGAAAAAGA CATCCACAGT ACAATTGGTG CGCAATGCCA
           Alistipes onderdonkii 13414_6#74 ATGAAAAAGA CATCCACAGT ACAATTGGTG CGCAATGCCA
        Odoribacter splanchnicus 18048_2#90 ATGAAAAAGA CATCCACAGT ACAATTGGTG CGCAATGCCA
           Alistipes onderdonkii 11861_6#62 ATGAAAAAGA CATCCACAGT ACAATTGGTG CGCAATGCCA
              Bacteroides faecis 18048_2#66 ATGAAAAAGA CATCCACAGT ACAATTGGTG CGCAATGCCA
       Bacteroides xylanisolvens 20298_3#31 ATGAAAAAGA CATCTACAGT ACAATTGGTG CGCAATGCCA
      Parabacteroides distasonis 18048_2#71 ATGAAAAAGA CATCTACAGT ACAATTGGTG CGCAATGCCA
       Bacteroides xylanisolvens 12718_7#32 ATGAAAAAGA CATCTACAGT ACAATTGGTG CGCAATGCCA
      Parabacteroides distasonis 18048_2#61 ATGAAAAAGA CATCCACAGT ACAATTGGTG CGCAATGCCA
            Bacteroides vulgatus 18048_2#68 ATGAAAAAGA CATCTACAGT ACAATTGGTG CGCAATGCCA
                                          521         560
          Bacteroides finegoldii 13414_6#45 TGACTATATC GTGGTAAACT CCGGAGGTGC AATCTTTCCC
           Alistipes onderdonkii 21673_4#13 TGACTATATC GTGGTAAACT CCGGAGGTGC AATCTTTCCC
           Alistipes onderdonkii 21673_4#9  TGACTATATC GTGGTAAACT CCGGAGGTGC AATCTTTCCC
           Alistipes onderdonkii 13414_6#74 TGACTATATC GTGGTAAACT CCGGAGGTGC AATCTTTCCC
        Odoribacter splanchnicus 18048_2#90 TGACTATATC GTGGTAAACT CCGGAGGTGC AATCTTTCCC
           Alistipes onderdonkii 11861_6#62 TGACTATATC GTGGTAAACT CCGGAGGTGC AATCTTTCCC
              Bacteroides faecis 18048_2#66 TGACTATATC GTGGTAAACT CCGGAGGTGC AATCTTTCCC
       Bacteroides xylanisolvens 20298_3#31 TGACTATATC GTGGTAAACT CCGGAGGTGC AATCTTTCCC
      Parabacteroides distasonis 18048_2#71 TGACTATATC GTGGTAAACT CCGGAGGTGC AATCTTTCCC
       Bacteroides xylanisolvens 12718_7#32 TGACTATATC GTGGTAAACT CCGGAGGTGC AATCTTTCCC
      Parabacteroides distasonis 18048_2#61 TGACTATATC GTGGTAAACT CCGGAGGTGC AATCTTTCCC




To further investigate the potential function of Group 2384 as a ceftriaxone resistance-
conferring beta-lactamase I performed a gain-of-function cloning experiment. A plasmid 
carrying a chloramphenicol resistance marker gene and the Group 2384 gene was designed 
with GeneArt (ThermoFisherScientific; Fig. 4.14). The Group 2384 gene was inserted within a 
tetracycline resistance gene, under the control of the tetracycline resistance gene promoter. 
The synthesised construct was transformed into electrocompetent E. coli cells via 
electroporation with the assistance of Mr Matthew Dorman. The transformed cells were 
grown on LB agar plates containing chloramphenicol (12.5 μg/mL) to check that the vector 
had been taken up by the E. coli cells. Transformed cells were also plated on LB agar containing 
chloramphenicol (12.5 μg/mL) and ceftriaxone at a concentration of 256 μg/mL (representing 
the observed B. faecis 18048_2#66 phenotype) and 4 μg/mL (slightly above the MIC of the 
untransformed E. coli). Whilst colonies were observed on the chloramphenicol control plates, 
no colonies were observed in the presence of either concentration of ceftriaxone. This 
suggests the Group 2384 gene may not infer ceftriaxone resistance and explain the 
unpredicted phenotype in B. faecis 18048_2#66.  
Figure 4.14. GeneArt construct containing Group 2384 candidate beta-lactamase gene. The plasmid pACYC184 
was used as the cloning vector, designed and synthesised using GeneArt (ThermoFisherScientific) to contain the 
gene sequence of the Group 2384 candidate beta-lactamase identified from Bacteroides faecis 18048_2#66. The 
Group 2384 gene was inserted within a tetracycline resistance gene, under the control of the tetracycline 





It is possible that a mutation in a shared candidate beta-lactamase in the B. faecis isolates 
could cause the unpredicted ceftriaxone resistance phenotype. The gene sequence for each 
of the seven shared candidate beta-lactamases were extracted from the three B. faecis 
isolates and used to infer phylogenetic trees for each gene from the nucleotide sequences 
(Fig. 4.15). I looked for non-synonymous mutations that would alter the amino acid sequence 
of the protein product and could result in altered activity between the resistant B. faecis 
18048_2#66 and more sensitive B. faecis 12718_7#26 and B. faecis 13470_2#65. Amino acid 
substitutions were identified in five of seven shared candidate beta-lactamases; in only one 
of these, “ampG2”, was there a substitution unique to resistant B. faecis 18048_2#66. AmpG2 
is a putative transporter related to AmpG, which possibly transports signal molecules into P. 
aeruginosa cells for the induction of the ampC beta-lactamase244. AmpG2 may function in a 
similar way; a non-synonymous mutation in this gene could potentially explain the phenotypic 
differences in these three isolates; however, it does not tell us exactly which beta-lactamase 
is degrading the ceftriaxone and amoxicillin antibiotics in B. faecis 18048_2#66. It could be 




Figure 4.15. Gene phylogenies of candidate shared beta-lactamases in three HBC Bacteroides faecis isolates. 
Seven genes (A-G) shared between three isolates of B. faecis from the HBC were found to contain markers of 
beta-lactamase related proteins from the NCBI Protein database. One of the isolates was observed to be resistant 
to ceftriaxone in the absence of any known clinically relevant beta-lactam resistance determinant. Amino acid 
substitutions were observed in five of the seven genes; only in one gene was the mutation unique to the resistant 















































Following these experiments, I applied a shotgun cloning approach to look for novel beta-
lactam resistance genes from the whole genomes of B. faecis 18048_2#66 and 
Lachnospiraceae nov. 20287_6#18. Both isolates were regrown from HBC glycerol stocks kept 
at -80 °C, single colonies purified and grown in culture overnight. The full length 16S rRNA 
sequences were amplified from these cultures using 7f and 1510r PCR primers and sequenced 
by Sanger sequencing at Eurofins Scientific (Germany). The 16S rRNA sequences were then 
checked against the whole genome sequence data for these isolates to confirm their identity 
and check for contamination. Following this quality control, genomic DNA was extracted from 
the culture pellets of each isolate using phenol:chloroform extraction method by Mr Mark 
Stares. These genomic samples were used as starting material for the Copy Control Fosmid 
Cloning Kit (Lucigen) to clone 25-40 kb fragments into E. coli using fosmid vectors and Lambda 
phages. I determined the ceftriaxone MIC of the recipient E. coli strain using Etests as before. 
The Copy Control Fosmid Cloning method was applied to each isolate individually and 
therefore represents shotgun cloning from purified isolates rather than mixed samples. This 
enables identification of the host of any novel antibiotic resistance genes discovered in these 
experiments. The kit includes control DNA of 40kb fragments, which was included as quality 
control alongside shotgun cloning of the two isolates with unpredicted ceftriaxone resistance. 
The fosmid vector carries a chloramphenicol resistance marker gene; the transformed cells 
were grown on LB agar plates containing chloramphenicol to check that the vector had been 
taken up by the E. coli cells. The transformed E. coli cells were also grown on LB agar plates 
containing ceftriaxone at a concentration of 256 μg/mL (representing the observed B. faecis 
18048_2#66 phenotype) and 4 μg/mL (slightly above the MIC of the untransformed E. coli).  
This procedure was repeated four times. Each time, hundreds of colonies were observed on 
the LB plates with chloramphenicol from the E. coli transformed with the control insert DNA. 
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However, only one or two colonies were observed from E. coli transformed with DNA from 
Bacteroides faecis 18048_2#66 or Lachnospiraceae nov. 20287_6#18 on the LB plates with 
chloramphenicol and no colonies on plates containing chloramphenicol and ceftriaxone.  
 
4.3 Discussion 
In this chapter I have determined the susceptibility or resistance of 73 phylogenetically diverse 
human commensal gut bacteria isolates against nine commonly used, clinically relevant 
antibiotics from the WHO list of essential medicines21. This phenotypic data helps to 
determine a comprehensive view of the impact of commonly used antibiotics across the 
diversity of gut microbiota. This offers insights into the spectrum of antibiotics which may be 
used to inform healthcare practices – such as which antibiotics to prescribe for infections 
caused by opportunistic pathogens from the gut. The main antibiotic from this study that 
would be useful to specifically target opportunistic anaerobic or gut bacteria is metronidazole, 
as most Bacteroidetes and Firmicutes tested were generally sensitive to this antibiotic, 
although this increases the likelihood of impacting more members of the gut microbiota.  
In addition to knowing which antibiotics to use in the case of infections by opportunistic gut 
bacteria, this phenotypic data can advise on which antibiotics to avoid if trying to minimise 
the impact on commensal gut microbiota. For example, ceftriaxone is a broad-spectrum 
antibiotic245 and therefore is useful for treating infections of unknown cause or with resistance 
to narrower spectrum antibiotics. Although typically administered via injection, not orally, 
ceftriaxone is known to have an impact on the commensal gut microbiota246 and here I have 
showed that members of all four key gut microbiota could be affected. On the other hand, 
amoxicillin is also considered relatively broad spectrum, but here the only isolates that were 
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sensitive were Firmicutes, and one Bacteroidetes. Amoxicillin is one of the most commonly 
prescribed drugs in the world and typically administered orally for e.g. ear infections or throat 
infections. Amoxicillin also showed high levels of Confirmed Resistance; therefore, this 
antibiotic should also be used with caution as it may target Firmicutes, some of our most 
important gut microbiota. Moreover, there are already relatively high levels of amoxicillin 
resistance caused by known genetic determinants in commensal Proteobacteria that could 
potentially be transferred to pathogenic bacteria, especially under the selective pressure of 
amoxicillin therapy. 
Another example of note is that of gentamicin: gentamicin is considered a broad-spectrum 
antibiotic, but one that does not work on anaerobes and streptococci. This is because 
gentamicin relies on oxygen-dependent transport into bacteria cells24. The results in Figure 
4.5 demonstrate that this appears true for anaerobic Bacteroidetes, which were largely 
considered resistant to gentamicin. However, several Firmicute isolates were considered 
intermediate sensitivity or even susceptible, despite Lachnospiraceae (making up the majority 
of the Firmicutes isolates screened here) reported to be obligate anaerobes247. Therefore, 
gentamicin may have a more extensive impact on commensal gut microbiota than previously 
realized. Interestingly, there were no antibiotics that both Bacteroidetes and Firmicutes were 
both generally resistant to: all the antibiotics tested here have the potential to cause harm to 
common commensal gut microbiota.  
The antibiotic resistance phenotypes were compared to the predicted resistance profiles 
based on the presence of genetic resistance determinants described in CARD, as determined 
in the previous chapter. The observations in this chapter follow a rule-based method of 
predicting antibiotic sensitivity phenotypes from antibiotic resistance genotypes. Rule-based 
methods have been found to be accurate for predicting antibiotic resistance in several species 
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of bacterial pathogens240,242,248. However, to my knowledge they have not been tested for 
accuracy in human gut commensal bacteria. I created a system to define the combined data 
as Confirmed Susceptibility, Confirmed Resistance, intermediate sensitivity (with or without 
genetic resistance determinants present), Unpredicted Susceptibility and Unpredicted 
Resistance. This revealed Unpredicted Susceptibility (False Positive results) to be most 
common in Proteobacteria and Unpredicted Resistance (False Negative results) most common 
in Bacteroidetes, but observed for all four phyla and all nine antibiotics.  
By identifying unpredicted resistances, this suggests that the results in the previous chapter 
where antibiotic resistance determinants are enriched in Proteobacteria is not a true 
reflection of an enrichment of phenotypic antibiotic resistance. As in the previous chapter, it 
is important to note that database bias may explain this: a database designed from pathogenic 
bacteria (which are predominantly Proteobacteria, see Fig 1.3) may be more likely to identify 
similar antibiotic resistance genes or mutations in bacterial isolates more closely related to 
pathogens. It is likely that this partially explains the difference in observed enrichment of 
antibiotic resistance genotypes and antibiotic resistance phenotypes. Indeed, using 
alternative databases with generally similar False Positive and False Negative rates supports 
this. Moreover, the system I defined to classify isolates as phenotypically susceptible or 
resistant used all the isolates studied. In the future, the system should be redefined using 
isolates within more closely related taxa. Once studies approach the magnitude of those 
performed in pathogenic isolates (e.g. hundreds or thousands of isolates per species), the 
species level would be the most appropriate taxon to use. However, that resistance is better 
predicted to some antibiotics than others may also reflect the main mechanism of resistance 
for these enzymes: antibiotic resistance caused by the presence or absence of a particular 
gene (e.g. beta-lactamases or tetracycline resistance proteins are more likely to be called 
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accurately than a single nucleotide mutation). The largest proportion of the Unpredicted 
Resistances in Bacteroidetes were for gentamicin (46 %), which as discussed is thought not to 
work on anaerobic organisms such as Bacteroidetes. However, there are several other types 
of Unpredicted Resistance observed in the Bacteroidetes isolates, as well as relatively high 
levels of Confirmed Resistance. This indicates that Bacteroidetes make important 
contributions to the antibiotic resistance potential of the gut microbiota, which may have 
implications for the treatment of opportunistic pathogens caused by members of this phylum.  
It was difficult to account for potential intrinsic resistances in this study to allow for the fact 
that current rules of antibiotic spectrum might not apply across the diversity of gut bacteria. I 
have already discussed one instance where Unpredicted Resistances might have been due to 
intrinsic resistance (gentamicin), but all the Proteobacteria isolates were also resistant to 
vancomycin as well. This antibiotic targets Gram-positive bacteria specifically, so this result is 
not surprising. In other cases, where there is variation on genotype/phenotype combinations 
between very closely related isolates, Unpredicted Resistances might indicate instances of 
novel antibiotic resistance genes or mutations.  
In this study I identified two isolates with the highest possible ceftriaxone resistance measured 
in the absence of any genetic determinants of beta-lactam resistance. I investigated these 
isolates, Bacteroides faecis 18048_2#66 and Lachnospiraceae nov. 20287_6#18, for novel 
antibiotic resistance genes. This included detailed analysis and experiments regarding one 
particular candidate beta-lactamase (“Group 2384”), although I was not able to confirm its 
function. The Group 2384 gene was integrated into the pACYAC184 plasmid within a 
tetracycline resistance gene and thus was under the control of the tetracycline resistance gene 
promoter. Accordingly, the Group 2384 gene should have been expressed; however, the 
mRNA may not have been translated into the protein product with potential beta-lactamase 
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activity. It is also possible that the observed phenotypic variation in the three B. faecis isolates 
could be caused by differences in gene expression that cannot be detected with WGS alone. 
Q-PCR or RNA-sequencing of isolates growing in the presence of antibiotics, such as 
ceftriaxone, are two methods that may help determine if this is the case. In particular, qPCR 
experiments would help identify if the expression level of the candidate Group 2384 beta-
lactamase is associated with the presence of mutations (as discussed towards the end of 
section 4.2.8) and/or differences in ceftriaxone sensitivity. 
Furthermore, I was unable to identify any other candidate novel antibiotic resistance genes 
with the comparative genomics method. This could be due to the presence of novel beta-
lactamases of less than 90 % similarity to beta-lactamases in the NCBI Protein database, 
though above 60 % similarity, no additional candidate beta-lactamases were identified. Below 
50 % similarity, additional candidate beta-lactamase genes were identified and so these may 
be of interest; however, high sequence similarity is usually required to infer functional 
similarity249. This can be extended to other observations of Unpredicted Resistance; less 
stringent similarity cut offs when searching for the presence of antibiotic resistance 
determinants may produce more hits that could explain these observations, however, the 
Unpredicted Susceptibility rate is likely to rise in response.  
The shotgun cloning method did not prove successful in identifying candidate novel antibiotic 
resistance genes during this study either. As hundreds of colonies were yielded from the 
control input DNA, this suggests the problem lies with the input DNA from Bacteroides faecis 
18048_2#66 and Lachnospiraceae nov. 20287_6#18. The input DNA is therefore likely a highly 
critical factor for this protocol. In the future, this method will continue to be optimised within 
our laboratory as it would be a valuable tool to have available. Identifying genes conferring 
phenotypes such as antibiotic resistance and improve genome annotation in these organisms, 
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many of which are novel and/or uncharacterized, would be especially useful. In particular, any 
novel antibiotic resistance genes from gut bacteria should be curated into databases of known 
antibiotic resistance genes so that they can be included in antibiotic resistance surveillance 
programmes, such as the European Antimicrobial Resistance Genes Surveillance Network 
(EURGen-Net)250. 
Although susceptibility was generally better predicted than resistance, there were relatively 
high rates of Unpredicted Susceptibility in the Proteobacteria. This means that antibiotic 
resistance can be overpredicted. This also has relevance for healthcare: if a bacterium was 
predicted to be resistant to a particular antibiotic, a patient might be prescribed a different 
antibiotic that could pose more harm by being broader spectrum or more toxic than was 
required. Unpredicted susceptibility could be due to mis-calling a mutation as present when 
it is in fact absent, or by identifying the presence of housekeeping genes involved in the 
regulation of antibiotic resistance genes (such as the vanR regulator of vancomycin 
resistance251) . It could also be due to lack of expression or compensatory mutations to offset 
any fitness cost associated with the predicted antibiotic resistance mechanism. Alternatively, 
the observed genetic determinants of resistance could be taxon-specific. If a resistance 
determinant is observed in a taxon other than what it has been described in in the literature, 
something may be missing from the original host that is required for the determinant to be 
expressed or functional. It is again important to acknowledge the caveat of using CARD, 
whereby the majority of its antibiotic resistance genes and mutations have been described in 
just a few species of pathogenic bacteria. Therefore, in the context of commensal gut bacteria, 
they may not function as described in pathogenic isolates. It would be interesting to 
investigate these Unpredicted Susceptibilities in more depth. For example, the impact of 
individual genes on false predictions could be studied: if the presence of a gene or mutation 
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always results in Unpredicted Susceptibility (i.e., despite its presence the isolate is susceptible 
to that antibiotic), then determinants with this pattern could be filtered out as a poor 
predictor of antibiotic resistance. Taking this work forward must also involve looking for 
antibiotic resistance genes from other sources (e.g. curating those from functional 
metagenomic studies of bacterial communities) and determining specific relationships 
between the presence of antibiotic resistance determinants in a genome and antibiotic 
sensitivity. To really understand these relationships, more isolates of commensal gut bacteria 
should be studied (on a scale similar to that of pathogenic bacteria) and MICs should be 
determined for a more specific antibiotic sensitivity measurement.  
This chapter highlights that currently a rule-based approach to estimating antibiotic sensitivity 
in human gut microbiota is not without flaws. Databases of antibiotic resistance determinants 
established through research on a relatively small number of pathogens, such as CARD, should 
therefore be used with caution when applied to more diverse, less well-characterised 
organisms – such as the human gut microbiota. As demonstrated, these methods can under-
predict the antibiotic resistance of such isolates and show bias towards Proteobacteria. These 
databases can be useful and accurate for well-studied pathogenic bacteria168,252, but if we are 
to accurately predict antibiotic resistance in the human gut microbiota and in metagenomic 
samples, more comprehensive databases of resistance genes are required. It may be 
necessary to have separate databases for common pathogens and for other bacteria, such as 
opportunistic pathogens, commensal gut microbiota, or other types of environmental 
bacteria. Since pathogens can acquire antibiotic resistance genes from environmental 
bacteria, these types of databases would be useful to help monitor the emergence of clinically 
relevant antibiotic resistance in clinical isolates of disease-causing bacteria. However, this will 
require additional similar studies comparing antibiotic resistance genotypes and phenotypes 
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but at a much larger scale, perhaps using high throughput alternative phenotyping methods 
such as plate based assays253,254.  
Moreover, functional metagenomics can be a very useful tool for identifying candidate novel 
antibiotic resistance genes139,141,169,176,255,256, but requires optimization if used to study 
individual isolates. Putative ARGs are often annotated as such based on nucleotide or amino 
acid similarity to known antibiotic resistance genes/proteins and as such it is unknown 
whether they will confer phenotypic resistance. Determining the level of resistance that can 
be conferred and the distribution of novel resistance genes should become a routine part of 
these experiments. Since understanding antibiotic resistance genes among communities of 
bacteria and in individual, uncharacterized bacteria is difficult, perhaps prioritising 
bacteria/antibiotics of special interest – such as clinical or ecological relevance – is needed to 
focus the efforts of novel antibiotic resistance gene discovery. 
Overall, this chapter shows that phenotypic antibiotic resistance in gut microbiota can vary 
between closely related isolates of commensal gut bacteria, much like in pathogenic bacterial 
species. Moreover, the Bacteroidetes and Firmicutes also demonstrate extensive phenotypic 
resistance, despite Proteobacteria appearing enriched for clinically relevant genetic 
determinants of antibiotic resistance in the previous chapter. These results further emphasise 
the role of the human gut microbiome as a reservoir for antibiotic resistance in terms of its 
occurrence and prevalence, but also that the extent of this is not yet fully known. In the next 
chapter, I will investigate the dynamics of antibiotic resistance in human gut microbiota and 
how commensal gut bacteria can evolve and spread antibiotic resistance.  
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Chapter 5. Modelling the development of antibiotic 
resistance in vivo 
 
5.1 Introduction 
In the previous two chapters antibiotic resistance genotypes and phenotypes in commensal 
human gut bacteria were investigated. In addition to determining the taxonomic distribution 
of genetic determinants of resistance and comparing antibiotic resistance genotype with 
phenotype, it is also important to understand the dynamics of how gut bacteria develop and 
spread antibiotic resistance in the human microbiota. Several in vitro studies have 
investigated the horizontal transfer of antibiotic resistance genes between closely related 
bacterial species, such as plasmids from Salmonella into E. coli257 or from Lactococcus spp. 
into Bacteroides, Bifidobacterium and Enterococcus spp.258, but results from in vitro 
experiments cannot easily be extrapolated to in vivo situations. In silico analysis of publicly 
available bacterial genomes has identified antibiotic resistance genes with high sequence 
similarity between human and animal gut bacteria and pathogens152,259, indicating horizontal 
transfer, but this is indirect evidence. For direct evidence, we need to study a baseline level of 
antibiotic resistance in the human gut microbiome and observe how it can change in response 
to selective pressure caused by antibiotic therapy.  
Studies with this goal have been performed before, such as those that use 16S rRNA gene 
sequencing to assess impact of antibiotics on the overall community178,260-262. For example, a 
study of combined amoxicillin and metronidazole on wild-type mice found that approximately 
70 % of 16S rRNA gene sequences in antibiotic treated mice were Proteobacteria, compared 
to just 1 % in control non-treated mice179. In addition, prolonged reductions in overall diversity 
were observed even after antibiotic treatment was stopped179. However, 16S rRNA gene 
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profiling studies do not allow for high-resolution taxonomic analysis, as often species share 
similar 16S rRNA gene sequences. Because of this, strains and some species (such as E. coli 
and Shigella) cannot be distinguished with this method263. Moreover, these studies rely on 
databases of characterised 16S rRNA gene sequences. As discussed previously, there are still 
uncharacterised human gut bacteria without reference genomes available, meaning not all 
16S rRNA gene sequences can be classified taxonomically and are therefore difficult to study. 
This is also true of whole genome shotgun metagenomics, which relies on databases of 
published reference bacterial genomes: previous studies using whole genome shotgun 
metagenomics have identified high levels of unclassified sequences264. Reference genome 
based metagenomics, where a custom database of reference genomes is curated and tailored 
for metagenomic analysis relating to the study being performed, is an emerging method to 
circumnavigate these problems151,265,266. This involves culturing bacteria present in the sample 
to be studied, identifying novel bacteria and generating new reference genomes for these 
organisms, and combining these into a database of reference genomes146,151. Reference 
genome based metagenomics was implemented in the present study to provide this tailored, 
high-resolution analysis of antibiotic resistance dynamics in gut microbiota. The culturing and 
WGS component of reference genome based metagenomics also assists strain-level 
resolution, which has typically been difficult with whole genome shotgun metagenomics due 
to limitations with sequencing depth and reference databases267. 
Studies on humans are often confounded by factors such as different genetics, diets, lifestyles, 
health condition, infection state and being limited to relatively few participants. Experiments 
in mice therefore offer a much higher level of control, as we can use mice with the same 
genetic background, from the same litter, that are fed the same diet and kept in controlled 
living conditions, and it is possible to study large numbers of individuals in these controlled 
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conditions. Previous models have used the di-associated mouse, in which a recipient and 
donor strain of interest are introduced into GF mice to assess plasmid conjugation frequency 
in the gut environment. This model has indicated that inter-species transfer is possible 
through the transfer of tetracycline and erythromycin resistance from Lactobacillus plantarum 
to Enterococcus faecalis268. Conventional mouse models have helped identify that transfer of 
plasmids bearing antibiotic resistance genes (ARGs) can occur at high frequency in the gut269, 
even when colonisation resistance is present. However, the di-associated model is considered 
the “worst case scenario” model due to the lack of colonisation resistance from indigenous 
microbiota and so does not model the typical gut environment270. Moreover, studies in wild-
type mice are not fully representative of biological processes in humans as mice have gut 
microbiomes that differ from humans271. Our lab has established methods to colonize mice 
with human-derived gut microbiota: these are GF mice colonised by gut bacteria of healthy 
humans following faecal transplant of human stool into the GF mice. This provides a very 
powerful tool for controlled experiments regarding the gut microbiome in a manner that is 
more representative of processes in humans. In addition, by culturing and sequencing whole 
genomes of bacteria isolated before and after antibiotic exposure, there is tremendous power 
to discriminate ARG-HGT events at a level not previously possible. 
In this chapter, I use mice with humanised gut microbiota to model dynamics of antibiotic 
resistance in the human gut bacterial community and individual strain evolution following 
antibiotic therapy. Amoxicillin was used as the antibiotic providing selective pressure on the 
gut bacteria of these humanised microbiota mice. Amoxicillin is considered a relatively broad-
spectrum penicillin, and is one of the most prescribed drugs globally18. Moreover, amoxicillin 
is often administered orally, and so can directly impact on our indigenous gut microbiota as 
well as the infections it is prescribed to treat. As we are still discovering novel and 
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uncharacterised members of the human gut microbiota, the full impact of broad-spectrum 
antibiotics such as amoxicillin on commensal gut bacteria remains to be defined. To 
investigate the comprehensive impact of amoxicillin on human gut bacteria including those 
considered uncharacterised, I combined large-scale culturing, reference genome based 
shotgun metagenomics and whole genome sequencing with experiments in humanised 
microbiota mice. Large-scale culturing of thousands of strains of human gut bacteria allows 
the type and extent of any genomic and phenotypic changes caused by amoxicillin therapy to 
be investigated by actively tracking the movement of genes conferring AMR. Therefore, this 
chapter aims to assess the impact of amoxicillin therapy on amoxicillin resistance in gut 
bacteria of mice colonised with human-derived intestinal microbiota, uniquely at both the 
community level and genome level of individual strains. 
 
5.2 Results 
5.2.1 Overview of mouse models 
To model the impact of amoxicillin on antibiotic resistance in the human gut microbiome, I 
utilised two mouse lines with human-derived gut microbiota that had been established in our 
laboratory prior to the start of my PhD. The mouse lines were established by performing faecal 
microbiota transplant (FMT) of homogenised stool from “healthy” human donors (“Donor 2” 
and “Donor 7”, who also contributed faecal samples for developing the HBC143) into germ free 
mice. Donors were considered healthy if they had not taken antibiotics in the six months prior 
to donating stool, suffered any gastrointestinal conditions or taken oral medications. FMTs 
were performed via oral gavage to each GF mouse weekly for three weeks to establish Donor 
2 and Donor 7 specific cohorts. This was repeated in several GF mice, which were then bred 
(e.g. Donor 2 mouse with Donor 2 mouse or Donor 7 mouse with Donor 7 mouse) to produce 
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two separate mouse lines. Culturing has been performed extensively on samples from human 
Donor 2 and Donor 7146,151. The gut microbiota of Donor 2 mice differs from Donor 7 mice in 
the following ways: different community composition (i.e., different bacteria, see Appendix 3, 
Fig. A3.1); different antibiotic resistance potential, including amoxicillin-resistant organisms 
and antibiotic-resistance genes present in each community (Appendix 3, Figure A3.2 & A3.3); 
colonisation resistance.  
Mice from each line were given amoxicillin orally via drinking water for seven days. Faecal 
samples were collected immediately before and after amoxicillin treatment. The amoxicillin 
was provided at a theoretically therapeutic dose (approximately 45 mg/kg/day), based on the 
concentration required to adequately exceed the minimum inhibitory concentration (MIC) of 
sensitive organisms in otitis media ear infections206. The quantity and concentration of 
drinking water containing amoxicillin was determined using the average weight of a mouse 
(30 g) and approximate volume of water consumed per mouse per day (5 ml). I performed 
deep bacterial culturing with three conditions (aerobic, anaerobic, and targeted for spore-
formers) on YCFA agar plates. YCFA is considered a medium able to culture a broad range of 
bacteria. Metascrape samples (metagenomic sequencing of the total bacterial growth on a 
culture plate) from vegetative bacterial growth on YCFA plates in anaerobic conditions have 
been shown to be representative of the community in the original stool sample that was 
cultured from146. Thus, we can use anaerobic vegetative metascrape samples  to represent 
the overall gut bacteria community, as well as targeted metascrapes for particular phenotypes 
such as antibiotic resistance. Each condition was plated in duplicate: with and without the 
addition of amoxicillin at a concentration of 8 mg/L in the agar plates. This concentration 
represents a MIC level where if some pathogenic bacteria are still able to grow in its presence 
they are considered clinically resistant according to EUCAST and CLSI guidelines; thus, this 
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concentration is used to select what can be considered amoxicillin-resistant bacteria. Details 
of each experiment performed are described and summarised below (Fig. 5.1, Table 5.1). 
In the initial experiment (“D7AMX1”), eight Donor 7 humanised microbiota mice were divided 
into two cages. Both cages received a therapeutic dose of amoxicillin as described above. Two 
faecal pellets were collected from each mouse on experimental days 0 (immediately before 
amoxicillin regime started), 3, 7 (amoxicillin regime ended), 10, 14 (seven day recovery) and 
35 (28 day recovery). Both pellets per mouse were weighed, then one was immediately frozen 
at -80°C and the remaining pellets were pooled per cage. Pooled pellets were homogenised 
100 mg/ml in sterile PBS and serially diluted 1 in 10, from 10-1 to 10-7. Dilutions were plated as 
described above (Fig. 5.1). In this experiment, individual colonies were isolated (Table 5.1). 
The Donor 7 humanised microbiota mouse experiment was repeated (“LJP01”), but instead of 
isolating individual colonies metascrapes were collected (Table 5.1). In this experiment, three 
cages each containing six Donor 7 humanised microbiota mice were treated with amoxicillin 
as before. Faecal samples were collected and processed as described for D7AMX1. Colonies 
were counted for all samples, conditions and time points. Bacterial growth on culture plates 
was mixed with 0.5 ml sterile PBS, scraped off each plate for Day 0, 7, 14 and 35 and collected 





Figure 5.1. Diagram of experiments assessing the impact of amoxicillin on mice with human-derived gut 
microbiota. The timeline illustrates the sampling days of the experiments and the duration of amoxicillin 
treatment. The experiments were performed in both Donor 2 and Donor 7 humanised microbiota mice. The 
lower diagram illustrates the sample processing and different culture conditions and culture plate set ups: faecal 
pellets were collected from each mouse at each experimental time point. Faecal pellets were weighed and 
homogenised 100 mg/ml in sterile PBS, then pooled in equal amounts per cage. Pooled faecal homogenates were 
diluted 1:10 from 10-1 to 10-7 and appropriate dilutions plated on YCFA agar plates, without and with amoxicillin 
added (final concentration 8 mg/L amoxicillin). Plates were incubated for 24 hours at 37°C in aerobic conditions, 
or 48 hours at 37°C in anaerobic conditions. In addition, aliquots of the pooled faecal homogenates were ethanol 
shocked (diluted 1:4 in 70 % ethanol for 30 minutes) to kill vegetative bacteria and select for ethanol-resistant 
spores. Ethanol shocked samples were plated on YCFA plus sodium taurocholate (STC, a bile salt to promote 
spore germination) and incubated at 37°C in anaerobic conditions. All conditions were plated in duplicate to 
allow metascrape collection (collection of the total bacterial growth on agar plate for total DNA extraction and 
metagenomic sequencing) and the isolation of individual colonies. Individual colonies were picked into 96 well 
plates (one isolate per well) containing YCFA broth and incubated for 24 hours (aerobic) and 48 hours (anaerobic) 
at 37°C. The full length 16S rRNA gene sequence was amplified by PCR from each isolated colony in broth and 
sequenced by Sanger sequencing to assign species- or genus-level taxonomy based on similarity to reference 16S 
rRNA gene sequences. 
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A similar mouse model experiment was performed using three cages each containing six 
Donor 2 humanised microbiota mice (LJP02). The experiment set up was identical to that of 
LJP01 (Fig. 5.1) except that Day 0 samples were collected from all cages. In the LJP02 
experiment all culturing plates were duplicated to allow both metascrapes to be collected and 
individual colonies to be isolated (Table 5.1). 
 
Mouse line No. mice Sex Colony counts Isolated colonies for WGS Metagenomics 
Donor 2 18 across 3 
cages 
F LJP02 LJP02 LJP02 
Donor 7 18 across 3 
cages 
F LJP01 û LJP01 
Donor 7 8 across 2 
cages 
M(4), F(4) û D7AMX1 û 
Table 5.1. Summary of experiments assessing the impact of amoxicillin on mice with human-derived gut 
microbiota and samples or data generated. The table details the mice groups included in each experiment and 
rationale. Sex: F = female, M = male (brackets indicate number of each). The last three columns indicate what 
data was collected from which experiments (D7AMX, LJP01 or LJP02). û indicates not generated as part of that 
experiment. 
 
5.2.2 Impact of amoxicillin on the bacterial load in mice with humanised gut microbiota 
The total number of colonies growing on each plate for all pooled homogenates, conditions 
and time points were counted to determine changes in bacterial load over the time course of 
the LJP01 and LJP02 mouse experiments (Fig. 5.3). Raw colony counts were converted to 
colony forming units of bacteria per gram (CFU/g) of stool, representing bacterial load. The 
data was combined across the Donor 2 and Donor 7 experiments to look for general trends in 
bacterial load. The CFU/g data was then tested for normal or log-normal distribution using the 
Anderson-Darling272, D’Agostino and Pearson273, Shapiro-Wilk274, and Kolmogorov- Smirnov 
tests275. As many of the colony count datasets did not pass the normality tests, a 
 
 153 
Figure 5.2. Bacterial load over the course of humanised microbiota mouse amoxicillin model experiments. 
Donor 2 and Donor 7 humanised microbiota mice were given a therapeutic dose of amoxicillin orally via drinking 
water for seven days; faecal pellets were collected per mouse, homogenized and pooled per cage per time point. 
The pooled homogenates were diluted and spread on agar plates in a variety of conditions: YCFA agar and 
anaerobic; YCFA agar plus 8 mg/L amoxicillin and anaerobic; YCFA agar, and aerobic; YCFA agar plus 8 mg/L 
amoxicillin and aerobic. Aliquots of each pooled homogenate was treated with 70 % ethanol for 30 minutes to 
select for spores, which were plated on YCFA agar + 1 % sodium taurocholate (STC) with and without 8 mg/L 
amoxicillin and grown anaerobically. Colonies were counted after 24 hours (aerobic growth) or 48 hours 
(anaerobic growth) and used to calculate the average bacterial load (colony forming units (CFU)/g stool) and 
standard deviation per cohort. A non-normal distribution was assumed for performing One-Way Anova (Kruskal-
Wallis) tests to determine statistically significant changes in bacterial load over the time course of the mouse 
experiments (comparisons were performed between consecutive time points for all time points e.g. Day 0 vs. 
Day 1, Day 1 vs. Day 3, etc. and between major time points i.e., Day 0 vs. Day 7, Day 7 vs. Day 14, Day 14 vs. Day 
35, Day 0 vs. 14, Day 0 vs. 35 and Day 7 vs. 35. The two-stage step-up method of Benjamini, Krieger and 
Yekutieli193 was used to correct for multiple comparisons by controlling the false discovery rate. * marks where 
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non-normal distribution was assumed for performing Kruskal-Wallis (One-way ANOVA of non-
parametric data) tests. Comparisons were performed between consecutive time points for all 
time points e.g. Day 0 vs. Day 1, Day 1 vs. Day 3, etc. and between major time points e.g. Day 
0 vs. Day 7, Day 7 vs. Day 14, Day 14 vs. Day 35, Day 0 vs. Day 14, Day 0 vs. Day 35, Day 7 vs. 
Day 35. The two-stage step-up method of Benjamini, Krieger and Yekutieli193 was used to 
correct for multiple comparisons by controlling the false discovery rate (q value significant < 
0.05). There were no significant changes to aerobic bacterial load.  
There was a significant increase in anaerobic vegetative bacterial load from plates without 
amoxicillin after the first day of treatment (Day 0 vs. Day 1, q value < 0.0001) and over the 
course of the amoxicillin therapy (Day 0 vs. Day 7, q value <0.0001). In addition, despite a 
significant reduction between Day 7 and Day 10 (q value 0.0124), the anaerobic vegetative 
load at recovery time points remained significantly higher than Day 0 (vs. Day 14 and Day 35, 
q values 0.0087 and 0.0201 respectively). However, Day 35 was significantly lower than Day 7 
(0.0087). This indicates that the total anaerobic vegetative load increased after amoxicillin 
treatment began and then decreased after the treatment was stopped, but not back to its 
original level. There was also a significant decrease in anaerobic vegetative bacterial load from 
plates containing amoxicillin between Day 7 and Day 10 (q value 0.0138), and overall between 
Day 7 and Day 35 (q value 0.0026). There was an overall significant decrease in anaerobic 
vegetative bacterial load from plates containing amoxicillin (Day 0 vs. Day 14 and Day 35, q 
values 0.0010 and 0.0002 respectively). This indicates an overall decline in the load of 
amoxicillin-resistant anaerobic vegetative bacteria during the experiment. 
The load of anaerobic spore-forming bacteria cultured on both plates with and without 
amoxicillin significantly decreased between Day 0 and Day 1 (q values 0.0003 and < 0.0001 
respectively). In addition, both sets of anaerobic spore-forming bacteria showed significant 
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decreases in load between Day 0 and Day 7 (q values 0.0019 and < 0.0001 respectively). There 
was a subsequent significant increase in anaerobic spore-forming bacteria from plates with 
without amoxicillin after treatment stopped (Day 7 vs. Day 10, q value < 0.0001). The load of 
anaerobic spore-forming bacteria from plates without amoxicillin were significantly higher at 
Day 35 than Day 7 (q value <0.0001), but not significantly different to Day 0. Anaerobic spore-
formers from plates with amoxicillin significantly increased between Day 10 and Day 14 (q 
value 0.0003), and between Day 14 and Day 35 (q value 0.0076). The Day 14 level was 
significantly higher than Day 0 (q value 0.00206) but whilst Day 35 was significantly higher 
than Day 7 (0.0163), it was not significantly different to Day 0. This indicates that the 
amoxicillin had a significant impact on reducing the load of spore-forming bacteria during the 
antibiotic treatment but that this community recovered in terms of CFU/g after the treatment 
stopped.  
 
5.2.3 Deep culturing and whole genome sequencing to improve taxonomic classification of 
metagenomic data 
Having studied the gross impact on bacterial load, the impact of amoxicillin on the diversity of 
the gut bacterial communities in these mice was investigated using high resolution 
metagenomics that can resolve to species and subspecies level. I first classified the 
metagenomic sequence reads from the metascrapes (total bacterial growth collected from 
culture plates) using Kraken211, comparing them to a database of publicly available reference 
genomes of gut bacteria (including the 737 from the HBC151; this database was created in 
December 2017 by Dr Sam Forster). To determine the taxonomic resolution, I calculated the 
percentage of reads in each sample that could be classified to species level using this Kraken 
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database and determined the average proportion of classified sequence reads for each culture 
condition (aerobic, anaerobic vegetative and anaerobic spore-forming; Figure 5.4). Although 
the aerobic and anaerobic vegetative metascrapes were relatively well classified (> 95 %), 
lower levels of classified sequence reads were observed for spore-forming metascrapes (71.9 
%). This indicates that this database is not optimal for classifying all of the metagenomic data 
generated in this study and I therefore sought to culture and whole genome sequence 
additional isolates to improve the taxonomic classification and downstream analysis. 
Figure 5.3. Proportion of classified metagenomic sequences reads from metascrapes of cultured faecal bacteria 
from mice with humanised gut microbiota. Sequence reads were assigned taxonomic classification using Kraken 
and a database containing publicly available gut bacterial and archaeal genomes, including those in the HBC151. 
The average percentage of classified reads for each culture condition was determined. Bars represent Standard 
Error of the Mean. This shows that this database was not capable of assigning taxa to all sequence reads, 
especially for spore-forming bacteria.  
 
To identify candidates of novel reference genomes that might explain some of the unclassified 
sequence reads, I assembled contigs de novo from unclassified reads in one metascrape 
sample from the Donor 7 and one from the Donor 2 mouse experiments. I then performed a 
BLASTn analysis of those contigs against the NCBI RefSeq database (as of April 2017). Overall, 
the majority of unclassified contigs from the Donor 7 mouse sample were most similar to 
































of the contigs had high similarity to a Turicibacter genome (Fig. 5.4A); this was also true of the 
Donor 2 mouse unclassified contigs (Fig. 5.4B). This indicated a Turicibacter-like organism 
could explain some of the unclassified data and would be a good candidate for a novel 
reference genome to add to the Kraken database.  
Subsequently, I isolated approximately 11,000 colonies from across all the culture conditions 
to identify previously uncultured bacteria, including this candidate Turicibacter-like organism, 
and obtain as much diversity from the gut microbiota of these mice as possible. Capillary 
sequencing of the  16S rRNA gene was performed for all isolates. This resulted in 8838 full 
length 16S rRNA gene sequences being returned; the reduction in numbers of isolates to 16S 
rRNA gene sequences is likely caused by the failure to grow in broth or contamination of 
isolates. The 16S rRNA gene sequences were analysed and assigned OTUs with Mothur208 
using a 99 % identity cut off (i.e., sequences 99 % similar to each other were grouped into one 
OTU) in terms of similarity to the HBC143 16S rRNA gene sequences. In total, 367 OTUs were 
observed.  
  
Figure 5.4. Diversity of the contigs assembled de novo from unclassified metagenomic sequence reads. De novo assembly was performed on the unclassified reads from a single 
metagenomic sample, with a high level of unclassified sequence reads, and the resulting contigs analysed using the NCBI RefSeq BLAST database containing all published genomes 
(as of April 2017). The chart shows the proportion of sequence reads by their most closely related reference genome (inner most ring: lowest taxonomic level e.g. domain; outer 
most ring: highest taxonomic level e.g. species). In this sample, the highest proportion of unclassified reads were most closely related to Turicibacter sanguinis, indicating that 
bacteria similar to this species would be useful to culture and generate new genomes from. 
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A rarefaction curve of this data was plotted: as the number of colonies picked increased, the 
number of OTUs isolated continued to increase even past 8000 colonies (Fig. 5.5). The trend 
was modelled to predict that the maximum OTU richness would feature 427 OTUs across the 
two mouse lines, but that approximately 30,000 colonies would be needed to be picked to 
recover all 427 OTUs. The 8838 colonies I isolated recovered approximately 86 % of the 
predicted total number of OTUs in gut microbiota of these mice.  
Figure 5.5. A rarefaction curve of the number of OTUs observed against the number of colonies picked. 11,000 
individual bacterial colonies were isolated from mice with humanised gut microbiota before and after amoxicillin 
treatment. 8838 full length 16S rRNA gene sequences were generated and grouped into operational taxonomic 
units (OTUs) using a 99 % similarity cut off. The number of new OTUs observed as the number of colonies picked 
increases was plotted, showing that even as we reach almost 9000 colonies new OTUs are still being obtained. 
The blue dotted lines mark the maximum numbers of isolates picked and number of OTUs observed. The trend 
in part A was modelled using nonlinear regression to produce a rarefaction curve (solid red line) and estimate 
the maximum number of OTUs likely to be found across the two mouse lines with humanised gut microbiota: 
the red dotted line represents this predicted maximum of 427 OTUs. It would be necessary to pick approximately 
30,000 colonies to recover the 427 OTUs. Dr Hilary Browne, Dr Sam Forster, Dr B. Anne Neville, Mr Mark Stares, 
Dr Elisa Viciani and Dr Ana Zhu all helped pick colonies from culture plates into broth cultures. 
 
 





















The consensus 16S rRNA gene sequence for each OTU was compared to 16S rRNA gene 
sequences in NCBI RefSeq (April 2017); the majority belong to Firmicutes (54.8%, Fig. 5.6) and 
Bacteroidetes (33.8%), with just a few Proteobacteria (11.4%) and Actinobacteria (1.36%).  
 
Figure 5.6. A phylogeny of the consensus sequences of 367 OTUs identified from 8838 full length 16S sequences 
generated in this study. 11,000 individual bacterial colonies were isolated from mice with humanised gut 
microbiota before and after amoxicillin treatment. 8838 full length 16S sequences were generated and grouped 
into operational taxonomic units (OTUs) using a 99 % similarity cut off. Consensus sequences of the 367 OTUs 
were compared to NCBI RefSeq (April 2017). The majority of the OTUs belong to the Bacteroidetes and Firmicutes 
phyla. 
 
Looking at the proportion of colonies picked per OTU shows that approximately 1100, or 13 
%, of the 8838 16S rRNA gene sequences were clustered in an OTU with 97 % nucleotide 
identity to Turicibacter sanguinis (Figure 5.7A). 16S rRNA gene sequences most similar to 
Turicibacter also demonstrated variability (Figure 5.7B), showing that these isolates are not all 
identical. Three isolates related to Turicibacter and 49 others with less than 97 % identity  
  
Figure 5.7. Diversity of OTUs isolated by culture from mice with human-derived microbiota. A) 16S rRNA gene amplification and Sanger sequencing was performed for all bacteria 
isolated in the mouse experiments described in this chapter, resulting in 8838 16S full length sequences. These were grouped into OTUs using Mothur and a 99 % cut off (i.e., 16S 
rRNA gene sequences >99 % similar to each other were considered one OTU); consensus OTU sequences were generated as part of this process. OTUs were named after the reference 
genome of highest similarity plus the length of the sequenced 16S rRNA gene and the percentage nucleotide identity to the reference sequence. For example, 
Turicibacter_sanguinis_strain_MOL361_1358_97.496 is the name of an OTU whose 16S rRNA gene is 1358 bases in length and 97.496% similar to the 16S rRNA gene sequence of 
Turicibacter sanguinis strain_ OL361. The proportion of all isolates each OTU contributed was calculated: 1127, or 13 %, were clustered in an OTU with 97 % identity to Turicibacter 
sanguinis. B) A phylogenetic tree of approximately 1127 16S rRNA gene sequences with 97 % identity to the reference Turicibacter sanguinis strain MOL361 genome shows there is 
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to known 16S rRNA gene sequences (and therefore potentially novel species) were purified 
and whole genome sequenced. In addition, 11 isolates representing very common OTUs (>20 
colonies isolated per OTU) and 135 isolates representing taxa that appeared to have increased 
in amoxicillin resistance during the experiment were purified and whole genome sequenced. 
Their relationship with the HBC isolates is demonstrated in Figure 5.8. 
 
Figure 5.8. The phylogenetic relationship between the HBC and 198 new genomes generated in this study. The 
Human Gut Bacteria Culture Collection currently contains 737 isolates of human gut bacteria. The amino acid 
sequences of 40 core genes were extracted from all genomes and used to infer a phylogeny to illustrate the 
taxonomic diversity of the HBC and 198 genomes generated in this thesis. The stars mark which genomes are 
considered ‘novel’ based on the similarity of their 16S rRNA gene sequence to known 16S rRNA gene sequences 
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All 198 new genomes were added to the Kraken database used earlier for reclassification of 
the metagenomic sequence reads from the metascrape data. The custom database contains 
publicly available gut bacteria genomes plus the 198 genome assemblies generated in this 
study (of which 52 represent isolates of potentially novel new taxa (16S ID < 98.7 %). The 
classification of metagenomic sequence reads to species level was improved from 95.6 % to 
99.1 % in aerobic metascrapes and 95.3 % to 96.5 % in anaerobic vegetative metascrapes 
(Figure 5.9). The spore-forming samples were still less well classified at 86.6 % but also the 
most improved (up from 71.9 %). The resolution of downstream metagenomic data analysis 
was higher as a consequence. 
Figure 5.9. Comparisons of proportion of classified metagenomic sequences reads from metascrapes of 
cultured faecal bacteria from mice with humanised gut microbiota using different databases of reference 
bacterial genomes. Sequence reads were assigned taxonomic classification using Kraken and a database 
containing publicly available gut bacterial and archaeal genomes, including those published by Forster et al. 
2019151 (the “original” database), plus the same collection with new genomes generated in this thesis added 
(“custom”). The average percentage of classified reads for each condition was determined. Bars represent 
Standard Error of the Mean. This shows improved classification rates for all conditions when using the custom 
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5.2.4 Impact of amoxicillin on the amoxicillin-resistant community 
The updated custom Kraken database was used to assign taxonomy to sequence reads and 
assess the impact of amoxicillin on the diversity of the amoxicillin-resistant community in 
humanised microbiota mice. Firstly, the raw read counts assigned to each species in the 
Kraken database were used to determine the Shannon index of alpha diversity. Alpha diversity 
indices were averaged over metascrape samples from plates containing 8 mg/L amoxicillin, 
combined across both the Donor 2 and Donor 7 experiments, for each of the three culture 
conditions (i.e., aerobic, anaerobic vegetative and anaerobic spore-forming from plates 
containing amoxicillin). 
Mean alpha diversity increased in aerobic and anaerobic vegetative metascrapes from plates 
with amoxicillin (Fig. 5.10) between Day 0 and Day 7, then decreased again after amoxicillin 
treatment had stopped, though remained higher than initial levels. This may indicate that the 
amoxicillin caused additional species to become resistant to amoxicillin within an individual, 
although this was not maintained after the treatment stopped. Alternatively, it may be that 
amoxicillin-resistant bacteria expanded in abundance from below detection level to above 
detection level, or that certain species of the same relative abundance were harmed by the 
amoxicillin, allowing the remaining species of that initial relative abundance to become 
detectable. In contrast,  anaerobic spore-forming metascrapes from plates with amoxicillin, 
alpha diversity increased over all time points. This indicates that more spore-forming species 
became resistant over the experiment, or became more detectable, even after the treatment 
was stopped. However, there was no significant difference between any consecutive time 
points (i.e., Day 0 vs. Day 7 , Day 7 vs. 14, Day 14 vs. 35), nor between the start and end of the 
experiment (Day 0 vs. 35) for any culture condition (statistical significance determined by 
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Mann-Whitney U tests212, adjusted for multiple-testing with the Benjamini, Hochberg, and 
Yekutieli method193; q value significant < 0.05). 
 
Figure 5.10. Changes in alpha diversity in metascrapes of cultured faecal bacteria from mice with humanised 
gut microbiota treated with amoxicillin. Sequence reads were assigned taxonomic classification using Kraken 
and a database containing publicly available gut bacterial and archaeal genomes plus genomes generated in this 
study. Raw read counts per species were used to determine alpha diversity at each experimental time point (Day 
0, 7, 14, 35) for three culture conditions (aerobic, anaerobic vegetative and anaerobic spore-forming), on agar 
plates with 8 mg/L amoxicillin added. The median alpha diversity increased in aerobic metascrapes from plates 
with amoxicillin during the amoxicillin treatment (between Day 0 and Day 7) and reduced after amoxicillin 
treatment had stopped (Day 14 and Day 35), but remained higher than its initial level. A similar pattern was seen 
in anaerobic vegetative metascrapes from plates with amoxicillin but to a lesser extent. In anaerobic spore-
forming metascrapes from plates with amoxicillin, where alpha diversity increased over all time points. There 
were no significant differences between consecutive time points (i.e., Day 0- vs. , Day 7 vs. 14, Day 14 vs. 35), 
nor between the start and end of the experiment (Day 0 vs.35) for any culture condition. Statistical significance 
determined by Mann-Whitney U tests212, adjusted for multiple-testing with the Benjamini, Hochberg, and 
Yekutieli method193; q value significant < 0.05. Error bars represent the range. Dr Kevin Vervier wrote the R scripts 
that measured and compared alpha diversity. 
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Beta diversity (Fig. 5.11) was also determined to identify whether individual samples (i.e., 
metascrapes from a particular cage of mice) changed in similar ways during the experiment. 
Bray-Curtis dissimilarity measures were determined from raw read counts and averaged over 
metascrape samples from plates containing 8 mg/L amoxicillin, across both experiments, for 
each of the three culture conditions (i.e., aerobic, anaerobic vegetative and anaerobic spore-
forming from plates containing amoxicillin). Although in all culture conditions beta diversity 
increased over the time course of the experiment, indicating that the amoxicillin-resistant 
communities belonging to different cages of mice became slightly more different from each 
other following amoxicillin therapy ( i.e., there was a cage-specific effect), again, there were 
no significant differences between consecutive time points (i.e., Day 0 vs. Day 7, Day 7 vs. 14, 
Day 14 vs. 35), nor between the start and end of the experiment (Day 0 vs. 35) for any culture 
condition (determined as described for alpha diversity). This indicates that overall, the 
amoxicillin-resistant communities belonging to different cages did not become significantly 
different from each other during or after amoxicillin treatment.  
 
  167 
Figure 5.11. Changes in beta diversity in metascrapes of cultured faecal bacteria from mice with humanised 
gut microbiota treated with amoxicillin. Sequence reads were assigned taxonomic classification using Kraken 
and a database containing publicly available gut bacterial and archaeal genomes plus genomes generated in this 
study. Raw read counts per species were used to determine beta diversity at each experimental time point (Day 
0, 7, 14, 35) for three culture conditions (aerobic, anaerobic vegetative and anaerobic spore-forming), on agar 
plates with 8 mg/L amoxicillin added. Median beta diversity increased in aerobic metascrapes over all time 
points. In both anaerobic vegetative and anaerobic spore forming metascrapes from plates without amoxicillin, 
beta diversity increased between Day 0 and Day 7, dropped slightly at Day 14 then increased again at Day 35. 
Anaerobic vegetative and anaerobic spore-forming metascrapes from plates with amoxicillin also show an 
increase in beta diversity from Day 0 to Day 7 which then decreases at both Day 14 and Day 35. There were no 
significant differences between consecutive time points (i.e., Day 0- vs. Day 7, Day 7 vs. 14, Day 14 vs. 35), nor 
between the start and end of the experiment (Day 0 vs.35). for any culture condition. Statistical significance 
determined by Mann-Whitney U test212, p value significant < 0.05. Error bars represent the range. Dr Kevin 
Vervier wrote the R scripts that measured and compared beta diversity. 
 
 
Despite the overall changes in diversity not being significant, it is possible that there were 
significant changes occurring in individual taxa. To assess this, the relative abundance of 
species in the amoxicillin-resistant communities for each culture condition (aerobic, anaerobic 
vegetative and anaerobic spore-forming metascrapes from plates containing amoxicillin) was 
determined. Read counts were normalised per sample and then the normalised values were 
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conditions. The species were then ranked by their mean relative abundance in each culture 
condition and the mean relative abundance of the top ten most abundant species plotted, 
with the relative abundance of the remaining species grouped as “Other”. This “Other” 
category formed the majority of (>92 %) the relative abundance of species in the anaerobic 
vegetative and spore-forming metascrapes from plates with amoxicillin (Fig. 5.12) at all time 
points.  
For the aerobic amoxicillin-resistant community, Enterococcus faecalis dominated at Day 0 
before amoxicillin therapy (mean relative abundance 78.5 % of sequence reads per sample) 
and was significantly reduced at Day 7 (0.88 % mean relative abundance, q value < 0.001; 
determined by unpaired t-tests with Welch’s correction276, adjusted for multiple-testing with 
the Benjamini, Hochberg, and Yekutieli method193 and significant < 0.05). The mean relative 
abundance of E. faecalis then increased by Day 14 (to 8.19 %), and was dominant again at Day 
35 (80.0 %, significantly increased from Day 14; q value < 0.001). Overall, there was no 
significant difference between the initial (Day 0, 78.5 %) and final measured mean relative 
abundance of E. faecalis (Day 35, 80.0 %), showing that although this species reduced in 
relative abundance following amoxicillin therapy it recovered to its initial level after treatment 
stopped.  
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Figure 5.12. Relative abundance of species in metascrape samples cultured from mice following amoxicillin 
therapy. Sequence reads were assigned taxonomic classification using Kraken and a database containing publicly 
available gut bacterial and archaeal genomes plus genomes generated in this study. Read counts were 
normalized per sample and the relative abundance of each species averaged across all samples for each culture 
condition. Species were ranked from highest to lowest mean relative abundance per culture condition and the 
top 10 species for each are shown in these bar plots. All other species were grouped as “Other”; this category 
made up over 92 % of the total relative abundance of bacteria in the anaerobic vegetative and anaerobic spore-
forming samples and so the y axis for these two conditions is limited to show the ten most abundant species 
more closely. Only metascrapes from plates containing amoxicillin are shown to represent the amoxicillin-
resistant community. The aerobic amoxicillin resistant community was dominated by Enterococcus faecalis at 
the start of the experiment and end of the experiment (Day 0 and Day 35) but was much less relatively abundant 
at days 7 and 14, which were dominated by Sporosarcina newyorkensis or Bacteroides fragilis and B. 
cellulosilyticus respectively. The anaerobic vegetative amoxicillin resistant community most obviously shows a 
reduction in Ralstonia picketti and expansion of B. cellulosilyticus from Day 0 over all other time points, plus an 
increase in “Other” species at Day 7 that was not maintained at days 14 or 35. Similarly, the anaerobic spore-
forming amoxicillin resistant community shows continual increases in “Other” species as well as a reduction in 
Hungatella hathewayi. 
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Whilst E. faecalis was less relatively abundant at Day 7 than Day 0, the amoxicillin-resistant 
aerobic community at Day 7 was dominated by Sporosarcina newyorkensis: S. newyorkensis 
was significantly higher at Day 7 (48.2 %) than Day 0 (0.17 %, q value < 0.001), but had reduced 
again by Day 14 (0.003 %, q value < 0.001). The relative abundance of S. newyorkensis was 
lowest at the end of the experiment (Day 35, 0.0005 %) but this was not significantly different 
from Day 14 or Day 0. Again, this shows that although this species increased in relative 
abundance following amoxicillin therapy it also returned to its initial level after treatment 
stopped. Bacteroides fragilis and B. cellulosilyticus were the dominant species at Day 14 (mean 
relative abundance 25.5 % and 25.3 % respectively). These two species were both significantly 
more relatively abundant at Day 14 than Day 7 (B. fragilis 1.2 %, B. cellulosilyticus 2.19 %) or 
Day 35 (B. fragilis 0.99 %, B. cellulosilyticus 0.47 %; q values all < 0.001). There was no 
significant difference between the initial and final relative abundance of B. fragilis and B. 
cellulosilyticus (Day 0: 0.16 % and 0.06 % respectively; Day 35: 0.99 % and 0.47 % respectively). 
This shows that these Bacteroides species became dominant in the aerobic amoxicillin-
resistant community in the initial seven day recovery period following treatment, but had 
returned to their initial level by the end of the experiment. Finally, the relative abundance of 
“Other” species increased significantly from Day 0 (4.40 %) to Day 7 (29.6 %, q value < 0.0001) 
and significantly decreased again between Day 7 and Day 14 (4.97 %, q value < 0.0001). There 
was a slight increase in the relative abundance of “Other” species at Day 35 (9.96 %), but this 
was not significantly different from Day 14 or Day 0. This indicates that less abundant 
amoxicillin-resistant aerobic species became more abundant during the amoxicillin therapy 
and then returned to their initial level after the treatment ended. Overall, this suggests the 
amoxicillin therapy caused significant changes to the relative abundance of several 
amoxicillin-resistant species capable of growing in aerobic conditions, but that the final overall 
composition of this community was similar to its initial state. 
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The amoxicillin-resistant anaerobic vegetative community was less dominated by particular 
species: the mean relative abundance of “Other” species was consistently high (>92 % of 
sequence reads), though there was a slight increase at Day 7 (94.0 % compared to 92.2 % at 
Day 0) that was not maintained by Day 14 (92.6 %) or 35 (92.3 %). Bacteroides fragilis was the 
most relatively abundant species at 2.38 % of sequence reads per sample at Day 0; this 
reduced to 1.14 % at Day 7, then increased to 1.73 % at Day 14 and 2.00 % at Day 35. There 
was also a reduction in Ralstonia picketti (1.24 % at Day 0 to < 0.0001 % at Day 7, 14 and 35) 
and an increase of B. cellulosilyticus from Day 0 (0.45 %) over all other time points (1.47 % at 
Day 7, 1.16 % at Day 14, 1.67 % at Day 35). However, none of these changes were statistically 
significant. This shows that the relative abundance of individual species in the amoxicillin-
resistant anaerobic vegetative community was not significantly affected by amoxicillin 
therapy. 
In the amoxicillin-resistant anaerobic spore-forming community, Hungatella hathewayi was 
the most relatively abundant species at Day 0 (4.55 %) that steadily reduced at each time point 
(2.04 % at Day 7, 1.92 % at Day 14 and 0.33 % at Day 35). There was also a slight increase in 
“Other” species overall (94.6 % at Day 0, 96.0 % at Day 7, 95.5 % at Day 14 and 97.8 % at Day 
35). However, none of these changes were statistically significant: the amoxicillin treatment 
did not have a major impact on the relative abundance of amoxicillin-resistant anaerobic 
spore-forming species. Overall, this suggests the amoxicillin therapy had more of an impact 
on the relative abundance of species in the amoxicillin-resistant aerobic community than the 
anaerobic vegetative or anaerobic spore-forming communities. 
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5.2.5 Characterisation of strain- and sequence-level changes in gut microbiota following 
exposure to amoxicillin  
While metagenomics provides interesting insights of particular taxa within a community, 
individual isolates provide the opportunity to link genotype to experimentally validated 
phenotype. As earlier discussed, 8838 isolates with 16S rRNA gene sequences were obtained 
in these experiments and assigned to 367 OTUs. A record was kept of which culture plates and 
thus conditions, experimental time point and mouse line that each colony was picked from. 
This allowed the investigation of the impact of amoxicillin therapy on particular OTUs. The 16S 
rRNA gene sequence data was used to determine which OTUs were picked from agar plates 
containing 8 mg/L amoxicillin after the mice received antibiotic treatment (Day 7, 14 or 35) 
but not before (Day 0). OTUs that fit this criteria therefore represent lineages of bacteria that 
have either increased in relative abundance to above the detection limit or have increased in 
amoxicillin resistance (from under to over 8mg/L) during the course of the experiment. 14 
OTUs fitted this criteria of only being picked from the amoxicillin agar plates after the mice 
received treatment. Isolates from before and after amoxicillin treatment in the mice of the 14 
candidate OTUs of increased amoxicillin resistance were purified and whole genome 
sequenced (Table 5.2). These whole genome sequences were then searched for in the 
metascrape data from plates containing amoxicillin at Day 0 using Mash213 to confirm the 
observations based on isolated colonies. All OTUs except Bacteroides stercoris 99.703 % and 
Shigella sonnei 99.757 % still fitted the criteria. For this reason, these two OTUs plus Alistipes 
senegalensis 98.49 %, Alistipes shahii 99.703 % and Anaerostipes caccae 99.773 % (isolates of 




  173 
Table 5.2. Candidate OTUs of potential increase in amoxicillin resistance following in vivo exposure to 
amoxicillin. OTUs were considered candidates of increased amoxicillin resistance if they were only isolated from 
agar containing amoxicillin after the mice received amoxicillin (Day 7/14/35) but not before (Day 0). The number 
of isolates in each OTU at Day 0 (plates without amoxicillin), Day 0 (plates with amoxicillin) and the later time 
points (Day 7, 14, 35 with amoxicillin) were calculated. Isolates of these OTUs were purified for whole genome 
sequencing to assess the impact of amoxicillin exposure on the genomes of these particular taxa. Beta-lactam 
resistance genes and mutations were predicted using ARIBA and CARD (none: no beta-lactam determinants). 
Phylum key: B: Bacteroidetes, F: Firmicutes; P: Proteobacteria. No WGS indicates where isolates could not be 
recovered or purified sufficiently for genomic DNA extractions: either the glycerol stocks were contaminated or 
unviable. Excluded indicates OTUs that did not pass the Mash analysis and were found with 99 % identity in Day 
0 metascrapes from plates containing amoxicillin. % in OTU column represents the similarity of the consensus 









OTU Phylum Day 0  
– 
Amox 







7 Alistipes senegalensis 
98.49 % 
B 1 0 1 No WGS No WGS 
7 Bacteroides stercoris 
99.703 % 
B 1 0 9 Excluded Excluded 
7 [Clostridium] populeti 
94.435 % 
F 2 0 2 None None 
7 Coprobacillus 
cateniformis 99.270 % 
F 1 0 1 None None 
7 Coprobacillus 
cateniformis 92.211 % 
F 6 0 2 None None 
7 Marvinbryantia 
formatexigens 92.942 % 
F 0 0 8 None None 
7 Sporosarcina 
newyorkensis 99.710 % 
F 9 0 1 None None 
2 Alistipes finegoldii 
99.851 % 
B 4 0 1 None None 
2 Alistipes shahii 99.703 % B 1 0 17 No WGS cfxA 
2 Anaerostipes caccae 
99.773 % 
B 2 0 2 None No WGS 
2 Enterococcus faecium 
99.791 % 
F 19 0 48 None None 
2 Flavonifractor plautii 
99.702 % 
F 1 0 22 None None 
2 Odoribacter splanchnicus 
99.556 % 
B 2 0 2 None cfxA 
2 Shigella sonnei 99.757 % P 2 0 7 Excluded Excluded 
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To assess strain-level genomic changes such as antibiotic resistance gene acquisition, the 
presence of known, clinically relevant beta-lactam resistance genes and mutations in these 
genomes was determined using the ARIBA and CARD as in Chapter 3. Table 5.2 summarises 
the different isolates that were whole genome sequenced for this purpose and whether or 
not and they were predicted to harbour beta-lactam resistance genes. Genetic determinants 
of beta-lactam resistance were observed in the genomes isolated after amoxicillin treatment 
in the mice, but not before, in one candidate OTU (Odoribacter splanchnicus 99.56 %). 
Specifically, isolates of this OTU did not appear to contain the cfxA beta-lactamase before 
amoxicillin treatment, but did afterwards. The 198 genome sequences generated in these 
mouse experiments were searched for the cfxA gene, identifying 46 observations of this gene. 
All cfxA genes from bacteria cultured from Donor 7 mice were identical (Fig. 5.13), and all cfxA 
genes from bacteria cultured from Donor 2 mice were identical, with the only difference 
between the two groups being a single nucleotide polymorphism at position 775 (A in Donor 
7 mouse cfxA genes, T in Donor 2 mouse cfxA genes). This suggests the O. splanchnicus 99.56 
% isolates may have acquired the cfxA beta-lactamase during the course of the experiment 
from Alistipes shahii 99.703 %, Bacteroides vulgatus 88.703 %, or Bacteroides ovatus 99.48 %. 
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Figure 5.13. A phylogeny of the cfxA gene from 46 genomes from isolates cultured from mice with human-
derived microbiota. Beta-lactam resistance genes and mutations were predicted using ARIBA148 with CARD151,152 
in genomes of OTUs considered candidates of increased amoxicillin resistance (only isolated from agar containing 
amoxicillin after the mice received amoxicillin (Day 7/14/35) but not before (Day 0)) and other genomes 
generated during this study. This identified cfxA genes in 46 isolates; the nucleotide genes were extracted and 
used to infer a phylogeny, showing that cfxA genes were identical across genomes from a particular mouse line. 
No isolates with the cfxA gene were whole genome sequenced from the Donor 2 mouse before the mice received 
amoxicillin. In the Donor 7 mice, there were a number of isolates with cfxA sequenced from before and after the 
mice received amoxicillin. 
 
The four O. splanchnicus isolates were cultured and three well-isolated colonies of each were 
used for amoxicillin MIC measurement with Etests as described previously. The two O. 
splanchnicus isolates from before amoxicillin treatment both had an average amoxicillin MIC 
Bacteroides stercoris 99.703% 25620_1#273
Bacteroides ovatus 99.48% 27339_1#169
Alistipes shahii 99.703% 27339_1#41
Alistipes shahii 99.703% 27339_1#46
Bacteroides stercoris 99.703% 25620_1#274
Alistipes shahii 99.703% 27339_1#178
Alistipes shahii 99.703% 27339_1#38
Bacteroides fragilis 99.836% 25620_1#279
Bacteroides stercoris 99.703% 25620_1#284
Bacteroides uniformis 99.703% 25620_1#257
Alistipes shahii 99.703% 27339_1#63
Alistipes shahii 99.703% 27339_1#59
Alistipes shahii 99.703% 27339_1#53
Bacteroides fragilis 99.836% 25620_1#259
Bacteroides stercoris 99.703% 25620_1#278
Bacteroides stercoris 99.703% 25620_1#282
Bacteroides stercoris 99.703% 25620_1#299
Alistipes shahii 99.703% 27339_1#19
Bacteroides stercoris 99.703% 25620_1#270
Alistipes shahii 99.703% 27339_1#180
Alistipes shahii 99.703% 27339_1#54
Bacteroides stercoris 99.703% 25620_1#239
Alistipes shahii 99.703% 27339_1#45
Alistipes shahii 99.703% 27339_1#50
Bacteroides fragilis 99.836% 25620_1#280
Alistipes shahii 99.703% 27339_1#22
Bacteroides vulgatus 88.703% 27339_1#166
Bacteroides stercoris 99.703% 25620_1#272
Odoribacter splanchnicus 99.556% 27339_1#77
Bacteroides stercoris 99.703% 25620_1#261
Bacteroides cellulosylticus 99.109% 25620_1#256
Alistipes shahii 99.703% 27339_1#49
Bacteroides stercoris 99.703% 25620_1#275
Alistipes shahii 99.703% 27339_1#20
Bacteroides stercoris 99.703% 25620_1#286
Bacteroides stercoris 99.703% 25620_1#281
Alistipes shahii 99.703% 27339_1#56
Bacteroides stercoris 99.703% 25620_1#277
Bacteroides stercoris 99.703% 25620_1#271
Bacteroides stercoris 99.703% 25620_1#283
Parabacteroides distasonis 99.259% 25620_1#247
Bacteroides stercoris 99.703% 25620_1#276
Bacteroides stercoris 99.703% 25620_1#298
Bacteroides stercoris 99.703% 25620_1#285
Alistipes shahii 99.703% 27339_1#42




Isolated after amoxicillin therapy
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of 13.3 mg/L; the two isolates from after amoxicillin treatment both had an average 
amoxicillin of > 256 mg/L (i.e., all biological replicates of these isolates grew at the maximum 
amoxicillin concentration of the Etest gradient). This suggests the acquisition of the cfxA  
beta-lactamase caused an approximately 19-fold increase in amoxicillin resistance in O. 
splanchnicus 99.56 %. O. splanchnicus is considered strictly anaerobic and non-spore-
forming277, therefore the relative abundance of O. splanchnicus in the anaerobic vegetative 
metascrape data from plates containing amoxicillin was determined (Fig. 5.14). This species 
was the 30th most abundant across these samples, and the mean relative abundance increased 
from 0.0033 % at Day 0 to 0.022 % at the end of the experiment (Day 35). However, there 
were no significant differences between the mean relative abundance values of O. 
splanchnicus between consecutive time points (Day 0 vs. Day 7, Day 7 vs. Day 14, Day 14 vs. 
Day 35), or after either recovery periods compared to the beginning (Day 0 vs. Day 14 and 35, 
q values determined by unpaired t-tests with Welch’s correction276 and adjusted for multiple-
testing with the Benjamini, Hochberg, and Yekutieli method193; q value significant < 0.05). 
Figure 5.14. Relative abundance of Odoribacter splanchnicus in anaerobic vegetative metascrape samples. The 
relative abundance of the “strictly anaerobic, non-spore-forming” Odoribacter splanchnicus species was 
determined in the anaerobic vegetative metascrapes from plates containing amoxicillin. The relative abundance 
of this species increased between Day 0 and Day 7 following amoxicillin therapy in mice with human-derived 
microbiota, decreased slightly at Day 14 and slightly increased again by Day 35. However, these differences were 
not significant. Q values were determined by unpaired t-tests with Welch’s correction276, adjusted for multiple-
testing with the Benjamini, Hochberg, and Yekutieli method193; q value significant < 0.05. Bars represent Standard 
Error of the Mean. 
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Eight of the candidate OTUs that had whole genome sequences for before and after 
amoxicillin therapy and were not excluded following the Mash213 analysis did not appear to 
have acquired a beta-lactamase that would explain the described observations. Consequently, 
a comparative genomics approach as described in Chapter 4 was applied to identify potentially 
novel beta-lactamases. Genes in each OTU that were shared by all isolates cultured on plates 
containing amoxicillin after the mice were treated with amoxicillin, but absent from isolates 
of the same OTU cultured on plates not containing amoxicillin from before the mice received 
therapy, were identified. Genes fitting these criteria were searched for 90 % similarity to beta-
lactamase amino acid markers as generated and described in Chapter 4. No genes were found 
to contain these markers with 90 % identity. 
Finally, single nucleotide polymorphisms (SNPs) were searched for in the same eight OTUs as 
above, plus Odoribacter splanchnicus 99.56 %. Paired-end sequencing reads from bacteria 
isolated after amoxicillin treatment were mapped against assembled contigs from an isolate 
cultured before amoxicillin treatment. Variant bcf files were produced and used to identify 
SNPs in coding sequences (open reading frames (ORFs) annotated as such if over 100 bases) 
and non-coding regions. ORFs and non-coding regions containing SNPs were compared to 
known protein sequences using BLASTx or to the nr/nt database using BLASTn (Table 5.3). 
Twenty-two ORFs containing SNPs were most similar to enzymes involved in metabolic 
processes such as kinases or reductase and three ORFs were most similar to restriction 
endonucleases, plus one ORF was annotated as an ABC transporter ATP binding protein. 
However, ten ORFs were annotated as uncharacterised or hypothetical proteins. 
  
Table 5.3. Mutations in open reading frames and non-coding regions of gut bacteria isolated after amoxicillin therapy in mice with human-derived gut microbiota. Raw sequencing 
reads from bacteria cultured from mice with human-derived gut microbiota after amoxicillin therapy (query samples) were mapped against reference genomes of bacteria from the 
same OTU that had been isolated before amoxicillin therapy. Variants were identified in open reading frames (ORFs) of more than 100 bases and non-coding regions: NS 
nonsynonymous; S synonymous; I insertion; SNP single nucleotide polymorphism. The sequence of ORFs and non-coding regions containing mutations were analysed with BLASTx 
(nr database) to identify the most similar proteins or with BLASTn (nr/nt database) to identify the most similar nucleotide sequences. 
 
O.T.U. Reference  Query  Feature Mutations Top BLAST hit 
[Clostridium] populeti 
94.435 % 
25620_1#243 25620_1#295 ORF 1 S Sensor histidine kinase [Eubacterium ramulus] 
   ORF 1 S Sensor histidine kinase [Eubacterium ramulus] 
   ORF 1 NS TPA: beta-glucosidase [Lachnospiraceae bacterium] 
   ORF 1 NS TPA: beta-glucosidase [Lachnospiraceae bacterium] 
   ORF 1 NS Putative uncharacterized protein [Clostridium sp. CAG:352] 
   Non-coding 1 SNP No similarity BLASTn nr/nt or BLASTx 
   ORF 3 NS Nitroreductase family protein [Beduini massiliensis] 
   ORF 4 NS; 1 S Uncharacterised protein RAG0 10061 [Rhynchosporium agropyri] 
   ORF 1 S TPA: phosphoenolpyruvate carboxykinase (ATP) [Blautia sp.] 
   ORF 1 NS Phosphoenolpyruvate carboxykinase [ATP] [[Clostridium] clostridioforme 90A7] 
   ORF 1 S MULTISPECIES: phosphoenolpyruvate carboxykinase (ATP) [Clostridiales] 
   ORF 1 S ABC transporter ATP-binding protein [Flavonifractor plautii] 
   Non-coding 1 SNP No similarity BLASTn nr/nt or BLASTx 
   ORF 5 NS; 2 S Gfo/Idh/MocA family oxidoreductase [Anaerobium acetethylicum] 
   ORF 6 NS; 1 S Gfo/Idh/MocA family oxidoreductase [Anaerobium acetethylicum] 
   ORF 1 NS Glucan 1,6-alpha-glucosidase [Clostridium sp. KLE 1755] 
   ORF 1 NS Alpha-glucosidase [Eisenbergiella massiliensis] 
Coprobacillus 
cateniformis 99.270 % 
25620_1#240 25620_1#297 Non-coding 1 SNP Helix-turn-helix domain-containing protein [Massilimicrobiota timonensis] 
Coprobacillus 
cateniformis 99.211 % 
25620_1#293 25620_1#300 ORF 1 S Hypothetical protein [Coprobacillus cateniformis] 
Marvinbryantia 
formatexigens 92.942 % 




O.T.U. Reference  Query  Feature Mutations Top BLAST hit 
   ORF 1 NS Peptidase [Lachnospiraceae bacterium] or Penicillin-binding protein A [uncultured 
Clostridium sp.] 
Sporosarcina 
newyorkensis 99.710 % 
25620_1#231 25620_1#325 ORF 1 NS Preprotein translocase subunit SecA [Sporosarcina newyorkensis] 
   ORF 1 NS; 1 S TrkH family potassium uptake protein [Sporosarcina newyorkensis] 
Sporosarcina 
newyorkensis 99.710 % 
25620_1#232 25620_1#325 ORF 1 NS; 1 S TrkH family potassium uptake protein [Sporosarcina newyorkensis] 
Alistipes finegoldii 
99.851 % 
27261_7#7 27339_1#174 ORF 1 NS Hypothetical protein/restriction endonuclease 
   ORF 1 NS Restriction endonuclease 
   ORF 1 I Leucine-rich repeat domain-containing protein [Alistipes finegoldii] 
   ORF 1 I Leucine-rich repeat domain-containing protein [Alistipes finegoldii] 
   ORF 1 I Leucine-rich repeat domain-containing protein [Alistipes finegoldii] 
   ORF 1 I Uncharacterised protein BN754_01505 [Alistipes finegoldii CAG:68] 
   ORF 2 I Glycosyl transferase 
   ORF 3 NS; 5 S Restriction endonuclease 
   ORF 2 NS: 5 S Restriction endonuclease 
Enterococcus faecium 
99.791 % 
27339_1#100 27339_1#138 ORF 1 NS Heavy metal translocating P-type ATPase [Enterococcus faecium] 
   ORF 1 NS MULTISPECIES: aldo/keto reductase [Enterococcus] 
Flavonifractor plautii 
99.702 % 
27339_1#70 27339_1#26 ORF 1 NS No similarity BLASTx; BLASTn similarity to Flavonifractor genome 
   ORF 1 NS Acetaldehyde dehydrogenase [Flavonifractor plautii ATCC 29863] 
   ORF 1 S Acetaldehyde dehydrogenase [Flavonifractor plautii ATCC 29863] 
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5.3  Discussion 
In this chapter I have studied the impact of amoxicillin therapy on amoxicillin resistance in 
mice with human-derived gut microbiota. Reference genome based metagenomics was used 
to observe changes to the pre-existing amoxicillin-resistant community that lasted beyond the 
end of the antibiotic treatment. A recent study on amoxicillin combined with clavulanate 
therapy in healthy adult humans also found gut microbiota compositional changes 
immediately after one week’s treatment278. Two weeks after treatment stopped, these 
changes were no longer apparent and the gut microbiota communities had reverted back to 
pre-treatment profiles278. However, that study mainly used 16S rRNA sequencing for profiling 
the gut community and only looked at relative abundances of bacterial families, whereas I 
have assessed the species level. In addition, the combination of culturing and WGS to generate 
study-specific reference genome databases for taxonomic classifications means my analysis in 
this thesis is tailored to the gut microbiomes being studied, providing higher taxonomic 
resolution. This may explain the disparity between the two studies. 
The amoxicillin-resistant community was studied in mice with human-derived microbiota by 
culturing faecal samples on agar plates, including plates containing amoxicillin at 8 mg/L 
amoxicillin, a concentration above which pathogenic bacteria can be considered resistant to 
amoxicillin. This was further divided into the aerobic, anaerobic vegetative and anaerobic 
spore-forming communities. The key findings from these humanised microbiota mouse 
experiments are illustrated in Figure 5.15. The amoxicillin therapy appeared to have an impact 
on the bacterial load of each of these communities, including the reduction of the amount of 
anaerobic spore-forming bacteria. An overall reduction in the total amount of gut bacteria 
following amoxicillin has been observed in previous studies179. However, in this study 
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Figure 5.15. The key findings from the humanised microbiota mouse experiments. An illustration of the changes to the amoxicillin-resistant spore-forming community (bacterial 
load and alpha diversity) and individual strains (relative abundance of Sporosarcina newyorkensis and acquisition of cfxA by Odoribacter splanchnicus). Mice with humanised gut 
microbiota were given amoxicillin therapy for seven days at a therapeutic concentration. Faecal pellets were collected before and after therapy to allow culturing of individual 
isolates, WGS and whole genome shotgun metagenomic sequencing of metascrape samples. 
Sample before Amx
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181 
  182 
there was a slight increase in anaerobic vegetative bacteria – perhaps utilising the space that 
had been made available by reductions in other bacteria. The amoxicillin-resistant anaerobic 
spore-forming bacteria also showed significant reductions in load; this indicates that the 
recommended therapeutic dose of amoxicillin206 is sufficient to kill some bacteria considered 
resistant. This is in line with what is expected for amoxicillin – even though it is considered 
broad spectrum, it targets more Gram-negatives than Gram-positives31. 
That spore-formers, a major but comparatively understudied part of the gut microbiome, are 
significantly reduced by amoxicillin highlights that the impact of antibiotics on the gut 
microbiota is not yet fully understood; this result is unexpected given the described amoxicillin 
spectrum of activity. To my knowledge, this is the first time the spore-forming community has 
specifically been studied for its response to antibiotics, by using a combination of culturing, 
WGS and reference genome based metagenomics. Antibiotic treatment can promote spore 
formation279 and the assumption could be made that spore-forming bacteria would therefore 
be protected against significant effects to their total abundance in the gut. However, if the 
spores re-enter the vegetative state they may not be protected and be impacted by the 
amoxicillin treatment. This could result in fewer spore-forming bacteria present to produce 
spores; during the targeted culturing there would then be fewer spores present. After the 
amoxicillin therapy ends, the spore-formers are able to recover and produce spores again, 
hypothetically leading to the findings observed in this chapter. In the future, quantitative 
methods for measuring bacterial load may provide more precise and insightful information280.  
Comparing alpha diversity in the amoxicillin-resistant spore-formers appeared to suggest that 
the richness of this community increased following amoxicillin treatment. This could be 
explained by previously susceptible species developing resistance. However, the amoxicillin-
resistant anaerobic vegetative and spore-forming communities comprised mostly lowly 
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abundant or rare species (> 90 % cumulative relative abundance), compared to the amoxicillin-
resistant aerobic community. The increase in richness could be due to a reduction in species 
such as E. faecalis, allowing lowly-abundant ones such as S. newyorkensis to reach the 
detectable limit in the metagenomic sequencing analyses and appear more relatively 
abundant. 
The amoxicillin-resistant aerobic community was initially dominated by E. faecalis, a Gram-
positive facultative anaerobe that is common in the gut281. This species was significantly less 
relatively abundant following amoxicillin therapy. In previous studies of antibiotics on the gut 
microbiome, enterococci have been observed to expand in the gut following antibiotic 
therapy282; however, this is dependent on the type of antibiotic. Amoxicillin has previously 
been shown to reduce Gram-positive cocci such as enterococci and increase enterobacteria 
instead283,284. Here, there was a small but insignificant increase in the relative abundance 
Enterobacteriaceae member E. coli. Two Bacteroides species (B. fragilis and B. cellulosilyticus) 
were dominant at Day 14, and three other Bacteroides species (B. thetaiotaomicron, B. 
uniformis and B. vulgatus) were also in the top ten most relatively abundant species at this 
time point in aerobic metascrapes. This is surprising given Bacteroides species are thought to 
be obligate anaerobes148. Colonies of these five Bacteroides species plus B. faecis, B. stercoris 
and B. xylanisolvens were all isolated from aerobic culture plates, indicating that this was not 
a “false positive” result in the metagenomic data. B. fragilis has been reported as growing in 
microaerophilic environments (≤ 0.05 % oxygen)285, and specific DNA mutations have resulted 
in strains being able to grow in up to 2 % oxygen. In addition, B. thetaiotaomicron has been 
shown to express scavenging enzymes when exposed to oxygen to degrade oxygen 
compounds and reduce their toxicity286. The Bacteroides strains growing under aerobic 
conditions here may have contained or developed mutations that were selected for, allowing 
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their growth under aerobic conditions. Whether or not this was caused by the amoxicillin 
treatment or by exposure to oxygen is not determinable in this study. How Bacteroides might 
adapt to aerobic conditions would be interesting to investigate in the future, as this would 
provide novel insights into their biology. 
The most obvious increase in relative abundance in the aerobic metascrapes was that of S. 
newyorkensis. S. newyorkensis is another Gram-positive cocci but one that is rare in its ability 
to form spores; it is also facultatively anaerobic. This may explain its presence and increase in 
relative abundance in the amoxicillin-resistant aerobic community (Fig. 5.15), following the 
reduction of E. faecalis. Sporosarcina species have only recently begun to be studied using 
genomics287, with S. newyorkensis first being described in 2012288. This species was first 
isolated from human blood288, which is typically considered a sterile environment and as such, 
the presence of bacteria in blood indicates infection. Therefore, this study provides insights 
into the effect of amoxicillin on newly-discovered bacteria, including ones that may have 
clinical relevance through the potential to cause infections. Another recent study has 
identified an increase in the relative abundance of a spore-former following beta-lactam 
treatment: Candidatus Borkfalkia ceftriaxoniphila289 was relatively lowly abundant in the gut 
prior to ceftriaxone treatment in humans and then dominated the community after 
ceftriaxone treatment264. There, Candidatus Borkfalkia ceftriaxoniphila was considered a 
potential keystone species in the recovery of the gut community following antibiotics; perhaps 
these temporarily dominant spore-formers aid the re-establishment of a diverse gut 
microbiome. 
In addition to examining the impact of amoxicillin on the amoxicillin-resistant community, I 
studied the impact on individual strains of gut bacteria. Detecting changes in the genotypic 
and phenotypic resistance profiles before and after therapeutic antibiotic exposure using 
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broad identified the acquisition of a known beta-lactamase by a commensal strain of gut 
bacteria). The cfxA beta-lactamase gene is localised on a mobile transposon290, and since being 
first described in B. fragilis290, cfxA and related genes have also commonly been found in 
Prevotella, Porphyromonas and Capnocytophaga species291. Prevotella species are common 
members of the gut microbiota292 and cfxA in Prevotella in particular is associated with 
increased beta-lactam resistance in periodontal infections292. Thus, the presence of cfxA in gut 
microbiota that can act as opportunistic pathogens has potential clinical relevance. 
Here, cfxA appears to have been acquired by an O. splanchnicus strain following amoxicillin 
therapy, possibly from another Bacteroidetes species, apparently conferring a 19-fold 
increase in amoxicillin resistance (Fig. 5.15). O. splanchnicus has been described as an 
opportunistic pathogen277; if we extrapolate beyond these experiments, the ability of O. 
splanchnicus to acquire beta-lactamases from the gut microbiome therefore has direct 
potential clinical relevance. A recent porcine model of amoxicillin treatment showed that 
amoxicillin promoted the enrichment of beta-lactamases including cfxA293. However, as 
previously discussed, using whole genome shotgun metagenomics to assess gene prevalence 
does not allow for the hosts of those genes to be identified, nor can it distinguish whether an 
increase in gene abundance is caused by the spread of that gene to additional species or the 
relative increase in abundance of the original host species. Here, I have used broad culturing 
and WGS to discriminate new hosts of antibiotic resistance genes. Therefore, the unique 
combination of humanised gnotobiotic mouse models, advanced culturing and genomic 
analysis in this chapter provides novel and deep understanding of how antibiotic treatment 
changes the resistance profile of the gut microbiota community and individual strains, with 
implications relevant to the dissemination of antibiotic resistance and the evolution of drug-
resistant infections.  
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There were other candidate OTUs that appeared to have acquired amoxicillin resistance over 
the course of the experiment in the absence of known beta-lactam resistance genes or 
mutations using the methods applied in this study. These OTUs could represent pre-existing 
amoxicillin-resistant species that have increased in relative abundance above the detection 
level. Alternatively, it could be due to other resistance mechanisms, such as developing 
mutations not listed in CARD that increased resistance. This would be in line with the issues 
predicting resistance in commensal gut bacteria using genomics from the previous chapter, 
and further highlights how improved annotation of intestinal microbiota would be beneficial. 
Isolates of these OTUs from after the amoxicillin treatment had SNPs compared to isolates 
from before the antibiotic therapy. The majority of the ORFs containing variant sites were 
involved with metabolic processes. One was annotated as a transporter protein, which could 
potentially be involved in the efflux or export of amoxicillin. In addition, one was similar to a 
penicillin-binding protein; the observed non-synonymous mutation could have resulted in a 
reduced affinity for amoxicillin. Several of the ORFs were annotated as hypothetical or 
uncharacterised proteins; thus their function is unclear. Potentially these may also be 
candidate novel amoxicillin-resistance genes – though this additionally emphasises the issues 
surrounding annotation of bacterial genomes and proteins. 
Overall, this chapter shows that amoxicillin has significant impacts on the amoxicillin-resistant 
community of gut bacteria in mice with human-derived microbiota, including relatively 
uncharacterised spore-forming bacteria. Moreover, a commensal Bacteroidetes strain of O. 
splanchnicus acquired the cfxA beta-lactamase gene from the surrounding gut microbiome 
following exposure to amoxicillin in vivo in these mice. Thus, this chapter further emphasises 
the role of the human gut microbiome as a reservoir for antibiotic resistance in terms of its 
antibiotic-resistant community- and strain-level changes following antibiotic treatment. 
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Chapter 6: Discussion 
  
6.1. Key messages and future work 
In this thesis, I explored the capacity of the human gut microbiome as a reservoir of antibiotic 
resistance. I determined that the majority of bacterial members of a normal, healthy gut 
microbiota possess genetic antibiotic resistance determinants using genomic studies of a 
unique human gut bacteria culture collection. I also generated antibiotic resistance 
phenotypes to link to these genotypes and identified the presence of resistances to antibiotics 
essential in medicine that were not predicted using a range of genome-based databases and 
methods. To my knowledge, this is the first time that such a large phylogenetically diverse 
collection of human commensal gut bacteria has been tested for resistance to multiple 
clinically relevant classes of antibiotics using phenotypic and/or genotypic approaches. This 
identified multiple instances of antibiotic resistance that could not be predicted using 
genomics, signifying that the full extent of antibiotic resistance in the microbiome is currently 
unknown. In addition, I combined deep culturing with reference genome-based 
metagenomics to study the impact of amoxicillin on the gut bacteria in mice with humanised 
microbiota, identifying the acquisition of a clinically relevant beta-lactamase by a potential 
opportunistic gut pathogen via HGT. This unique combination of techniques therefore enabled 
strain-level discrimination of antibiotic-induced genetic changes. Overall, this thesis highlights 
the power of a combined genomic and culture-based approach to investigate the gut 
resistome. 
The overall widespread distribution of resistance determinants in the HBC (Chapter 3) is 
concerning in its implications for the potential horizontal transfer of antibiotic resistance 
genes among resident and transient members of the gut microbiome. With approximately 52 
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% of commensal gut bacteria possessing ARGs there are more opportunities for these HGT 
events to occur than if only a small minority of gut bacteria harboured ARGs. Thus, the 
majority of the human microbiome is in theory capable of contributing to the spread of 
antibiotic resistance. Indeed, this was in part demonstrated by the acquisition of the cfxA 
beta-lactamase gene in isolates of Odoribacter splanchnicus following exposure to amoxicillin 
(Chapter 5); this transfer event conferred high-level beta-lactam resistance in the recipient O. 
splanchnicus strain. This shows how antibiotics can lead to the movement of clinically relevant 
ARGs and cause increased antibiotic resistance in gut bacteria. If this occurs in pathogens or 
opportunistic pathogens, then this could result in antibiotic-resistant infections. Though cfxA 
has not currently been detected in bacteria belonging to other phyla, possibly due to phyla 
HGT barriers, O. splanchnicus has been described as an opportunistic pathogen and thus this 
event has potentially direct clinical impacts. Moreover, if cfxA were to become located within 
a more promiscuous mobile element or plasmid, it could hypothetically spread to more 
distantly related taxa such as Enterobacteriaceae and cause highly beta-lactam resistant 
infections. 
However, antibiotic resistance in commensal gut bacteria can also be a benefit to the gut 
microbiome: for example, beta-lactamase-producing resident bacteria may be protected 
against the effects of beta-lactam therapy. The action of the beta-lactamase to degrade the 
antibiotic may also protect other resident commensal bacteria. Moreover, antibiotic resistant 
commensals can protect against colonisation by antibiotic-resistant pathogens294. As 
antibiotic resistance in commensals can be considered both an issue and a benefit, it is 
important in the future to define which antibiotic resistance genes are most likely to spread 
to opportunistic or obligate pathogens, plus which commensal gut bacteria are most likely to 
cause opportunistic infections. 
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That isolates representing novel taxa were also found to contain known antibiotic resistance 
genes highlights that we cannot fully understand which bacteria carry antibiotic resistance 
genes until we have identified all bacterial species that inhabit the gastrointestinal tract. One 
approach for this would be continuing to predict the presence of antibiotic resistance genes 
and mutations in genomes of newly cultured human gut bacteria as they become publicly 
available. For example, PATRIC194 provides a genome annotation services that includes 
CARD163,164 for annotating antibiotic resistance genes; NCBI has its own AMRFinderPlus295 tool 
for identifying antimicrobial resistance genes in whole genome sequences. These tools could 
be programmed to run automatically when new bacterial genomes are uploaded, allowing 
antibiotic resistance genotype to be readily available and curated. An alternative approach for 
determining which bacteria carry antibiotic resistance genes or mutations would be to search 
for known genetic antibiotic resistance determinants in metagenome-assembled genomes 
(MAGs); this may help to increase the phylogenetic diversity being studied. However, MAGs 
are limited due to the absence of isolates for phenotypic analysis plus can result from mixed-
assemblies of closely related strains296, potentially introducing spurious results. Unless this 
can be resolved, culturing and studying whole genome sequences remains the most accurate 
way of surveying the distribution of genetic determinants of antibiotic resistance. 
Continuing to culture gut bacteria from stool samples remains imperative for identifying novel 
isolates and studying the presence of antibiotic resistance genes and mutations. In addition, 
this will help improve taxonomic classification of metagenomic sequencing. In Chapter 5, 
despite isolating approximately 11,000 individual isolates and generating study-specific 
reference genomes there were still metagenomic sequences identified in metascrapes 
derived from faecal samples that could not be assigned taxa. Isolating additional colonies 
could be beneficial, though I predicted that around three times as many colonies picked in this 
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study would need to be isolated to recover all predicted OTUs. Presently, this would require 
huge manual effort, as culturing anaerobic bacteria is difficult to automate due to the space 
restrictions inside an anaerobic cabinet. The culturomics approach297 could be implemented, 
which uses multiple types of media to select for different bacteria and mass-spectrometry to 
rapidly identify those bacteria. Targeted culturing such as ethanol selection for spore-formers 
may help reduce the number of additional colonies that need to be picked; developing more 
advanced selective culturing may assist further. As technology improves, it will become easier 
to isolate all the possible bacteria residing in the gut. There is a particular need for high-
throughput, broad-scale culturing of gut bacteria from diverse peoples across the globe to 
recover maximum diversity. 
In addition to isolating and studying novel genomes, novel antibiotic resistance genes are also 
important to discover for improving the annotation of antibiotic resistance in bacterial 
genomes and metagenomes belonging to diverse microbiomes. As shown in this thesis, rule-
based methods are not accurate for predicting phenotypic resistance in gut bacteria, which as 
discussed could have direct clinical implications. Though other studies have shown higher 
rates of accuracy for rule-based genomic prediction of antibiotic resistance in 
pathogens240,242,248, a recent bioRxiv preprint showed that accuracy could vary between 
laboratories studying the same WGS datasets of carbapenem-resistant clinical isolates240,298. 
Identifying known point mutations is especially difficult as they could be masked by 
sequencing errors or consensus sequences240. In addition, it can be hard to identify mutations 
causing antibiotic resistance phenotypes in the first place299, and so databases of point 
mutations should be considered particularly incomplete299.  
In Chapter 4, it was shown difficult to identify or validate candidate novel antibiotic resistance 
genes from individual gut bacteria using functional metagenomics or cloning of a specific 
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candidate gene. In the future, qPCR or RNASeq of candidate resistance genes or mutations 
may provide insights into their expression that could explain differing antibiotic resistance 
phenotypes been closely related bacteria. In addition, integration sites of cloning vectors 
(such as of the GeneArt synthesised Group2384-carrying plasmid) could be investigated to see 
if this affects the expression of the insert candidate gene. Alternative recipient strains instead 
of E. coli could be used; however, classic genetics techniques are more limited for gut bacteria 
than for pathogens and so presently few alternatives exist.  Moreover, successful shotgun 
cloning from pure cultures of isolated bacteria is crucial for better annotating gut bacteria and 
should continue to be optimised. Developing genetic techniques for gut bacteria will take time 
but is essential if we are to better understand our gut microbiota. In particular, improving 
annotation of antibiotic resistance would be useful to study antibiotic resistance on a global 
scale: it is possible that one day commercial microbiome sequencing services could be 
combined with surveillance of antibiotic resistance genes to help achieve this. 
Discovering novel antibiotic resistance genes and mutations will help improve the accuracy of 
rule-based antibiotic resistance prediction methods. It is important for these methods to be 
accurate: if WGS-AST becomes a routine procedure in healthcare, we need to ensure patients 
are receiving antibiotics that are effective but not causing unnecessary harm to their gut 
microbiota. False predictions of susceptibility or resistance may result in patients being 
treated with antibiotics that do not work or with antibiotics that cause significant impacts to 
their gut microbiota when a narrower-spectrum antibiotic would have been sufficient. 
Fortunately, rule-based methods have been shown to be more accurate for specific species of 
pathogenic bacteria299. If this type of study is expanded with additional isolates per species or 
isolation source, comparable to that of studies in pathogens, we may be able to increase the 
accuracy of genome-based antibiotic resistance predictions in gut bacteria. Studying more 
 
 192 
isolates would allow the approach developed in this thesis to define gut bacteria resistant or 
susceptible to be limited to more specific taxa (such as species rather than across all four phyla 
studied here), which may further improve WST-AST accuracy. Measuring MIC instead of zone 
of inhibition would also provide more direct information and enable antibiotic concentration 
breakpoints to be determined for gut bacteria. Moreover, expanded databases with genetic 
antibiotic resistance determinants from a wide range of bacterial sources may result in less 
bias towards pathogenic Proteobacteria. In the future, WGS-AST could become a gold-
standard method for inferring phenotypic antibiotic resistance in commensal gut bacteria, as 
well as clinical isolates of bacterial pathogens. 
Expanding the number of bacteria (e.g., the entire HBC) and range of antibiotics (e.g. all of 
those on the WHO essential list) studied in this thesis would provide further insights into the 
impact of antibiotic spectrum on the gut microbiome. For example, in Chapter 4 gentamicin 
was effective against four Firmicutes bacteria considered strict anaerobes. Aminoglycoside 
uptake is thought to require quinones, lipid-soluble membrane electron carriers required for 
aerobic respiration300 – which are typically only present in Alpha-, Beta- and 
Gammaproteobacteria300. These findings highlight how current knowledge of antibiotic 
spectrum is based on a limited set of bacterial species and that some antibiotics – such as 
gentamicin – may have under-realised impacts on the gut microbiota. This is important to 
understand more fully since the use of antibiotics is known to have long term impacts on the 
gut microbiome with potentially serious implications for our health. This knowledge could 
eventually be used to establish a framework to guide antibiotic selection in a clinical setting 
and ultimately guide microbiota-dependent personalised medicine. Furthermore, with 
research into gut microbiota-based therapeutics advancing rapidly, perhaps in the future a 
scenario will exist where when taking an antibiotic the patient is also prescribed a specific 
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probiotic containing bacteria likely to be harmed by that antibiotic or that aid gut microbiome 
recovery. Mouse models with humanised microbiota are essential for early testing of these 
proposed probiotics or any gut microbiota-based therapy. 
Though the mouse model system described requires optimisation, it resulted in remarkable 
discrimination that identified the acquisition of a beta-lactamase by a commensal strain of gut 
bacteria. Eight other OTUs were observed to have gained several SNPs following antibiotic 
therapy, but these require further investigation and validation to confirm their hypothetical 
role in increased amoxicillin resistance. Moreover, the model could be easily altered to study 
other antibiotics, such as those of last resort, or gut microbiomes with different features from 
alternative human donors. Off-target effects of particular antibiotic therapy (e.g. increased 
resistance to other antibiotics that were not used as the therapy) could also be studied. These 
experiments will help to understand the species- and strain-level ecological dynamics of 
antibiotic resistance that occur in the gut following antibiotic treatment. This information 
could aid personalised microbiome-based medicine. 
 
6.2. Concluding remarks 
High-throughput ‘omics’ studies have been extremely useful for gaining understanding into 
the gut microbiota and resistome, and microbiomes more generally. In this thesis, whole 
genome sequencing was used to map the distribution of genetic antibiotic resistance 
determinants in individual isolates of phylogenetically diverse commensal gut bacteria and 
identify many unpredicted resistances to antibiotics considered essential in medicine. 
Moreover, high-throughput culturing and whole genome sequencing identified a 1 in 11,000 
horizontal gene transfer event of a clinically relevant beta-lactamase. However, a return to 
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classical microbiology to complement these techniques would enable better resolution of 
high-throughput and large-scale sequencing studies, as well as increased understanding of the 
biology of the individual bacteria themselves. This is critical if we are to fully understand the 
role of each member of the gut microbiota and how they contribute to the overall microbiome 
function and therefore our health. Only when this is achieved will understanding the spread 
of antibiotic resistance, the complete gut resistome, detailed microbiome function and 
personalised microbiome-based medicine become possible. 
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Appendix 1. CARD determinant groupings 
Table A1.1. Genetic determinants of antibiotic resistance as described in CARD were grouped by the antibiotic to which they are described as conferring 
resistance. If more than one antibiotic class was included for a single determinant, these determinants were grouped as “non-specific”. The exception 
is for resistances to Macrolide, Lincosamide, Pleuromutilin and Streptogramin (MLPS) antibiotics, as resistance determinants against these antibiotics 




Custom group CARD antibiotic class 
1 Acridine dye Acridine dye 
9 Aminocoumarin Aminocoumarin antibiotic 
170 Aminoglycoside Aminoglycoside antibiotic 
2 Antibacterial free 
fatty acids 
Antibacterial free fatty acids 
51 Beta-lactam Carbapenem 
3 Beta-lactam Carbapenem;cephalosporin 
3 Beta-lactam Carbapenem;cephalosporin;cephamycin 
48 Beta-lactam Carbapenem;cephalosporin;cephamycin;penam 
85 Beta-lactam Carbapenem;cephalosporin;cephamycin;penam;penem 
194 Beta-lactam Carbapenem;cephalosporin;penam 
2 Beta-lactam Carbapenem;penam 
184 Beta-lactam Cephalosporin 
29 Beta-lactam Cephalosporin;cephamycin 






Custom group CARD antibiotic class 
347 Beta-lactam Cephalosporin;penam 
114 Beta-lactam Cephamycin 
31 Beta-lactam Monobactam;carbapenem;cephalosporin 
11 Beta-lactam Monobactam;carbapenem;cephalosporin;cephamycin;penam 
12 Beta-lactam Monobactam;carbapenem;cephalosporin;cephamycin;penam;penem 
18 Beta-lactam Monobactam;carbapenem;cephalosporin;penam 
7 Beta-lactam Monobactam;carbapenem;cephalosporin;penam;penem 
1 Beta-lactam Monobactam;carbapenem;penam 
11 Beta-lactam Monobactam;cephalosporin 
16 Beta-lactam Monobactam;cephalosporin;cephamycin 
8 Beta-lactam Monobactam;cephalosporin;cephamycin;penam;penem 
33 Beta-lactam Monobactam;cephalosporin;penam 
167 Beta-lactam Monobactam;cephalosporin;penam;penem 
29 Beta-lactam Penam 
24 Beta-lactam Penam;penem 
4 Beta-lactam N/A 
1 Bicyclomycin Bicyclomycin 
47 Chloramphenicol Phenicol antibiotic 
8 Elfamycin Elfamycin antibiotic 
31 Diaminopyrimidine Diaminopyrimidine antibiotic 
125 Fluoroquinolone Fluoroquinolone antibiotic 
28 Fosfomycin Fosfomycin 
6 Fusidic acid Fusidic acid 
77 Glycopeptide Glycopeptide antibiotic 
4 Isoniazid Isoniazid 






Custom group CARD antibiotic class 
13 MLPS Lincosamide antibiotic 
1 MLPS Lincosamide antibiotic;pleuromutilin antibiotic 
5 MLPS Lincosamide antibiotic;streptogramin antibiotic;pleuromutilin antibiotic 
3 MLPS Macrolide antibiotic 
4 MLPS Macrolide antibiotic;lincosamide antibiotic 
33 MLPS Macrolide antibiotic;lincosamide antibiotic;streptogramin antibiotic 
5 MLPS Macrolide antibiotic;streptogramin antibiotic 
1 MLPS Pleuromutilin antibiotic 
11 MLPS Streptogramin antibiotic 
6 MLPS Streptogramin antibiotic;pleuromutilin antibiotic 
2 Nitrofuran Nitrofuran antibiotic 
1 Nitroimidazole Nitroimidazole antibiotic 
3 Non-specific Aminoglycoside antibiotic;aminocoumarin antibiotic 
5 Non-specific Aminoglycoside antibiotic;cephalosporin;cephamycin;penam 
2 Non-specific Aminoglycoside antibiotic;tetracycline antibiotic;phenicol antibiotic 
1 Non-specific Cephalosporin;penam;peptide antibiotic 
6 Non-specific Fluoroquinolone antibiotic;acridine dye 
1 Non-specific Fluoroquinolone antibiotic;acridine dye;triclosan 
5 Non-specific Fluoroquinolone antibiotic;aminocoumarin antibiotic 
5 Non-specific Fluoroquinolone antibiotic;aminoglycoside antibiotic 
2 Non-specific Fluoroquinolone antibiotic;cephalosporin;cephamycin;penam 
1 Non-specific Fluoroquinolone antibiotic;cephalosporin;glycylcycline;cephamycin;penam;tetracycline antibiotic;rifamycin antibiotic;phenicol 
antibiotic;triclosan 
1 Non-specific Fluoroquinolone antibiotic;cephalosporin;glycylcycline;penam;tetracycline antibiotic;acridine dye;rifamycin antibiotic;phenicol 
antibiotic;triclosan 






Custom group CARD antibiotic class 
1 Non-specific Fluoroquinolone antibiotic;cephalosporin;penam;tetracycline antibiotic;peptide antibiotic;acridine dye 
6 Non-specific Fluoroquinolone antibiotic;diaminopyrimidine antibiotic;phenicol antibiotic 
2 Non-specific Fluoroquinolone antibiotic;glycylcycline;tetracycline antibiotic;diaminopyrimidine antibiotic;nitrofuran antibiotic 
1 Non-specific Fluoroquinolone antibiotic;lincosamide antibiotic;nucleoside antibiotic;acridine dye;phenicol antibiotic 
1 Non-specific Fluoroquinolone antibiotic;monobactam;carbapenem;cephalosporin;cephamycin;penam;tetracycline antibiotic;phenicol 
antibiotic;penem 
4 Non-specific Fluoroquinolone antibiotic;monobactam;carbapenem;cephalosporin;glycylcycline;cephamycin;penam;tetracycline antibiotic;rifamycin 
antibiotic;phenicol antibiotic;triclosan;penem 
3 Non-specific Fluoroquinolone antibiotic;monobactam;cephalosporin 
1 Non-specific Fluoroquinolone antibiotic;nucleoside antibiotic;acridine dye;phenicol antibiotic 
16 Non-specific Fluoroquinolone antibiotic;nybomycin 
5 Non-specific Fluoroquinolone antibiotic;tetracycline antibiotic 
4 Non-specific Fluoroquinolone antibiotic;tetracycline antibiotic;acridine dye 
1 Non-specific Fluoroquinolone antibiotic;tetracycline antibiotic;nitroimidazole antibiotic 
10 Non-specific Glycylcycline;tetracycline antibiotic 
1 Non-specific Isoniazid;ethionamide 
3 Non-specific Isoniazid;triclosan 
1 Non-specific Macrolide antibiotic;aminocoumarin antibiotic 
3 Non-specific Macrolide antibiotic;carbapenem;tetracycline antibiotic;acridine dye;diaminopyrimidine antibiotic;phenicol antibiotic 
1 Non-specific Macrolide antibiotic;fluoroquinolone antibiotic 
3 Non-specific Macrolide antibiotic;fluoroquinolone antibiotic;aminoglycoside antibiotic;carbapenem;cephalosporin;cephamycin;penam;tetracycline 
antibiotic;acridine dye;phenicol antibiotic 
1 Non-specific Macrolide antibiotic;fluoroquinolone antibiotic;aminoglycoside antibiotic;carbapenem;tetracycline antibiotic 
4 Non-specific Macrolide antibiotic;fluoroquinolone antibiotic;aminoglycoside antibiotic;cephalosporin;penam;tetracycline antibiotic;aminocoumarin 
antibiotic;diaminopyrimidine antibiotic;phenicol antibiotic 
4 Non-specific Macrolide antibiotic;fluoroquinolone antibiotic;aminoglycoside antibiotic;cephalosporin;tetracycline antibiotic 






Custom group CARD antibiotic class 
4 Non-specific Macrolide antibiotic;fluoroquinolone antibiotic;cephalosporin;fusidic acid 
1 Non-specific Macrolide antibiotic;fluoroquinolone antibiotic;cephalosporin;glycylcycline;cephamycin;penam;tetracycline antibiotic;aminocoumarin 
antibiotic;rifamycin antibiotic;phenicol antibiotic;triclosan 
1 Non-specific Macrolide antibiotic;fluoroquinolone antibiotic;cephalosporin;penam;tetracycline antibiotic;aminocoumarin 
antibiotic;diaminopyrimidine antibiotic;phenicol antibiotic 
4 Non-specific Macrolide antibiotic;fluoroquinolone antibiotic;lincosamide antibiotic;carbapenem;cephalosporin;tetracycline antibiotic;rifamycin 
antibiotic;diaminopyrimidine antibiotic;phenicol antibiotic;penem 
1 Non-specific Macrolide antibiotic;fluoroquinolone antibiotic;monobactam;aminoglycoside 
antibiotic;carbapenem;cephalosporin;cephamycin;penam;tetracycline antibiotic;peptide antibiotic;acridine dye;aminocoumarin 
antibiotic;diaminopyrimidine antibiotic;sulfonamide antibiotic;phenicol antibiotic;penem 
2 Non-specific Macrolide antibiotic;fluoroquinolone antibiotic;monobactam;aminoglycoside 
antibiotic;carbapenem;cephalosporin;cephamycin;penam;tetracycline antibiotic;peptide antibiotic;aminocoumarin 
antibiotic;diaminopyrimidine antibiotic;sulfonamide antibiotic;phenicol antibiotic;penem 
6 Non-specific Macrolide antibiotic;fluoroquinolone antibiotic;monobactam;carbapenem;cephalosporin;cephamycin;penam;tetracycline 
antibiotic;peptide antibiotic;aminocoumarin antibiotic;diaminopyrimidine antibiotic;sulfonamide antibiotic;phenicol antibiotic;penem 
5 Non-specific Macrolide antibiotic;fluoroquinolone antibiotic;penam 
2 Non-specific Macrolide antibiotic;fluoroquinolone antibiotic;penam;tetracycline antibiotic 
2 Non-specific Macrolide antibiotic;fluoroquinolone antibiotic;rifamycin antibiotic 
2 Non-specific Macrolide antibiotic;fluoroquinolone antibiotic;tetracycline antibiotic;acridine dye;phenicol antibiotic 
3 Non-specific Macrolide antibiotic;fluoroquinolone antibiotic;tetracycline antibiotic;phenicol antibiotic 
6 Non-specific Macrolide antibiotic;lincosamide antibiotic;streptogramin antibiotic;oxazolidinone antibiotic;phenicol antibiotic 
1 Non-specific Macrolide antibiotic;lincosamide antibiotic;streptogramin antibiotic;oxazolidinone antibiotic;phenicol antibiotic;pleuromutilin 
antibiotic 
1 Non-specific Macrolide antibiotic;lincosamide antibiotic;streptogramin antibiotic;tetracycline antibiotic 
4 Non-specific Macrolide antibiotic;monobactam;tetracycline antibiotic;aminocoumarin antibiotic 
4 Non-specific Macrolide antibiotic;penam 
1 Non-specific Macrolide antibiotic;penam;antibacterial free fatty acids 
4 Non-specific Macrolide antibiotic;peptide antibiotic 






Custom group CARD antibiotic class 
4 Non-specific Monobactam;carbapenem;cephalosporin;cephamycin;penam;phenicol antibiotic;penem 
1 Non-specific Monobactam;carbapenem;cephalosporin;cephamycin;penam;tetracycline antibiotic;penem 
3 Non-specific Nucleoside antibiotic;acridine dye 
1 Non-specific Peptide antibiotic;polyamine antibiotic 
6 Non-specific Peptide antibiotic;rifamycin antibiotic 
1 Non-specific Rifamycin antibiotic;isoniazid 
1 Non-specific Rifamycin antibiotic;polyamine antibiotic 
1 Non-specific Tetracycline antibiotic;benzalkonium chloride;rhodamine 
7 Non-specific N/A 
4 Nucleoside Nucleoside antibiotic 




56 Peptide Peptide antibiotic 
8 Polyamine Polyamine antibiotic 
1 Pyrazinamide Pyrazinamide 
13 Rifamycin Rifamycin antibiotic 
1 Sulfonamide Sulfonamide antibiotic 
6 Sulfonamide Sulfonamide antibiotic;sulfone antibiotic 
52 Tetracycline Tetracycline antibiotic 







Appendix 2. HBC antibiotic resistance determinant groupings 
Table A2.1. The genetic determinants of antibiotic resistance predicted in the HBC genomes, as described in CARD, were grouped by the antibiotic to 
which they are described as conferring resistance. If more than one antibiotic class was included for a single determinant, these determinants were 
grouped as “non-specific”. The exception is for resistances to Macrolide, Lincosamide, Pleuromutilin and Streptogramin (MLPS) antibiotics, as 
resistance determinants against these antibiotics can have cross-resistance to each other. 
Custom Group CARD antibiotic classes Antibiotic resistance 
gene/determinant 
Mechanism 
Acridine dye Acridine dye emeA Antibiotic efflux 
Aminocoumarin Aminocoumarin antibiotic mdtA Antibiotic efflux 
Aminocoumarin Aminocoumarin antibiotic mdtB Antibiotic efflux 
Aminocoumarin Aminocoumarin antibiotic mdtC Antibiotic efflux 
Aminoglycoside Aminoglycoside aac(6')-Ie-aph(2'')-Ia Antibiotic inactivation 
Aminoglycoside Aminoglycoside aac(6')-Ii Antibiotic inactivation 
Aminoglycoside Aminoglycoside aac(6')-Iih Antibiotic inactivation 
Aminoglycoside Aminoglycoside aadA Antibiotic inactivation 
Aminoglycoside Aminoglycoside aadK Antibiotic inactivation 
Aminoglycoside Aminoglycoside ant(6)-Ia Antibiotic inactivation 
Aminoglycoside Aminoglycoside Ant(6)-Ib Antibiotic inactivation 
Aminoglycoside Aminoglycoside aph(2'') Antibiotic inactivation 
Aminoglycoside Aminoglycoside aph(2’’)-If Antibiotic inactivation 




Custom Group CARD antibiotic classes Antibiotic resistance 
gene/determinant 
Mechanism 
Aminoglycoside Aminoglycoside aph(3'')-Ib  Antibiotic inactivation 
Aminoglycoside Aminoglycoside aph(3')-Ia Antibiotic inactivation 
Aminoglycoside Aminoglycoside aph(3')-IIIa Antibiotic inactivation 
Aminoglycoside Aminoglycoside aph(6)-Id Antibiotic inactivation 
Aminoglycoside Aminoglycoside kdpE Antibiotic efflux 
Aminoglycoside Aminoglycoside antibiotic acrD Antibiotic efflux 
Beta-lactam Carbapenem, cephalosporin, penam shv Antibiotic inactivation 
Beta-lactam Cephalosporin cblA_1 Antibiotic inactivation 
Beta-lactam Cephalosporin cepA Antibiotic inactivation 
Beta-lactam Cephalosporin, monobactam, penam oxy_2 Antibiotic inactivation 
Beta-lactam Cephalosporin, penam bcI Antibiotic inactivation 
Beta-lactam Cephalosporin, penam bcII Antibiotic inactivation 
Beta-lactam Cephalosporin, penam oxa_114a Antibiotic inactivation 
Beta-lactam Cephamycin cfxA Antibiotic inactivation 
Beta-lactam Cephamycin cmy_101 Antibiotic inactivation 
Beta-lactam Monobactam, cephalosporin, penam, penem tem Antibiotic inactivation 
Beta-lactam Monobactam, cephamycin, cephalosporin, penam, carbapenem, penem K. pneumoniae ompK35 Resistance by absence or reduced 
permeability to antibiotic 
Beta-lactam Penam blaZ Antibiotic inactivation 
Beta-lactam Penam, carbapenem, cephamycin, cephalosporin act Antibiotic inactivation 
Beta-lactam Penam carbapenem, cephamycin, cephalosporin act_1 Antibiotic inactivation 
Beta-lactam Penam, carbapenem, cephamycin, cephalosporin, penem, monobactam K. pneumoniae ompK36 Resistance by absence or reduced 
permeability to antibiotic 
Beta-lactam Penam carbapenem, cephamycin, cephalosporin, penem, monobactam ompC Resistance by absence or reduced 
permeability to antibiotic 




Custom Group CARD antibiotic classes Antibiotic resistance 
gene/determinant 
Mechanism 
Beta-lactam Penam, cephalosporin oxa_347 Antibiotic inactivation 
Beta-lactam Penam ,cephalosporin oxa_4 Antibiotic inactivation 
Beta-lactam Penam ,cephalosporin, monobactam acc Antibiotic inactivation 
Beta-lactam Penam, cephalosporin, monobactam oxy Antibiotic inactivation 
Beta-lactam Penam, monobactam, penam, carbapenem, cephamycin, cephalosporin K. pneumoniae ompK37 Resistance by absence or reduced 
permeability to antibiotic 
Beta-lactam Penem, penam len_1 Antibiotic inactivation 
Chloramphenicol Phenicol antibiotic cat Antibiotic inactivation 
Chloramphenicol Phenicol antibiotic E. faecalis 
chloramphenicol+ 
Antibiotic inactivation 
Diaminopyrimidine  Diaminopyrimidine antibiotic dfrA14 Antibiotic target replacement 
Diaminopyrimidine  Diaminopyrimidine antibiotic dfrC Antibiotic target replacement 
Diaminopyrimidine  Diaminopyrimidine antibiotic dfrE Antibiotic target replacement 
Diaminopyrimidine  Diaminopyrimidine antibiotic dfrF Antibiotic target replacement 
Diaminopyrimidine  Diaminopyrimidine antibiotic dfrG Antibiotic target replacement 
Elfamycin Elfamycin E. coli ef-tu Antibiotic target alteration 
Fluoroquinolone Fluoroquinolone antibiotic emrA Antibiotic efflux 
Fluoroquinolone Fluoroquinolone antibiotic emrB Antibiotic efflux 
Fluoroquinolone Fluoroquinolone antibiotic emrR Antibiotic efflux 
Fluoroquinolone Fluoroquinolone antibiotic mdtH Antibiotic efflux 
Fluoroquinolone Fluoroquinolone antibiotic patA Antibiotic efflux 
Fosfomycin Fosfomycin E. coli cyaA Antibiotic target alteration 
Fosfomycin Fosfomycin E. coli glpT Antibiotic target alteration 
Fosfomycin Fosfomycin E. coli uhpA Antibiotic target alteration 
Fosfomycin Fosfomycin E. coli uhpT Antibiotic target alteration 




Custom Group CARD antibiotic classes Antibiotic resistance 
gene/determinant 
Mechanism 
Fosfomycin Fosfomycin fosA5 Antibiotic inactivation 
Fosfomycin Fosfomycin fosA7 Antibiotic inactivation 
Fosfomycin Fosfomycin fosB Antibiotic inactivation 
Fosfomycin Fosfomycin mdtG Antibiotic efflux 
Glycopeptide Glycopeptide antibiotic vanA Antibiotic target alteration 
Glycopeptide Glycopeptide antibiotic vanC Antibiotic target alteration 
Glycopeptide Glycopeptide antibiotic vanD Antibiotic target alteration 
Glycopeptide Glycopeptide antibiotic vanHA Antibiotic target alteration 
Glycopeptide Glycopeptide antibiotic vanHD Antibiotic target alteration 
Glycopeptide Glycopeptide antibiotic vanRA Antibiotic target alteration 
Glycopeptide Glycopeptide antibiotic vanRC Antibiotic target alteration 
Glycopeptide Glycopeptide antibiotic vanRD Antibiotic target alteration 
Glycopeptide Glycopeptide antibiotic vanSA Antibiotic target alteration 
Glycopeptide Glycopeptide antibiotic vanSC Antibiotic target alteration 
Glycopeptide Glycopeptide antibiotic vanTC Antibiotic target alteration 
Glycopeptide Glycopeptide antibiotic vanXA Antibiotic target alteration 
Glycopeptide Glycopeptide antibiotic vanXD Antibiotic target alteration 
Glycopeptide Glycopeptide antibiotic vanXYC Antibiotic target alteration 
MLPS Lincosamide antibiotic lmrB Antibiotic efflux 
MLPS Lincosamide antibiotic lnuC Antibiotic inactivation 
MLPS Lincosamide antibiotic lnuG Antibiotic inactivation 
MLPS Lincosamide antibiotic macrolide antibiotic, streptogramin antibiotic ermB Antibiotic target alteration 
MLPS Lincosamide antibiotic, streptogramin antibiotic, macrolide antibiotic ermG Antibiotic target alteration 
MLPS Macrolide antibiotic mefA antibiotic efflux 




Custom Group CARD antibiotic classes Antibiotic resistance 
gene/determinant 
Mechanism 
MLPS Pleuromutilin antibiotic, lincosamide antibiotic lsaE Antibiotic efflux 
MLPS Pleuromutilin antibiotic, lincosamide antibiotic, streptogramin antibiotic eatAv Antibiotic efflux 
MLPS Streptogramin antibiotic, lincosamide antibiotic, macrolide antibiotic ermQ Antibiotic target alteration 
MLPS Streptogramin antibiotic, lincosamide antibiotic, pleuromutilin antibiotic lsaA Antibiotic efflux 
MLPS Streptogramin antibiotic, macrolide antibiotic mel Antibiotic efflux 
MLPS Streptogramin antibiotic, macrolide antibiotic msrC Antibiotic efflux 
MLPS Streptogramin antibiotic, macrolide antibiotic, lincosamide antibiotic ermD Antibiotic efflux 
MLPS Streptogramin antibiotic, pleuromutilin antibiotic vgaC Antibiotic efflux 
Mupirocin Mupirocin ileS antibiotic target alteration 
Nitrofuran Nitrofuran antibiotic nfsA antibiotic target alteration 
Nitroimidazole Nitroimidazole antibiotic msbA Antibiotic efflux 
Non-specific Acridine dye, fluoroquinolone antibiotic blt Antibiotic efflux 
Non-specific Acridine dye, fluoroquinolone antibiotic cdeA Antibiotic efflux 
Non-specific Aminocoumarin antibiotic, aminoglycoside antibiotic baeR Antibiotic efflux 
Non-specific Aminocoumarin antibiotic, aminoglycoside antibiotic baeS Antibiotic efflux 
Non-specific Aminocoumarin antibiotic, aminoglycoside antibiotic cpxA Antibiotic efflux 
Non-specific Aminoglycoside antibiotic, fluoroquinolone antibiotic mipA Resistance by absence or reduced 
permeability to antibiotic 
Non-specific Aminoglycoside antibiotic, tetracycline antibiotic, phenicol antibiotic ykkC Antibiotic efflux 
Non-specific Cephalosporin, macrolide antibiotic, aminoglycoside antibiotic, fluoroquinolone 
antibiotic 
axyX Antibiotic efflux 
Non-specific Cephalosporin, macrolide antibiotic, aminoglycoside antibiotic, fluoroquinolone 
antibiotic 
axyZ Antibiotic efflux 
Non-specific Fluoroquinolone antibiotic, acridine dye norA Antibiotic efflux 
Non-specific Fluoroquinolone antibiotic, macrolide 
antibiotic, penam, cephamycin, cephalosporin, tetracycline antibiotic 




Custom Group CARD antibiotic classes Antibiotic resistance 
gene/determinant 
Mechanism 
Non-specific Fluoroquinolone antibiotic, penam, cephamycin, cephalosporin acrF Antibiotic efflux 
Non-specific Fluoroquinolone antibiotic, penam, macrolide antibiotic crp Antibiotic efflux 
Non-specific Fluoroquinolone antibiotic, penam, macrolide antibiotic mdtE Antibiotic efflux 
Non-specific Fluoroquinolone antibiotic, penam, tetracycline antibiotic, macrolide antibiotic evgA Antibiotic efflux 
Non-specific Glycopeptide antibiotic, streptogramin antibiotic, lincosamide antibiotic, macrolide 
antibiotic, phenicol antibiotic, pleuromutilin antibiotic 
Propionibacterium 23S 
rRNA 
Antibiotic target alteration 
Non-specific Glycopeptide antibiotic, streptogramin antibiotic, lincosamide antibiotic, macrolide 
antibiotic, phenicol antibiotic, pleuromutilin antibiotic 
S. pneumoniae 23S 
rRNA 
Antibiotic target alteration 
Non-specific Glycopeptide antibiotic, streptogramin antibiotic, macrolide antibiotic, phenicol 
antibiotic, lincosamide antibiotic, pleuromutilin antibiotic 
E. coli 23S rRNA Antibiotic target alteration 
Non-specific Glycopeptide antibiotic, streptogramin antibiotic, macrolide antibiotic, phenicol 
antibiotic, lincosamide antibiotic, pleuromutilin antibiotic, oxazolidinone antibiotic 
S. aureus 23S rRNA Antibiotic target alteration 
Non-specific Glycopeptide antibiotic, tetracycline antibiotic, glycylcycline, nucleoside 
antibiotic, aminoglycoside antibiotic, peptide antibiotic 
rrsB Antibiotic target alteration 
Non-specific Glycopeptide antibiotic, tetracycline antibiotic, peptide antibiotic, aminoglycoside 
antibiotic, nucleoside antibiotic, glycylcycline 
M. abscessus 16S rRNA Antibiotic target alteration 
Non-specific Macrolide antibiotic, cephalosporin, aminoglycoside antibiotic, fluoroquinolone 
antibiotic 
axyY Antibiotic efflux 
Non-specific Macrolide antibiotic, cephalosporin, aminoglycoside antibiotic, fluoroquinolone 
antibiotic 
oprZ Antibiotic efflux 
Non-specific Macrolide antibiotic, fluoroquinolone antibiotic efmA Antibiotic efflux 
Non-specific Macrolide antibiotic, penam, fluoroquinolone antibiotic gadW Antibiotic efflux 
Non-specific Macrolide antibiotic, penam, fluoroquinolone antibiotic gadX Antibiotic efflux 
Non-specific Nucleoside antibiotic, acridine dye mdtN Antibiotic efflux 
Non-specific Nucleoside antibiotic, acridine dye mdtO Antibiotic efflux 
Non-specific Nucleoside antibiotic, acridine dye mdtP Antibiotic efflux 




Custom Group CARD antibiotic classes Antibiotic resistance 
gene/determinant 
Mechanism 
Non-specific Nucleoside antibiotic, phenicol antibiotic, lincosamide antibiotic, fluoroquinolone 
antibiotic, acridine dye 
mdtM Antibiotic efflux 
Non-specific Penam, cephamycin, cephalosporin, fluoroquinolone antibiotic acrE Antibiotic efflux 
Non-specific Penam, macrolide antibiotic, fluoroquinolone antibiotic mdtF Antibiotic efflux 
Non-specific Peptide antibiotic, macrolide antibiotic mgrB Resistance by absence, antibiotic efflux 
and antibiotic target alteration 
Non-specific Tetracycline antibiotic, benzalkonium chloride, rhodamine mdfA Antibiotic efflux 
Non-specific Tetracycline antibiotic, cephalosporin, rifamycin antibiotic, phenicol 
antibiotic, glycylcycline, penam, fluoroquinolone antibiotic, triclosan 
acrA1 Antibiotic efflux 
Non-specific Tetracycline antibiotic, diaminopyrimidine antibiotic, glycylcycline, nitrofuran 
antibiotic, fluoroquinolone antibiotic 
oqxA Antibiotic efflux 
Non-specific Tetracycline antibiotic, fluoroquinolone antibiotic E. coli lamB Resistance by absence or reduced 
permeability to antibiotic 
Non-specific Tetracycline antibiotic, glycylcycline, rifamycin antibiotic, phenicol 
antibiotic, fluoroquinolone antibiotic, penam, cephamycin, cephalosporin, triclosan 
acrS Antibiotic efflux 
Non-specific Tetracycline antibiotic, macrolide antibiotic, fluoroquinolone antibiotic, penam evgS Antibiotic efflux 
Non-specific Tetracycline antibiotic, nitrofuran antibiotic, fluoroquinolone 
antibiotic, glycylcycline, diaminopyrimidine antibiotic 
oqxB Antibiotic efflux 
Non-specific Tetracycline antibiotic, penam, cephalosporin, glycylcycline, rifamycin 
antibiotic, phenicol antibiotic, triclosan, fluoroquinolone antibiotic 
acrB Antibiotic efflux 
Non-specific Tetracycline antibiotic, penam, cephalosporin, rifamycin antibiotic, phenicol 
antibiotic, glycylcycline, fluoroquinolone antibiotic, triclosan 
acrA Antibiotic efflux 
Non-specific Tetracycline antibiotic, penam, cephalosporin, rifamycin antibiotic, phenicol 
antibiotic, glycylcycline, fluoroquinolone antibiotic, triclosan 
marR Antibiotic efflux and antibiotic target 
alteration 
Non-specific Tetracycline 
antibiotic, penem, penam, carbapenem, cephamycin, cephalosporin, rifamycin 
antibiotic, phenicol antibiotic, monobactam, glycylcycline, fluoroquinolone 
antibiotic, triclosan 
marA Antibiotic efflux and reduced 




Custom Group CARD antibiotic classes Antibiotic resistance 
gene/determinant 
Mechanism 
Non-specific Tetracycline antibiotic, phenicol antibiotic, aminoglycoside antibiotic ykkD Antibiotic efflux 
Non-specific Tetracycline antibiotic, phenicol 
antibiotic, glycylcycline, penam, cephalosporin, rifamycin 
antibiotic, fluoroquinolone antibiotic, triclosan 
acrA2 Antibiotic efflux 
Non-specific Tetracycline antibiotic, rifamycin antibiotic, phenicol antibiotic, aminocoumarin 
antibiotic, fluoroquinolone 
antibiotic, penam, cephamycin, cephalosporin, glycylcycline, macrolide 
antibiotic, triclosan 
tolC Antibiotic efflux 
Non-specific Tetracycline antibiotic, rifamycin antibiotic, phenicol 
antibiotic, glycylcycline, penam, cephalosporin, triclosan, fluoroquinolone antibiotic 
ramR Antibiotic efflux 
Non-specific 
 
emrD Antibiotic efflux 
Non-specific 
 
emrE Antibiotic efflux 
Nucleoside Nucleoside antibiotic sat2 Antibiotic inactivation 
Nucleoside Nucleoside antibiotic sat4 Antibiotic inactivation 
Nucleoside Nucleoside antibiotic tmrB Reduced permeability to antibiotic 
Peptide Peptide antibiotic bacA Antibiotic target alteration 
Peptide Peptide antibiotic bcrA Antibiotic efflux 
Peptide Peptide antibiotic bcrB Antibiotic efflux 
Peptide Peptide antibiotic bcrC Antibiotic efflux 
Peptide Peptide antibiotic eptA Antibiotic target alteration 
Peptide Peptide antibiotic mprF Antibiotic target alteration 
Peptide Peptide antibiotic mprF3 Antibiotic target alteration 
Peptide Peptide antibiotic mprF4 Antibiotic target alteration 
Peptide Peptide antibiotic pmrF Antibiotic target alteration 
Peptide Peptide antibiotic ugd Antibiotic target alteration 




Custom Group CARD antibiotic classes Antibiotic resistance 
gene/determinant 
Mechanism 
Sulphonamide Sulfonamide antibiotic, sulfone antibiotic sul2 Antibiotic target replacement 
Tetracycline Tetracycline antibiotic emrK Antibiotic efflux 
Tetracycline Tetracycline antibiotic emrY Antibiotic efflux 
Tetracycline Tetracycline antibiotic P. acnes 16S rRNA Antibiotic target alteration 
Tetracycline Tetracycline antibiotic tet_40 Antibiotic efflux 
Tetracycline Tetracycline antibiotic tet_J Antibiotic efflux 
Tetracycline Tetracycline antibiotic tet_K Antibiotic efflux 
Tetracycline Tetracycline antibiotic tet44 Antibiotic target protection 
Tetracycline Tetracycline antibiotic tetA_46 Antibiotic efflux 
Tetracycline Tetracycline antibiotic tetA_P Antibiotic efflux 
Tetracycline Tetracycline antibiotic tetB_P Antibiotic target protection 
Tetracycline Tetracycline antibiotic tetM Antibiotic target protection 
Tetracycline Tetracycline antibiotic tetO Antibiotic target protection 
Tetracycline Tetracycline antibiotic tetQ Antibiotic target protection 
Tetracycline Tetracycline antibiotic tetS Antibiotic target protection 
Tetracycline Tetracycline antibiotic, glycylcycline tetA Antibiotic efflux 
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Table A2.2. A complete list of HBC isolates and the antibiotic resistance genes and mutations identified in their genomes. The genetic determinants 
of antibiotic resistance predicted in the HBC genomes, as described in CARD, were grouped by the antibiotic to which they are described as conferring 
resistance. If more than one antibiotic class was included for a single determinant, these determinants were grouped as “non-specific”. The exception 
is for resistances to Macrolide, Lincosamide, Pleuromutilin and Streptogramin (MLPS) antibiotics, as resistance determinants against these antibiotics 
can have cross-resistance to each other. The table can be viewed here: 
https://docs.google.com/spreadsheets/d/1zwmhUicOW3JVW_9y6P6LssbavW47EFiRq4_wwnS9CMg/edit?usp=sharing 
This table can also be found on the CD included with the hard copy of this thesis.
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Appendix 3: Gut microbiota community composition in mice 
with human-derived gut microbiota 
 
Figure A3.1. The relative abundance of species cultured from stool of Donor 2- and Donor 7-derived mice under 
anaerobic vegetative conditions. One faecal pellet was collected from each of five mice housed together in a 
single cage, of both Donor 2 and Donor 7 mouse lines. The stools were weighed and homogenised 100mg/ml, 
then pooled per mouse cage in equal volumes. The pooled samples were diluted and plated on YCFA agar and 
cultured at 37°C for 48 hours. The total growth was collected from each plate and total DNA extracted for 
metagenomic sequencing. Sequences reads were taxonomically classified using Kraken and a database of all 
publicly available gut bacterial genomes (as of December 2017) plus the HBC reference genomes. Classified read 
counts per species were normalised against the total number of classified reads per sample. The relative 


























































Figure A3.2. The relative abundance of amoxicillin-resistant species cultured from stool of Donor 2- and Donor 
7-derived mice under anaerobic vegetative conditions. One stool was collected from each of five mice housed 
together in a single cage, of both Donor 2 and Donor 7 mouse lines. The stools were weighed and homogenised 
100mg/ml, then pooled per cage in equal volumes. The pooled samples were diluted and plated on YCFA agar 
containing 8 mg/L amoxicillin (a level considered ‘clinically resistant’ by CLSI and EUCAST) and cultured at 37C 
for 48 hours. The complete growth was collected from each plate and total DNA extracted for metagenomic 
sequencing. Sequences reads were taxonomically classified using Kraken and a database of all publicly available 
gut bacterial genomes plus the HBC reference genomes. Classified read counts per species were normalised 
against the total number of classified reads per sample. The relative abundance of the top 25 most abundant 

































Relative abundance of amoxicillin−resistant species in Donor 2 and Donor 7 mice














Figure A3.3. Antibiotic resistance genes (ARGs) identified in Donor 2- and Donor 7-derived mice. One stool was 
collected from each of five mice housed together in a single cage, of both Donor 2 and Donor 7 mouse lines. The 
stools were weighed and homogenised 100mg/ml, then pooled per cage in equal volumes. The pooled samples 
were diluted and plated on YCFA agar and cultured at 37C for 48 hours. The complete growth was collected from 
each plate and total DNA extracted for metagenomic sequencing. The presence of ARGs in the CARD, ResFinder 
and MegaRes databases were predicted from the metagenomic sequence reads using ARIBA. Results using each 
database were combined to count the different ARGs predicted to be present in the gut community of each 
mouse line. 19 different ARGs were predicted in total, with Donor 7 mice predicted to harbour more antibiotic 
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